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A quantitative and qualitative analysis of the various sub-types of antigen-
specific CD4+ T cells in autoimmunity is important because they have a central role
in an immune response. Although it has been possible to study the humoral response
in detail in many autoimmune diseases, the analysis of antigen-specific T cells lags
far behind. A major impediment has been the innate low affinity of the T cell
receptor for its bipartite ligand - MHC plus peptide. The arrival of MHC class I
tetramers shed new light on the CD8+ T cell response, and provided one solution to
these challenges. Although monomeric HLA binding is of too low an affinity to be
useful in T cell labelling, fluorochrome labelled tetrameric HLA-peptide complexes
bind stably to antigen-specific CD8+ T cells due to the higher avidity gained by
multimerisation. These MHC-peptide TCR interactions are, therefore, able to detect
specific cellular immune responses in a similar way to the way antigen-antibody
interactions have been used to examine the humoral immune response. There is
currently no evidence that this technique overestimates the number of antigen-
specific T cells. The need to explore the role of CD4+ T cells in autoimmunity and
infection has lead several groups to try to develop MHC class II tetramers. All have
met with varying technical difficulties, primarily because successful MHC class II
multimer formation requires the conformationally correct interaction of three
components - a and P chain, and peptide - rather than the two in MHC class I.
However, the successes that have been reported suggested that MHC class II tetramer
analysis could be undertaken and applied to examine autoimmune T cell populations.
I chose Goodpasture's disease as a pilot autoimmune disease to explore the
potential of MHC class II tetramers. Although Goodpasture's disease is an
uncommon autoimmune disorder that causes rapidly progressive glomerulonephritis
and lung haemorrhage, it provides an amenable model for tetramer analysis of
autoreactive T cells for a number of reasons:
• The 'Goodpasture' antigen is known
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• Both predisposing and protective HLA class II molecules have been
identified
• Three nested sets of naturally processed peptides from the antigen that are
presented bound to HLA-DR15 have been identified biochemically.
Here I describe the formation of functional recombinant MHC class II
proteins that are capable of being multimerised to form fluorochrome labelled
multimeric complexes. Two different approaches have been used. One approach
utilised the Drosophila S2 expression system and adapted the C-terminals of the
MHC class II alpha and beta chains through the addition of an acid-base leucine
zipper motif in order to maintain the stability of their heterodimeric association in
solution. Protein tags were also added to the C-terminals together with the BirA site-
specific biotinylation sequence. Both HLA-DR15 and HLA-DR7 were adapted in
this way. The other, more novel approach, utilised a bacterial expression system and
aimed to improve the heterodimeric chain pairing of the MHC class II peptide-
binding domain through the construction of a two-domain single chain MHC class II
peptide, linking the (31 domain directly to the al domain, similar to the rat RTlb
construct of Burrows et al (Burrows et al., 1999). HLA-DR15, HLA-DR7 and I-Ed
were adapted in this way. The conformationally correct nature of both of these
approaches and their peptide-specific binding are demonstrated.
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Before discussing MHC multimers in some detail, I feel that it would be
appropriate to provide some background to autoimmune glomerulonephritis and the
role of T cells within this. I will also provide an overview of the established methods
ofT cell assessment before describing the aims behind this thesis.
2 Autoimmunity, Nephritis and the Cellular Immune
Response
2.1 Autoimmunity - General concepts
Autoimmune diseases can be broadly distinguished by two main patterns -
those primarily restricted to a single organ and those that are systemic. Classical
examples of the former include multiple sclerosis (MS) affecting neuronal axons of
the central nervous system, type I insulin-dependent diabetes mellitus (IDDM)
affecting the pancreatic islets, and Goodpasture's disease affecting the glomerular
and alveolar basement membranes. Systemic lupus erythematosus (SLE) and
rheumatoid arthritis provide examples of the latter.
It is thought that these autoimmune diseases are initiated in a similar manner
to protective adaptive immune responses by the activation of antigen-specific T cells.
Such activation can result in direct and indirect tissue injury. Cytotoxic CD8+ T cells
and macrophages inappropriately activated by CD4+ T cells can result in marked
tissue damage. This damage may be furthered by autoantibodies produced by self-
reactive B cells through inappropriate CD4+ T cell help. These processes also lead to
activation of the other components of the humoral response such as complement
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factors. Although the final response pathways are similar, many questions remain
(Theofilopoulos, 1995):
• The principles governing the nature and extent of the autoimmune
process
• The nature of the inciting antigen
• The nature of the environmental factors precipitating the process
• The nature of the genes that predispose and accelerate the
autoimmune process
• The discriminating characteristics of auto-pathogenic T cells and
antibodies
• The nature of the mechanisms that control relapses and remissions
In the majority, if not all, cases, these questions remain largely unanswered.
Recent data points to a genetic bias towards autoimmunity in the form of an
"autoimmune profile" that was evident even in first-degree relatives of those with
both organ-specific and systemic autoimmune disease (Maas et al., 2002). Such a
profile may form a basis for more specific genetic and environmental factors that
affect the nature and extent of autoimmune disease. One such specific factor is the
inciting antigen, which remains obscure for many human autoimmune diseases,
particularly the systemic diseases. For although the autoantibodies and their
corresponding antigens may be apparent, ambiguities remain as to their relevance in
terms of disease initiation, particularly when there is a large diversity of
autoantibodies in a particular disease process. Moreover, the role and specificity of
auto-reactive T cells remains elusive (Abbas et al., 1996, Roncarolo and Levings,
2000). A better knowledge of the inciting antigen and its relationship to auto¬
reactive T cells would, therefore, act as a springboard to a greater understanding of
the autoimmune disease process by permitting a more thorough dissection of the
other factors involved and their mechanistic relationship. One human autoimmune
disease where a greater understanding of the inciting antigen has been gained is
Goodpasture's Disease (vide infra).
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2.2 Human Glomerulonephritis - The role of the cellular immune
response
Human glomerulolnephritis may be divided into those diseases that primarily
affect the glomeruli and those where the glomerular damage is secondary to a more
systemic disease process. In both instances some diseases will have a better-defined
inciting antigen than others, which are currently idiopathic. The initial work that
established the immune aetiology of glomerulonephritis concentrated on the role of
the humoral arm of the immune system (Reviewed in (Robson, 2000)). The central
hypothesis at that time was that the presence of immune complexes within the
glomeruli initiated a common pathway of activation of the complement system
resulting in neutrophil recruitment and platelet activation with consequent glomerular
injury. However, this hypothesis has proven inadequate at explaining the diversity of
glomerulonephritis and the tendency of glomerular lesions to sclerose (Rovin and
Schreiner, 1991).
Initial studies in human glomerulonephritis showed the presence of
monocytes within the glomeruli particularly in the context of cellular crescents
(Magil and Wadsworth, 1982), although the suggestion at that time was more of a
clearance role for these cells (Magil and Wadsworth, 1981). Further work involving
more than 340 renal biopsy samples stained using the non-specific esterase reaction
to detect monocytes revealed the presence of these cells in proliferative
glomerulonephritis. Indeed, it was found that monocyte infiltration correlated with
proteinuria, cellular crescents and neutrophil infiltration, strongly suggesting a direct
role for these cells in glomerular injury (Ferrario et al., 1985). Using a panel of
monoclonal antibodies Hooke et al (Hooke et al., 1987) found that in proliferative
glomerulonephritis monocyte and granulocyte numbers significantly increased within
the glomerular tuft, without any significant changes to intra-glomerular T cell
numbers. However, they did find significant increases in interstitial T cell numbers
in cases of proliferative glomerulonephritis, and an inverse correlation between total
interstitial leukocyte count and renal function.
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The absence of a significant increase in intra-glomerular T cell numbers was
not born out by other studies using different panels of monoclonal antibodies.
Nolasco et al (Nolasco et al., 1987) found significant increases in overall intra-
glomerular leukocyte numbers in proliferative glomerulonephritis, with a significant
increase in CD4+ T cells in crescentic biopsies, almost exclusively seen within
glomerular tufts. This finding was particularly notable in anti-glomerular basement
membrane disease. Moreover, a significant correlation between total intra-
glomerular T cell and monocyte numbers was found. This finding was noted in
another study (Bolton et al., 1987), which also found an association between
interstitial leukocyte infiltration and renal function. Furthermore, the authors went
on to suggest an inverse correlation between CD4+ T cells and responsiveness to
pulse methlyprednisolone therapy, with anti-GBM disease biopsies revealing the
most marked increase in CD4+ T cells within glomeruli. Neale et al also published
similar findings with respect to intra-glomerular T cell infiltration and fibrin
deposition in proliferative glomerulonephritis (Neale et al., 1988). Markovic-
Lipkovski et al (Markovic-Lipkovski et al., 1990) found indications of activation of
infiltrating leukocytes within and around affected glomeruli in cases of proliferative
glomerulonephritis. Once again, there was a predominance of CD4+ T cells
particularly in cases of rapidly progressive glomerulonephritis. These findings
would suggest more strongly a significant role for the cellular arm of the immune
system, particularly the orchestrating CD4+ T cells, in proliferative
glomerulonephritis. The importance of the cellular arm of the immune system is
particularly well highlighted by a more recent study of pauci-immune (ANCA-
positive) rapidly progressive glomerulonephritis. In this disease the humoral
components are usually absent, but a significant influx of T cells with the majority
expressing a memory phenotype (CD45RO) is seen, together with macrophages and
a local up-regulation of tissue factor indicating cellular activation (Cunningham et
al., 1999). The discrepancies seen between studies may be explained by a multitude
of reasons including timing of biopsies in relation to disease initiation (Markovic-
Lipkovski et al., 1990) as well as antibody sensitivity and specificity.
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Expanding on this foundation of the role of the cellular arm of the immune
response in glomerulonephritis, one must also begin to consider the relative
predominance of specific components of the cellular response. A growing number of
T cell subtypes have been identified in both murine models and human disease
(Mosmann and Sada, 1996). The role of these within the context of
glomerulonephritis has been postulated to explain the different patterns of
glomerulonephritis, although a greater understanding of the role of these T cell
subtypes is still needed to provide a basis for therapeutic intervention (Reviewed in
(Holdsworth et al., 1999)).
2.3 Experimental Crescentic Glomerulonephritis - The role of the
cellular immune response
The role of cell-mediated immunity in glomerulonephritis has been more
clearly demonstrated in experimental models (Alderwegen et ah, 1997, Rovin and
Schreiner, 1991). The importance of such immunity is particularly well
demonstrated by the models of crescentic glomerulonephritis, which were one of the
first to establish an immunological role in such conditions.
Crescentic glomerulonephritis was first induced in sheep by repeated
administration of heterologous crude GBM preparations in Freund's complete
adjuvant (Steblay, 1962). Steblay noted the presence of anti-GBM antibodies to the
heterologous immunising GBM in sheep dying of nephritis, but further postulated a
possible role for sensitised cells. Direct evidence of the role of such "sensitised
cells" came a decade later when Bhan et al (Bhan et ah, 1978) used an implanted
antigen model of crescentic glomerulonephritis. The group transferred rabbit gamma
globulin-sensitised lymph node cells into Lewis rats that had been administered
rabbit anti-rat GBM immunoglobulin. This group found that only those rats given
lymph node cells from donors sensitised to rabbit gamma globulin showed segmental
cellular crescents with necrosis in their glomeruli, whereas those rats given serum
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from the same sensitised donors only showed linear immunoglobulin staining within
their glomeruli.
To this point the evidence for a role for cell-mediated immunity has been
obtained within the context of functional humoral immunity. A chicken model of
experimental allergic glomerulonephritis (EAG) developed by Bolton et al (Bolton et
al., 1984) provided more specific evidence for cellular immunity. In this model
chickens were immunised with bovine glomeruli in FCA and were noted to develop
proliferative crescentic glomerulonephritis with linear deposition of IgG. In the
group of chemically bursectomized chickens, IgG deposition was seldom noted yet
there was no significant difference in glomerular proliferation and crescent formation
between the groups. There was, therefore, no correlation between IgG deposition
and proliferative changes within the glomeruli. This group went on to transfer EAG
by using sensitised mononuclear cells eluted from nephritic kidneys, with these cells
being characterised as lymphocytes (Bolton et al., 1988). Transfer of eluted
immunoglobulin from nephritic kidneys resulted in linear IgG deposition on
glomeruli but without proliferative changes.
Based on Steblay's classic model of crescentic glomerulonephritis, Pusey et
al developed a rat model of EAG using a single injection of homologous GBM
preparation in FCA as the inciting agent in Brown Norway rats (Pusey et al., 1991).
They noted that although the injection of the homologous GBM preparation alone
resulted in the production of anti-GBM antibodies, it was only with the addition of
FCA that glomerular IgG deposition and nephritis occurred. This finding would
indicate a role for T cells in the pathogenesis of glomerulonephritis and would also
be in keeping with the other animal models discussed below. This group have used
this model of EAG to investigate the pivotal role of T cells in disease pathogenesis
(Reynolds et al., 1991, Reynolds et al., 1993). They have also documented disease
prevention through the use of T cell blocking antibodies (Reynolds et al., 2002,
Reynolds and Pusey, 1994, Reynolds et al., 2000). This work is reviewed by
Nikolic-Paterson (Nikolic-Paterson, 2001). Using this model, other groups have
attempted to map the T cell epitopes (Luo et al., 1996). Further confirmation for the
role of CD4+ T cells in mediating crescentic glomerulonephritis has been recently
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obtained by Wu et al using the same model (Wu et al., 2002). This group
demonstrated that transfer of sensitised a3 Type IV NCI-specific T cell lines
resulted in classic crescentic changes within glomeruli although without the antibody
deposition.
Using a murine model of EAG, Kalluri et al (Kalluri et al., 1997) immunised
different mouse strains with bovine a3 Type IV collagen NCI domains. Although
all strains developed antibodies to the bovine antigen, only certain mouse strains
developed glomerulonephritis. This variability was seen to be linked to the murine I-
As region suggesting a role for the T cell repertoire in disease development.
Using an implanted antigen model of crescentic glomerulonephritis similar to
that previously used (Bhan et al., 1978), the group led by Holdsworth and Tipping
have performed a series of experiments that not only reveal T cell participation in
this model of crescentic glomerulonephritis, but also shed some light on the role of
CD4+ T cell subsets. Their basic model is a result of rats being pre-immunised with
sheep globulin in FCA subcutaneously before being administered sheep anti-rat
GBM antibody. Using this model the group was able to demonstrate the
accumulation of intra-glomerular T cells preceding macrophage accumulation, with
the administration of cyclosporin abrogating both the accumulation of T cells and
macrophages, as well as proteinuria (Tipping et al., 1985). As a further refinement,
the group performed a T cell depletion experiment using anti-CD5 and anti-CD4
monoclonal antibodies 24 hours after administering the sheep anti-rat GBM
antibody. This resulted in a significant reduction in CD4+ T cells within glomeruli,
with a significant attenuation of macrophage accumulation and crescent formation
without altering the formation of anti-sheep globulin (Huang et al., 1994). The fact
that T cell depletion did not completely abolish glomerular injury in this model could
suggest that other mechanisms also contribute, although the time delay to depletion
would not fully support this suggestion. Further cell depletion studies using anti-
CD4 or anti-CD8 monoclonal antibody or macrophage depletion by
microencapsulated clodronate indicated that both CD4+ and CD8+ T cells were
necessary for glomerular macrophage recruitment and glomerular injury in the
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Sprague-Dawley rats studied. Moreover, there was no evidence that the CD8+ T
cells acted in a directly cytotoxic manner (Huang et ah, 1997b). In order to perform
these experiments cell deletion knockout mice were used homozygous for CD4
and/or CD8 deficiency. In this setting the mice were not sensitised prior to the
induction of glomerulonephritis using sheep anti-mouse GBM immunoglobulin.
Crescentic glomerulonephritis with severe renal injury developed after 14 to 21 days
in wild type mice, but was more or less completely abrogated in CD4-/- and
combined CD4/CD8 -/- mice. In these mice there was a significant reduction in
macrophage numbers and glomerular injury, once again highlighting the pivotal role
of CD4+ T cells in this model of crescentic glomerulonephritis (Tipping et al., 1998).
Taking the planted antigen model one stage further, the group used the same
principle in immunoglobulin heavy chain (p) deficient mouse strain. These p chain
deficient mice do not develop mature B cells nor do they produce immunoglobulin.
Despite the complete lack of immunoglobulin there was no significant effect on the
development of proliferative crescentic glomerulonephritis (Li et al., 1997). These
final two experiments were replicated by Rosenkranz et al (Rosenkranz et al., 2000)
who also showed the importance of y5 T cells in this model of crescentic
glomerulonephritis.
The importance of the cellular immune system in glomerulonephritis has also
been shown in murine lupus nephritis. Previous work had shown the importance of
B cells (Chan and J. Shlomchik, 1998), but the role of antibodies in this model was
unclear. Using an antibody-deficient strain of the lupus-prone MRL/lpr mouse Chan
et al (Chan et al., 1999) were able to demonstrate interstitial nephritis, vasculitis and
glomerular injury indicating an antibody-independent mechanism for renal and
vascular disease in this model. This model not only shows the importance of the
cellular immune system, but also indicates alternative roles for B cells as antigen
presenting cells (APC's) or cytokine producers activating T cells.
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2.4 Summary
The pivotal role of the cellular arm of the immune system within autoimmune
glomerulonephritis has been demonstrated through both human pathological
assessment using monoclonal antibodies, and experimental animal models. In the
latter case specific cellular depletion experiments clearly point to a central role for T
cells in glomerulonephritis and crescent formation. However, T cells are a
heterogeneous group of cells with different antigen specificities, cytokine release
profiles, and effector functions. Although the role of this group of cells is clearly key
to autoimmune glomerulonephritis, and autoimmune disease in general, a greater
understanding of the T cell phenotypes involved is necessary. Therefore, a better
way of assessing the T cell phenotypes in autoimmune disease is needed. This has
been the impetus behind the development ofMHC multimers (vide infra).
3 Goodpasture's Disease
3.1 Aetiology and Pathogenesis
Goodpasture's disease is a clinical condition characterised by rapidly
progressive glomerulonephritis (Figure 1.1a), pulmonary haemorrhage in 50 - 75%
of cases, and the presence of autoantibodies to a specific component of the
glomerular and alveolar basement membrane that is seen as linear IgG staining
within glomeruli (Figure 1.1b). The disease affects people of both sexes and all ages,
although there are two incidence peaks in the third and sixth decades of life (Hudson
et al., 2003, Savage et al., 1986, Turner and Rees, 1996). The pathogenic nature of
the autoantibodies was established by Lerner (Lerner et al., 1967), and has since been
well documented by several clinical observations (Phelps, 2000). Although the
primary target for the autoimmune response has been well defined, and is localised to
the non-collagenous (NCI) domain of the a3 chain of type IV collagen (Butkowski
et al., 1987, Saus et al., 1988, Wieslander et al., 1984, Wieslander et al., 1987), the
inciting factors have not been clearly defined. As with the majority of autoimmune
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conditions, both genetic and environmental factors appear to be involved in disease
aetiology.
Figure 1.1 - Pathology of Goodpasture's Disease
a) Haematoxylin & eosin stain b) Anti-IgG immunofluorescence
A renal biopsy of a patient with Goodpasture's disease showing a haemorrhagic cellular crescent
occupying the glomerular space (* in a) as well as the linear deposition of IgG along the glomerular
basement membrane stained by direct immunofluorescence (b). (Courtesy ofDr C. Bellamy)
There is strong evidence for HLA-linked disease susceptibility to
Goodpasture's disease, with certain HLA Class II alleles being more frequently
found in patients than controls (Fisher et al., 1997, Phelps and Rees, 1999, Rees et
al., 1984). Although one possibility for this linkage is that of linkage disequilibrium
of other associated genes, the nature of the association with respect to the exact
HLA-DR loci involved strongly suggests that the association is due to the HLA-
DRB1 alleles themselves and their peptide-binding characteristics (Phelps et al.,
2000, Phelps and Rees, 1999). These strong MHC associations, when taken together
with the experimental work outlined above, would suggest that the autoimmune
process in this disease is likely to be T cell dependent. This notion is strengthened by
the class-switched nature of the autoantibody response that also indicates the need
for CD4+ T cell help (Segelmark et al., 1990). Furthermore, recent work has found
an increased frequency of a3(IV) NCI reactive CD4+ T cells during the acute disease
process (Salama et al., 1999, Salama et al., 2001). However, environmental factors
also appear to be important in precipitating the disease process, with reports of
Goodpasture's disease being precipitated by lithotripsy and exposure to hydrocarbon
fumes (Turner and Rees, 1996).
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3.2 The Goodpasture Auto-antigen
3.2.1 The antibody epitope
The Goodpasture antigen was initially localised to the non-collagenous
domain of Type (IV) collagen (Figure 1.2) (Wieslander et al., 1984, Wieslander et
al., 1987, Wieslander et al., 1985), before being finally isolated in 1988 by Hudson
and co-workers who localised the antigen to the NCI domain of the newly
discovered a3(IV) collagen chain (Butkowski et al., 1987, Saus et al., 1988). The
human Goodpasture antigen was later cloned and confirmed to be the NCI domain of
a3(IV) collagen (Turner et al., 1992).
Figure 1.2 - ot3-a4-a5 Type (IV) collagen protomer network
In the glomerular basement membrane each type (IV) collagen protomer is composed of a3, a4 and
a5 (IV) collagen chains in a trimeric association. Protomers create basement-membrane networks by
uniting at their NCI domains to form a hexameric interface, and also uniting four 7S domains at the
N-terminal. The a3-a4-a5 (IV) network differs from other type (IV) collagen networks due to its
greater number of disulfide cross-links between the triple helical domains, which increases its
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The pathogenic nature of the autoantibody response in Goodpasture's Disease
was demonstrated via passive transfer experiments conducted by Lerner et al (Lerner
et al., 1967). The presence and nature of these circulating antibodies was later
confirmed by Wilson et al (Wilson and Dixon, 1973). The autoantibody response
has been demonstrated to be specific to the NCI domain of a3(IV) collagen in
separate laboratories (Dehan et al., 1996, Derry et al., 1991, Neilson et al., 1993,
Saus et al., 1988, Turner et al., 1994). Further, the antibodies appeared to have
restricted specificity (Hellmark et al., 1994, Meyers et al., 1998). Subsequent work
has endeavoured to dissect out the antibody binding epitopes, and in so doing has
alluded to both the conformational and cryptic nature of these epitopes (Flellmark et
al., 1997, Kalluri et al., 1991, Leinonen et al., 1999). Initial studies were performed
using linear peptide sequences and provided conflicting data on the epitopes,
although there was concordance on the limited heterogeneity of the antibody
response. Epitopes were postulated at both the carboxy terminal of the NCI domain
(Kalluri et al., 1991, Kalluri et al., 1996, Penades et al., 1995) and the amino terminal
(Levy et al., 1997, Levy et al., 1996). Later studies used recombinant DNA
technology to engineer chimeric NCI domains using a combination of al type IV
collagen and a3 type IV collagen NCI domain sequences in order to better define the
autoantibody epitopes. These later studies have resulted in a broad agreement that
the major antibody epitope is at the amino terminus («317-31) (Hellmark et al., 1999a,
Hellmark et al., 1999b, Netzer et al., 1999, Ryan et al., 1998), with a further minor
epitope at the carboxy terminus (a3127-141) (Borza et al., 2000, Netzer et al., 1999) of
the a3(IV) NCI domain. More recent work has furthered our understanding of the
conformational nature of the major autoantibody epitope using site-directed
mutagenesis. This has highlighted key amino acid residues within this epitope that
are important to its tertiary and quaternary structure (David et al., 2001, Gunnarsson
et al., 2000). Although the homologous nature of both the major and minor
autoantibody epitopes was alluded to in earlier work (Netzer et al., 1999), the
significance of this has only been recently realised with the crystallographic
determination of the Goodpasture antigen by Hudson and co-workers (Borza et al.,
2002, Sundaramoorthy et al., 2002) (Figure 1.3).
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The three-dimensional structure and the location of epitopes were determined by computer modeling
of the crystal structure of the al-al-a2(lV) NCIhexamer and the apparent quaternary structure of the
e?3-«4-a5(IV)NCl hexamer. The hexamer is composed of two «3 monomers (red), two a4 monomers
(blue), and two aS monomers (green). The locations of the major EA (yellow) and minor EB (orange)
regions that encompass two dominant epitopes for Goodpasture antibodies are depicted. The epitopes
reside in the a3(IV) NCI domain, near the triple helical junction, and they are partially sequestered by
interactions with the a5(IV) and a4(]V) NCI domains, respectively. Adapted from (Hudson et ah,
2003)
3.2.2 The CD4+ T cell epitope
Unlike the B cell mediated antibody response, CD4+ T cells recognize their
antigenic epitopes in the form of processed peptides in association with MHC Class
II molecules on the surface of antigen presenting cells. Furthermore, the affinity of
the immunoglobulin-like T cell receptor is a thousand-fold weaker than the typical
antibody affinity for its ligand such that the binding interaction alone cannot be used
to identify the T cell epitope. Two approaches have therefore been employed in
order to ascertain the presence and identity of T cell epitopes within the Goodpasture
antigen.
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The first approach assesses the proliferative responses of T cells when
incubated with antigen presenting cells that have been pulsed with a3(IV) NCI.
Certainly, this approach has demonstrated that T cells from patients with
Goodpasture's disease specifically proliferated when incubated with either purified
or recombinant a3(IV) NCI domains (Derry et al, 1995, Marelli-Berg et ah, 1996).
This approach has allowed the formation of some short-term CD4+ T cell lines
specific for a3(IV) NCI and restricted by HLA-DR (Marelli-Berg et al., 1996). The
approach has since been refined to delineate the T cell epitopes more precisely using
overlapping peptides to two major areas (a37i.90 and a3131.150), and two minor areas
(a3i-2o and 0,331.50) (Cairns et al., 2003, Cairns et al., 1999). Two of these epitopes
are close to the major (0,331.50) and minor (ot3i3i_i5o) antibody epitopes. Although
this provides valuable information on T cell epitopes, it does not provide information
concerning the specific cell phenotypes. Therefore, significant problems still remain
with this. Foremost amongst these is the relatively low frequency of antigen-specific
T cells in peripheral blood such that their in vitro expansion may result in the
expansion of apparently irrelevant T cell populations (Merkel et al., 1996), at the
expense ofpoorly proliferating yet autoantigen-specific T cells. This latter issue was
addressed to a small extent by the more recent study of Caims et al that utilised
cytokine analysis of the responding T cells and blocking monoclonal antibodies
against MFIC antigens (Cairns et al., 2003). This study confirmed that the
proliferative cell response to the a3(NCl) peptides was mediated by T cells
restricted predominantly by HLA-DR. However, the techniques used bulk T cell
cultures that are likely to have blurred important details of the responses seen.
The second approach utilized biochemical techniques to tease out which
peptides from the a3(NCl) domain are processed and displayed to T cells for their
immune recognition. This approach has identified three groups of peptides each
centred on a common core sequence and about the length of the MHC Class II
peptide-binding groove (a32i-40, ot36i-go, a3i6i-i8o)- Interestingly, the naturally
processed and presented peptide nested sets had intermediate affinity for HLA-
DR15. The inference from this finding is that antigen presentation to T cells in this
situation is affected more by processing constraints rather than antigen-MHC Class II
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affinity (Phelps, 2000, Phelps et al., 2000, Phelps et al., 1998, Phelps et ah, 1996).
These findings, however, must be taken in the context of the contrived in vitro
system from which they were found.
Despite the drawbacks of the two separate approaches, there does appear to
be some agreement between them. The data from the T cell proliferation
experiments show that two of the four epitopes (a33i.5o and a37i-9o) overlap two of
the naturally processed epitopes (a32i-4o and a36i-8o)- These epitopes overlap with
the antibody epitopes. More recent work indicates the exquisite sensitivity of the
postulated T cell epitopes to cleavage by endosomal proteases (Phelps, personal
communication). This would appear to reiterate the suggestion of processing
constraints affecting peptide presentation.
3.3 A Model Disease
Studies on autoimmunity to date have focused on experimental work using
inbred animal strains, primarily mouse and rat models of various autoimmune
disease processes. Few of these models are clearly defined with respect to their
inciting antigen, MHC linkage or their relationship to their human counterparts, and
as such dissecting out disease mechanisms becomes difficult. In contrast to this lack
of clarity, Goodpasture's disease, although an uncommon clinical entity, is emerging
as an archetypal autoimmune disease in many ways.
First, the auto-antigenic target has been clearly established as the a3(NCl)
domain of type IV collagen as indicated above. Furthermore, recombinant
expression of this antigen has been established enabling more detailed dissection of
the antigenic epitopes (Hudson et al., 1993a, Hudson et al., 1993b, Turner et al.,
1992). This has more recently resulted in the identification of the crystallographic
structure of the antigen (Sundaramoorthy et al., 2002). The unequivocal
determination of an inciting antigen with such clarity is certainly uncommon
amongst autoimmune conditions (Elson and Barker, 2000). Furthermore, the
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relatively small size of the antigen permits for more detailed examination of the
interactions between antigenic peptides and MHC Class II molecules.
Second, and in addition to the above, information is gathering as to the
processing and presentation of a3(IV) NCI (Phelps et al., 1998, Phelps et al., 1996).
This information is simply not available for any other autoimmune disease or
experimental model. To date this information has enabled more detailed assessment
of the autoimmune response in this disease setting (Cairns et al., 2003).
Furthermore, such dissection of the antigen has enabled the identification of not only
the antibody-binding epitopes, but has also led to the identification of the main T cell
epitopes.
Third, there are distinct HLA associations (Fisher et al., 1997, Huey et al.,
1993, Phelps and Rees, 1999, Rees et al., 1984). The positive association of HLA-
DRB1*1501 with Goodpasture's disease is amongst the strongest reported for
autoimmune diseases. Other HLA-DRB1 alleles also appear to influence disease
outcome from susceptibility (HLA-DRB1*04) through neutrality (IILA-DRB1 *03)
to protection (HLA-DRB1*07) (Phelps and Rees, 1999). Although such an
association could be related to linkage disequilibrium of an associated gene, current
work v/ould indicate that the association is directly related to the peptide-binding
characteristics of the HLA molecules themselves (Phelps et al., 2000, Phelps and
Rees, 1999). The limited number of alleles involved also simplifies further analysis.
Fourth, Goodpasture's disease has a consistent presentation and course across
populations. It has a definite period of onset and tends to present as a severe
glomerulonephritis that progresses to end-stage renal failure within weeks to months.
It is usually a "one-shot" disease rather than a relapsing-remitting disease like some
autoimmune conditions. Effective treatment protocols are available and activity can
be monitored through an assessment ofautoantibody levels (Reviewed in (Phelps and
Turner, 2000, Turner and Rees, 1996)). The relatively well-defined nature of disease
initiation and termination with or without therapy would allow assessment and
comparison of the immune response over the entire period of disease activity and
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recovery. This may well provide further information into tolerance breakdown and
recovery in autoimmune diseases.
Fifth, although quite good rat models exist, murine models of Goodpasture's
disease are being actively developed both within inbred strains and in HLA-DR
transgenic animals (Dr Phelps, personal communication). Furthermore, several
stable T cell clones and hybridomas which recognise human a3(IV)NCl-derived
peptides have been generated in Balb/c mice (Bowie et al, Aberdeen, unpublished)
and in HLA-DR15 transgenic mice (Marley et al, Edinburgh, unpublished).
The detailed knowledge of both the antigen and HLA-DR association
therefore provide a unique opportunity to study the cellular arm of the immune
response within an autoimmune disease in man, whilst the presence of a murine
disease model allows for more detailed parallel investigation. Furthermore, such
detailed knowledge also provides the exceptional prospect of utilising recent
innovations in T cell assessment through the use of MHC Class II tetramer
technology vide infra.
4 Established Methods of T cell Assessment
4.1 Identifying Antigen-specific T cells
The role of the cellular arm of the immune system in general and in
association with the humoral arm in autoimmune disease states is well documented
(Janeway et al., 2001). However, a major obstacle to the study of human
autoimmunity has been the difficulty of identifying the autoantigen-specific T
lymphocytes that are fundamental to the initiation and perpetuation of the
autoimmune response. T cells are more difficult to characterise than plasma cells
due to their more diverse functionality, and the technical difficulty of studying their
membrane-bound receptors as compared to secreted antibodies. As a result of these
difficulties, many techniques have been developed to identify, enumerate and
characterise autoantigen-specific T lymphocytes to date, however, their sensitivity,
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specificity and utility have not always been ideally suited to the task in hand
(Reviewed in (Hickling, 1999)). The main techniques are briefly described below.
Other techniques are available for use in murine models exploiting the possibility of
TCR transgenic animals through the use of specific V region monoclonal antibodies
(McHeyzer-Williams and Davis, 1995) and multiparameter flow cytometry
(McHeyzer-Williams et al., 1996). However, these techniques are not extendable to
human studies.
4.2 Lymphoproliferation Assay
This assay relies upon antigen-specific T cells proliferating in response to
their specific antigen. This is usually measured from the incorporation of tritiated
thymidine into their DNA. PBMC's are incubated in the presence of either the test
antigen or a control stimulus for 3-7 days before tritiated thymidine is add for 6-18
hours prior to assessing the amount of incorporated radiolabel. The amount of
incorporated radiolabel provides a measure of DNA synthesis for the whole cell
population, and needs to be compared to a similar cell population that has only been
incubated in culture medium or in the presence of a control antigen. The results are
usually expressed as a ratio or stimulation index.
This assay provides a good indication of T cell division in response to a test
antigen, but does not necessarily reflect the complete response of the T cell
population to the stimulus. Some T cells may simply respond through cytokine
release without undergoing proliferation. Therefore, it does not allow for assessment
of individual cell responses, and in its simplest state is neither sensitive nor
quantitative enough to allow a longitudinal comparison of the numbers of antigen-
specific T cells in a series of PBMC samples (Hickling, 1999).
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4.3 Limiting-Dilution Assay
Limiting dilution analysis estimates the 'precursor frequency' of T cells with
a particular specificity. Successful application of this technique requires antigen-
specific precursors within the PBMC population that both respond and survive over
the culture period, and a means of analysing this response through proliferation,
cytokine production or cytotoxicity.
Multiple lymphoproliferation assays are prepared using an excess of specific
antigen, growth factors and irradiated antigen-presenting cells, to which dilutions of
the cell population under investigation are added such that the only limiting
parameter is the number of antigen-specific T cells present. At least 24 replications
of each dilution are set up. The cells are cultured for 10-14 days to allow
differentiation and expansion. Functional assays can then be used to assess cytokine
production within the culture supernatant or cytotoxicity of the expanded T cell
population within each microtitre well. Assuming that 'single-hit' kinetics apply, the
number of non-responding wells follows a Poisson distribution, and from this
statistical approaches can be used to calculate the precursor cell frequency.
The assay is not only critically dependent upon cell survival in vitro and a
detectable functional end-point, it is critically dependent on a clear distinction
between 'positive' and 'negative' wells. The definition of a 'positive' well may
involve defining a threshold, and in so doing the estimate of precursor frequency can
be greatly affected by even the slightest alteration of this subjective threshold.
Although there have been developments of this technique, the overall drawbacks
remain unchanged. Furthermore, the assay does not provide a measure of the
effector function of the responding cells, and serves only to give an indication of T
cell responsiveness (Ford and Burger, 1983). This has been recognized recently in
the comparison of this technique to that of MHC tetramers, with the latter
demonstrating the functionally diverse nature of the polyclonal response to a single
antigen (Lim et al., 2000).
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Despite these drawbacks, much has been gleaned using this technique as
regards T cell frequency and effector type in the setting of autoimmune disease in
general (Zhang et al., 1994), and specifically in the context ofGoodpasture's Disease
(Lightstone et ah, 2001, Salama et ah, 1999, Salama et ah, 2001). Salama et al found
increased frequencies of CD4+ T cells reactive with «3(IV) NCI during acute
Goodpasture's Disease (ranging from 1:6300 to 1:65000), with the numbers
decreasing during recovery (Salama et ah, 2001).
4.4 ELISPOT Assay
The ELISPOT assay is an adaptation of the antigen-capture ELISA technique
into a more sensitive method for measuring the responses of T cell populations to
their cognate antigen. The assay detects the production of cytokines by activated
antigen-specific T cells that have been incubated in vitro with the antigen of interest.
The PBMC population of interest is incubated with the antigen of interest for 18-36
hours before adding the cells to microtitre wells that have been pre-coated with an
anti-cytokine antibody. If an activated T cell is secreting the cytokine of interest it
will be captured by the coating antibody. Once the cells are removed from the wells
a second antibody to the cytokine that is enzyme labelled can be added to reveal the
presence of cytokine-producing cells by the visualised 'spots' in the wells (Hickling,
1999, Tough and Sprent, 1998).
This assay is 20-100 fold more sensitive than the LDA in measuring the
frequency of specific T cells (Murali-Krishna et al., 1998, Tough and Sprent, 1998).
The disadvantages of this technique include the need for manual enumeration of the
spots so adding subjectiveness to the process, the requirement for at least a period of
in vitro incubation, and the difficulty of determining whether individual cells are
capable of secreting mixtures of cytokines as has been postulated (Abbas et al., 1996,
Kelso, 1995).
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4.5 Intracellular Cytokine Analysis
Flow cytometry techniques have been developed to allow the analysis of
intracellular cytokines to assess the frequency and phenotype of antigen-specific T
cell populations. This technique allows for the simultaneous analysis of multiple
cytokines at the level of a single T cell (Waldrop et al., 1997), although the cells
require permeabilisation. The cells of interest are stimulated for about 5 hours with
the antigen of interest in the presence of an inhibitor of intracellular protein transport
(eg brefeldin A) to promote the intracellular accumulation of cytokines. The cells
are then fixed and permeabilised before being stained for the presence of the
cytokines of interest using directly conjugated anti-cytokine monoclonal antibodies.
The technique allows for the analysis of large numbers of T cells in a short
period of time as well as enabling better phenotypic assessment of individual T cells
within the stimulated T cell population. Like the ELISPOT assay, this technique is
not reliant upon cell proliferation and the minimal stimulation times improve assay
sensitivity. The major disadvantages, however, are that the T cells have to be killed
and permeabilised in order to detect them, and that the antigenic specificity of
individual T cells cannot be assessed.
4.6 Cell Surface Affinity Matrix Assay
This technique was developed as a refinement of the above in order to allow
for the analysis and sorting of live cells according to the molecules secreted. In
essence an artificial matrix specific to the cytokine of interest is created on the cell
surface using bi-specific antibodies prior to the cells being activated with the antigen
of interest for a defined period of time. The secreted cytokines bind to the matrix
and are subsequently labelled with specific fluorescent or magnetic reagents to allow
for cytometric analysis and sorting of the live cells. In order to prevent diffusion of
the selected cytokine away from the secreting cell, the growth medium is made more
viscose during the stimulation period (Manz et al., 1995).
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Although a sensitive technique that allows for the isolation of live T cells,
one of the main drawbacks is that the affinity matrix is specific to only one cytokine .
Nevertheless, it has been successfully used to isolate functionally active antigen-
specific CD8+ T cells (Oelke et ah, 2000).
5 Major Histocompatibility Complex Multimers
5.1 The T Cell Receptor Ligand
Over the last decade the crystal structures of TCRs and TCR-ligand
complexes have been elucidated (Reinherz et ah, 1999). In contrast to
immunoglobulins, T cells only recognise their cognate antigens on cell surfaces in
association with self-MHC molecules. Furthermore, the cognate antigen is a small
peptide derived from the processing of the whole antigen, varying in length from 8-
10 amino acids (MHC Class I - CD8+ T cell interaction) (Falk et ah, 1991, Hunt et
ah, 1992, VanBleek and Nathenson, 1990) to 13-17 amino acids (MHC Class II -
CD4+ T cell interaction) (Chicz et ah, 1993, Chicz et ah, 1992, Rudensky et ah,
1992, Rudensky et ah, 1991). The peptide antigen is held within a defined peptide-
binding groove formed by the MHC molecule (Buus et ah, 1987), with the nature of
the groove differing between MHC Class I (Figure 1.4) and Class II (Figure 1.5)
molecules (Gauthier et ah, 1998, Smith et ah, 1998, Stern et ah, 1994). The
assessment of TCR-ligand interactions has been difficult not only due to the
membrane-bound nature of the primary molecules but also due to their very low
affinity which has required technological innovations for its assessment (Reviewed
in (Davis et ah, 1998)).
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Peptides are bound to the MHC class 1 molecules by their ends. At the amino terminus a cluster of
tyrosine residues common to all MHC class I molecules form hydrogen bonds with the bound peptide,
while a second cluster of residues form hydrogen bonds and ionic interactions with the carboxy
terminus of the bound peptide (Janeway et al., 2001).









Peptides are bound to MHC class II molecules by a series of hydrogen bond interactions along the
length of the binding groove that is open at both ends. At the amino terminus the hydrogen bonds are
made with the MHC class II polypeptide backbone, whereas over the length of the peptide interactions
are with the side chains ofhighly conserved amino acid residues (Janeway et al., 2001).
Chapter 1 - Introduction 23
Formation ofMHC Class II - Peptide Multimers
One of the major problems with previously established techniques for
tracking antigen-specific T cells is their use of surrogate markers of antigen
specificity and/or their reliance on functional assays of T cell proliferation or
cytokine secretion that may therefore result in a significant underestimation of
antigen-specific T cell numbers. Moreover, by their nature these techniques would
be unable to provide clear phenotypic data on antigen-specific T cells. Unlike the B
cell compartment where ligand binding can be used to specifically track B cells
(Hayakawa et al., 1987, McHeyzer-Williams et al., 1991), the inherently low affinity
of the bipartite T cell ligand has hampered this as a tracking technique (Davis et al.,
1998, Matsui et al., 1991). Therefore, in order to utilise the TCR-ligand interaction
as a tracking technique one must have information regarding both the TCR-MHC
restriction as well as knowledge of the bound antigenic peptides related to the
specific MHC restriction.
5.2 Development of MHC Class I Multimers
Altman et al have developed a technique to circumvent the fast dissociation
rate ofmonomeric soluble peptide-MHC complexes from their T cell ligand (Altman
et al., 1996). Soluble peptide-MHC complexes were formed into multimeric units
enabling more than one TCR per antigen-specific T cell to be bound, slowing their
inherently fast dissociation rate and increasing the avidity of the complex through
this simultaneous and serial engagement process (Matsui et al., 1994). By linking
these multimeric complexes to a fluorochrome they could be used as an
immunological stain (Figure 1.6). This approach involved the production of soluble
HLA-A2 alpha chains (Garboczi et al., 1992) that had been modified at the COOH-
terminus by the addition a 15-amino acid substrate peptide for BirA-dependent
biotinylation (BSP) (Schatz, 1993). The alpha chains were produced in E.coli as
inclusion bodies and refolded in the presence of [32-microgIobulin and the specific
antigenic peptide prior to purification and biotinylation. The COOH-terminus
biotinylation served to both correctly orientate the refolded monomers and
tetramerise them by binding to phycoerthyrin-labeled avidin in a 4.1 molar ratio.
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Figure 1.6 —MHC Class I tetramer
A schematic adapted from (Hugues et al., 2002) illustrating four MHC Class I units each with a linked
peptide covalently bound to fluorochrome-labelled streptavidin. This illustrates the archetype MHC
Class 1 tetramer.
Using this strategy and refolding with two different HLA-A2-restricted HIV
epitopes - Gag (77-85) and reverse transcriptase Pol (309-317) - the investigators
were not only able to specifically stain HLA-A2-restricted HIV-specific CTL lines
and clones, but were also able to demonstrate the antigen-specific functionality of the
stained cells by using cytotoxicity assays. The reagents were also able to identify
antigen-specific CD8+ T cells from an HLA-A0201+ HIV-seropositive donor's
peripheral blood mononuclear cells using flow cytometry. The specificity of the
isolated cells was confirmed using peptide-dependent cytotoxicity. The frequency of
antigen-specific T cells identified using these reagents was seen to be in keeping with
estimates from TCR cDNA libraries and 10- to 50-fold greater than frequencies
previously obtained using LDA. The utility of this methodology was further
demonstrated by using it to phenotype the antigen-specific CD8 T cells isolated
(Altman et al., 1996).
This technique has revolutionised the study of complex antigen-specific
CD8+ T cell populations. The approach, including monomer formation in E.coli, has
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now become a standard technique for tracking and analysing antigen-specific CD8+
T cells and has resulted in significant changes to our understanding of CD8+ T cell
dynamics (Doherty, 1998, Ogg and McMichael, 1998). These are outlined briefly
below:
5.2.1 The anti-viral T cell response
One of the first questions to be tackled using tetramers was that of T cell
number and phenotype during viral infection. Murali-Krishna et al (Murali-Krishna
et al., 1998) assessed the T cell response in C57BL/6 and BALB/c mice during the
course of a primary infection by the lymphocytic choriomeningitis virus (LCMV).
This group found the size of the specific viral response to be higher than previously
demonstrated using LDA. 23% of CD8+ T cells in C57BL/6 mice and 56% of CD8+
T cells in BALB/c mice were found to be specific to the single LCMV epitope tested
using MHC class I tetramers, and were also noted to be functional using an IFNy
ELISPOT assay. Therefore, the suggestion from this is that the T cell proliferation
seen with viral infections is primarily antigen-specific, rather than bystander
activation. Moreover, in following the course of the immune response, it was found
that only approximately 5% of the activated CD8+ T cells entered into the memory
pool, with the size of this pool being dependent on the initial response burst size.
This finding of antigen-specific expansion rather than bystander activation was also
found in humans in the context of Epstein-Barr virus (EBV) infection (Callan et al.,
1998).
Extending their initial development ofMHC class I tetramers, Ogg et al (Ogg
et al., 1998) used HLA-A*0201 tetramers loaded with either HIV Gag (77-85) or
HIV Pol (476-484) to assess the correlation between HIV-specific CTL activity and
plasma RNA viral load. Using two-colour FACS staining they were able to detect
tetramer-positive cells at levels as low as 0.02% of CD8 T cells, finding a
significant positive correlation between tetramer staining and fresh cytolysis using
51Cr-release cytotoxic assay. They were also able to show an inverse association
between HLA-A*0201-restricted HIV-specific effector CTLs and plasma viral RNA
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load. Gray et al {Gray, 1999 #65} independently confirmed the frequency of HIV-
specific CD8 T cells, although their findings showed that the tetramer-positive cells
were primarily of memory rather than effector phenotype. Moreover, they showed
that anti-retroviral therapy reduces both viral RNA load and activated HIV-specific
CTLs, suggesting that without consistent stimulation antigen-specific CTLs
disappear.
The pattern of immune response has also been followed during bacterial
infection. Using the model of Listeria monocytogenes infection of BALB/c mice
Busch et al (Busch et al., 1998) were able to demonstrate synchronous changes in
L.monocytogenes-specific CTL populations differing in epitope specificity.
5.2.2 Evolution of the T cell response
Further studies using L.monocytogenes epitope loaded MHC class I tetramers
revealed that activated effector CTL proliferation could occur in the absence of the
specific antigen, but that memory CTL generation required antigen presentation.
Moreover, the memory response is established before the completion of the primary
T cell response (Busch et al., 2000). The maturation of the CTL memory response
was also assessed using a novel approach based on MFIC class I tetramer association
and dissociation rates in the context of an L.monocytogenes epitope. This technique
showed an increase in overall T cell affinity for antigen as the memory T cells
expanded to form recall effector T cells (Busch and Pamer, 1999). The idea of clonal
maturation of the immune response is supported independently by a study using
multiparameter flow cytometry (McHeyzer-Williams et al., 1996).
Similar work on CD8+ T cell populations was also carried out using the
LCMV model that revealed the stochastic nature of the memory T cell pool
(Blattman et al., 2000). This latter group did not, however, find the same affinity
maturation in the T cell response as noted above.
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5.2.3 Characterization ofauto-antigen specific T cells
MHC class I tetramers have also been used to characterize the TCR affinity to
a potential auto-antigenic peptide over the course of development of overt diabetes in
NOD mice (Amrani et al., 2000). This group found an outgrowth of T cells
expressing higher avidity TCRs as the disease progressed, with the TCR reactivity
becoming more focused in terms of epitope recognition.
Taking this one stage further, self-specific T cells have been traced using
MHC class I tetramer technology in the context of a transgenic mouse with an
oligoclonal self-specific T cell population (Visser et ah, 2000). In this model,
C57BL/10 mice express influenza nucleoprotein (NP) fragment 328-498 under the
control of the H-2K promoter resulting in negative selection of T cells expressing a
transgenic TCR specific for NP366-374. Despite this selection, T cells with TCRs
having a low avidity for NP366-374 were found using murine MHC class I (Db)
tetramers loaded with NP366-374. This indicates that, at least in this model, low
avidity T cells can escape negative selection mechanisms, and that tetramer
technology can be used to identify these self-reactive T cells.
5.2.4 Sensitivity and specificity ofpeptide-MHC class I tetramers
Although the specificity of this technique was assessed in each of the studies
above, Burrows et al (Burrows et al., 2000b) further investigated the fine specificity
of the approach. The group used a panel of EBV responsive CTL clones and a panel
of HLA-B8 tetramers loaded with either the relevant EBV epitope or single amino
acid variants of this. The study clearly demonstrated the ability of the tetramers to
stain specific clones with an intensity that correlated with the peptide activity in
cytotoxicity assays irrespective of the tetramer staining temperature. Moreover,
tetramer staining of fresh PBMCs was just as specific as T cell clones. One
interesting point found in this study was that a peptide-MHC complex that binds an
antigen-specific T cell might be a null ligand for the T cell, and as such fail to induce
a productive signal (agonist or antagonist). The findings were replicated in a
different system, although in this instance null ligands did not bind to antigen-
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specific T cells (Buslepp et al., 2001). Broadly speaking these studies suggest that
peptide-MHC tetramer staining correlates with the functional avidity of CTL clones.
A study by Derby et al (Derby et al., 2001) would add a cautionary note to this broad
statement, as they found that two intermediate-avidity clones showed an inverse
relationship with tetramer staining that was not entirely accounted for by
compensating for TCR levels. Once again, the staining temperature did not affect the
final outcome. A study by Echchakir et al also found a lack of correlation
(Echchakir et al., 2002). Therefore, the correlation with functional avidity may not
be as direct as initially suggested, rather the association may be related to tetramer
binding stability (Dutoit et al., 2002).
MHC class I tetramers have also been used to select CD8+ T cells for
cloning. Dunbar et al (Dunbar et al., 1998) used HLA-A2 tetramers loaded with
influenza matrix protein peptide 58-66 to identify and phenotype reactive CD8+ T
cells form PBMCs of HLA-A2+ individuals. They were able to identify antigen-
specific T cells at levels as low as 1 in 58,000 PBMCs, and were also able to
phenotype and clone these cells. Lim et al (Lim et al., 2000) used HLA-A2 loaded
with HTLV-I Taxi 1-19 peptide to isolate Tax 11-19-reactive T cells from PBMCs of
an HLA-A*0201 -expressing patient with HTLV-I-associated myelopathy. Of the 25
tetramer binding CTL clones tested 17 different clonal populations were identified by
determination of TCR Vfl-chain usage. The cytotoxic effector function of the 9
clones tested was found to be nearly identical, in broad agreement with the
suggestion that tetramer staining correlates with CTL functional avidity. Despite
their similarities in cytotoxicity assays, these clones were qualitatively different in
terms of proliferation and cytokine production, highlighting the benefits of this
technology at better delineating T cell phenotype.
The findings above highlight one of the advantages of this T cell assay
technique in being independent of T cell survival, expansion or effector function.
One caveat to this advantage, however, was raised by a study of plasma membrane
lipid-rafts and TCR arrangement on CD8+ T cells (Drakelll and Braciale, 2001).
This study found that disruption of plasma membrane lipid organisation resulted in a
loss of tetramer binding without altering TCR levels, and further indicated that there
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is a transition to tetramer binding upon activation of antigen-specific CTLs. This
finding would, therefore, suggest that the technique might not be able to identify
naive-resting CTLs. Further work independently confirmed this notion, showing
differences between the binding of dimeric peptide-MHC complexes to naive and
activated CD8+ T cells at low concentrations of dimeric peptide-MFIC complex
(Fahmy et al., 2001). This latter group also highlighted the role of lipid rafts in TCR
rearrangement, and showed that the addition of cholesterol to naive CD8+ T cells
enhanced their avidity for the dimeric peptide-MHC complexes at low concentrations
of complex.
The studies performed with MHC class I tetramers have all used a double-
labelling approach with anti-CD8 antibodies. The possibility of such antibodies
blocking tetramer interaction has been raised indicating that CD8 may play a critical
role in the initial interaction between peptide-MHC class I tetramers and their
cognate TCR ligand (Denkberg et ah, 2001). This highlights the importance of
sequential staining with tetramer complex prior to anti-CD8 antibody.
The tetramer approach has also been used to stain CD8+ T cells in both frozen
and lightly fixed tissue sections, extending the method to archival specimens. The
technique required amplification of the tetramer stain by using rabbit anti-FITC
antibodies and Cy3-conjugated goat anti-rabbit antibodies. Moreover, the blocking
effect of some anti-CD8 antibodies on tetramer staining was again found (Skinner et
al., 2000).
5.2.5 Therapeutic potential
With the potential to isolate antigen-specific CTLs, the therapeutic potential
of MHC class I tetramers has also been keenly investigated (Reviewed in (Xu and
Screaton, 2002)). The primary approach has investigated the utility of using this
technology to identify antigen-specific CTLs in order to adoptively transfer them for
therapeutic purposes. The second approach has investigated the use of antigen-MHC
Class I tetramers as a form of antigen-specific immunotherapy.
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Yee et al (Yee et al., 1999) formed an array of CTL clones from human
HLA-A2 donor PBMCs reactive with one of two human melanoma antigens,
MART-1 and gplOO. Having formed these clones HLA-A2 tetramers were loaded
with one of two epitopes from these antigens and used to identify high and low
avidity T cell subpopulations from both the T cell clones and heterogeneous cultures
of bulk stimulated CTLs. They concluded that it would be possible to isolate
tumour-reactive CTLs for adoptive therapy. Of interest to the above discussion,
Echchakir et al (Echchakir et al., 2002) used HLA-A2 tetramers loaded with a
mutated a-actinin-4 peptide (an antigenic peptide isolated from non-small cell lung
cancer) to show a higher functional avidity of tumour-infiltrating CTLs compared to
those isolated from PBMCs. The suggestion of selective in situ expansion of
functionally higher avidity anti-tumour CTLs may have a bearing on such
immunotherapy.
Another group has taken a further step towards peptide-specific
immunotherapy by targeting tumour lysis using MHC class I tetramers (Robert et al.,
2000). Specific anti-tumour marker monoclonal antibody Fab fragments were
chemically coupled to the streptavidin molecules that were used to tetramerise
biotinylated HLA-A2-influenza matrix peptide monomers. These conjugates were
able to specifically bind cell lines expressing the relevant tumour antigen (e.g. CEA)
and were specifically lysed by influenza matrix peptide-specific CTLs. Although an
entirely in vitro experiment, targeting of tumour cells using similar techniques is
feasible if a similar but smaller conjugate could be constructed to improve in vivo
targeting.
A different approach to anti-tumour therapy would be to isolate and generate
peptide-specific alloreactive T cells against a synthetic peptide bound to nonself-
MHC molecules. The sensitivity of the tetramer approach in identifying such
allorestricted T cells from a population of alloreactive T cells was demonstrated by
Moris et al (Moris et al., 2001). This group suggested that such an approach could
be also be used to generate donor allorestricted CTLs specific for a leukaemia
tumour antigen to enhance graft-vs-leukamia reaction at the time of allogeneic bone
marrow transplantation.
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Maile et al (Maile et al., 2001) investigated the possibility of immune
response modulation using MHC class I tetramers as direct immune modulators.
Using H-2Db tetramers loaded with HY peptide (male antigen), they were able to
identify male-antigen-reactive CTLs in two sets of female mice (wild-type C57BL/6
and HYTCR transgenic mice). Moreover, they noted that although a single dose of
the tetramer resulted in priming of the T cell response to male skin grafts, repeated
intraperitoneal doses of the peptide-loaded tetramer resulted in reduced T cell
responsiveness to male skin grafts. This was noted to be associated with reduced
levels of CD8, and may well be due to activation-induced cell death of the more
responsive CTLs. This work not only raised the possibility of antigen-specific
immunotherapy, but also highlighted the utility of the tetramer approach in
identifying antigen-specific T cells in naive animals.
5.2.6 Utility of the tetramer approach
From the above discussion it can be seen that this new approach has seen a
revolution in our understanding of the CTL response. The technique is exquisitely
specific and sensitive, detecting antigen-specific CD8+ T cells down to a level of
0.02% (Dunbar et al., 1998), although it may not be as sensitive as initially thought
in identifying nai've antigen-specific T cells (Drakelll and Braciale, 2001). However,
the approach has enabled improved CTL cloning and has been shown to provide a
possible alternative approach to assessing TCR functional avidity (Dutoit et al.,
2002, Lim et ai., 2000). The door has also been opened to peptide-specific
immunotherapy. The discrepancies with the well established LDA reveal that the
latter is able to detect only those T cells with long term growth potential, rather than
the true antigen-reactive pool (Kuroda et al., 1998, McMichael and O'Callaghan,
1998). Moreover, there is no evidence that this tetrameric approach overestimates
the number of antigen-specific T cells (McMichael and Kelleher, 1999).
Although this technique is able to detect antigen-specific T cells independent
of survival, expansion or effector function, its one major drawback is that the
antigenic epitope must be known in the context of a particular MHC class I. Thus,
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the reagents must be custom made for each individual TCR ligand specificity.
However, the success of this new technique is highlighted by the establishment of a
tetramer synthesis facility by the National Institute of Health in the United States
(http://www.niaid.nih.gov/reposit/tetramer/index.html). This facility not only
provides for custom synthesis of MHC class I tetramers, but also offers information
on tetramer synthesis and staining protocols (Dunbar and Ogg, 2002).
5.3 Development of MHC class II Multimers
The development of MHC class I multimers offered the potential for
enormous advances in other research areas involving not only MHC class II-
restricted CD4+ T cells, but also NK cells and glycolipid-specific T cells restricted by
CD1 isoforms (Dunbar and Ogg, 2002). However, these other avenues have required
the development of new techniques to form the monomeric building blocks of the
final functional oligomers. Indeed, the inertia experienced in developing MHC class
II oligomers led to the convening of a workshop at the US National Institute of
Allergy and Infectious Diseases in September 2002 to address the problems faced.
The consensus reached was that whereas many pMHC class II tetramers have been
proven to be effective, why others have been less than useful remains "an inexact
science" (Hackett and Sharma, 2002).
Fundamental differences between MHC class I and class II molecules have
certainly hindered the engineering of stable MHC class II protein constructs
(McMichael and Kelleher, 1999). One of the most fundamental differences is the
essentially monomeric nature of the MHC class I peptide binding groove, with the
single MHC class I heavy chain being stable in solution complexed with its
essentially invariant light chain, p2-microglobulin. In stark contrast, the MHC class
II peptide-binding groove is formed by two heterodimeric heavy chains that tend to
dissociate if not associated with a cell membrane or high-affinity peptide. Moreover,
whereas the MHC class I peptide-binding groove is enclosed so limiting the size and
position of bound peptides, the MHC class II peptide-binding groove is open-ended
Chapter 1 - Introduction 33
Formation ofMHC Class II - Peptide Multimers
so accommodating peptides of considerably different lengths (Chicz et al., 1992,
Rudensky et al., 1992). The peptides bound to MHC class II can, therefore, bind in
two or more frames making the definition of a peptide-binding motif a unique
challenge to MHC class II (Buus, 1999, Chicz et al., 1993, Godkin et al., 2001,
Kasson et al., 2000). Although many of these differences and their associated
problems can and have been overcome, the remaining issues in this field have
hindered further development. These issues include circulating CD4+ T cell
frequency, TCR avidity, T cell activation state and staining properties (Cameron et
al., 2001, Kwok et al., 2002).
5.3.1 The generation ofpeptide-MHC class II complexes
One of the first hurdles in the formation of MHC class II oligomers is the
formation of the monomeric subunits. Initially soluble MHC class II proteins were
prepared by proteolytic cleavage of the extracellular domains from B cell lines
(Gorga et al., 1987). However, the complexes purified had a high degree of
endogenous peptide occupancy making homogenous loading with a defined peptide
difficult (Dornmair and McConnell, 1990). Such MHC class II proteins would also
require further modification to enable their oligomerisation. Two alternative
techniques for the consistent production of homogenous MHC class II proteins were
developed: expression of MHC class II subunits in E.coli followed by in vitro
refolding, and secretion of soluble folded MHC class II protein from insect cells.
The bacterial expression system has had limited success, with several human
and murine MHC class II proteins being produced, but has been hampered by the
intrinsic structural instability of soluble MHC class II proteins. The murine MHC
class II protein I-Ek was one of the first to be produced using this expression system.
The basic technique involves the separate formation of the a and (3 chains within
bacterial inclusion bodies followed by purification of the separate chains. The
purified chains are then refolded by rapid dilution into a refolding buffer with or
without the antigenic peptide of interest. The proteins formed were demonstrated to
be conformationally correct and able to stimulate antigen-specific T-cells,
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demonstrating that glycosylation was not necessary for these properties (Altman et
al, 1993). The I-Ek proteins formed by this group have since been used in the
formation of tetramers by the addition of a BSP at the carboxy-terminal of the
truncated I-Eka chain allowing tetramerisation through the avidin-biotin interaction
(Giitgemann et al., 1998). The bacterial expression system has been used to form
only a few other MHC class II proteins to date, namely HLA-DR1 (Frayser et al.,
1999), HLA-DR2 (Arimilli et al., 1995, Nag et al., 1994, Nag et al., 1996), and HLA-
DR5 (Stockel et al., 1997, Stockel et al., 1994). Of these, only HLA-DR1 has been
used in the formation of oligomers (Cameron et al., 2001, Cochran et al., 2000). One
of the main drawbacks of this technique is the need for in vitro refolding of the
subunits that requires optimisation for each MHC class II protein expressed. This
optimisation is highlighted by the finding that the design of a linker peptide between
an antigenic peptide and the amino terminus of the p chain can significantly affect
the yield and stability of an expressed MHC class II protein (Cunliffe et al., 2002,
Wyer et al., 2001). This has meant that although the principles of this expression
system could be applicable to other MHC class II proteins, difficulties have been
encountered in their expression and/or refolding (Frayser et al., 1999). This variation
in refolding is in contrast to the relatively standardised production of MHC class I
proteins using the same expression system.
In order to overcome the in vitro refolding problems inherent in the bacterial
expression system, insect cell expression systems have been used with a greater
degree of success by several research groups, yielding several recombinant MHC
class II proteins. The expression systems used have been based on either a
baculovirus vector or a metallothionein-inducible Drosophila vector. Both systems
lead to the production of soluble, correctly folded MHC class II subunits which are
variably associated with or without peptide, depending upon the exact expression
system used. The added benefit of insect expression is that it leads to a degree of
glycosylation (Stern and Wiley, 1992), although this is unlikely to replicate the
naturally expressed protein.
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The baculovirus system was the first to be utilised. Soluble HLA-DR1
extracellular domains were expressed using baculovirus vectors containing the
separate a and p chains co-transfected into Sf9 cells. The HLA-DR1 protein was
secreted into the growth medium and was found to be conformationally correct using
a variety of biophysical methods, including peptide binding which was also seen to
stabilise the HLA-DR1 protein (Stern and Wiley, 1992). The HLA-DR1 protein was
also noted to be essentially empty of endogenous peptides allowing the generation of
homogenous peptide/MHC complexes by the addition of the appropriate peptide
(Stern et al., 1994). In an attempt to improve the yield, stability, and homogeneity of
expressed MHC class II proteins Kozono et al (Kozono et al., 1994) engineered a
flexible peptide linker onto the amino terminus of the P chain of I-Ek and I-Ad
murine class II proteins. This linker enabled the covalent attachment of various
peptides to the class II proteins in a manner that allowed their uniform occupation of
the class II peptide-binding groove to which they were linked. This linker was noted
not to significantly affect T cell recognition (Fremont et al., 1996, Kozono et al.,
1994). This development acted as the spring board for a series of MHC class II
proteins with linked peptides including I-Ad and I-Ek (Crawford et al., 1998), I-Ab
(Rees et al., 1999), I-As? (Liu et al., 2000), and HLA-DR4 (Kotzin et al., 2000,
Meyer et al., 2000). All of these MHC class II proteins have been used to form
tetramers through the engineering of a site-specific biotinylation sequence at the
carboxy terminus of the p chain.
Earlier work had indicated the importance of the transmembrane domain to
heterodimeric chain pairing (Cosson and Bonifacino, 1992), and so attempts were
made to improve heterodimeric chain pairing and thus the stability and solubility of
the heterodimeric complex by the addition of leucine zipper dimerisation domains to
the carboxy termini of the extracellular a and p chains (O'Shea et al., 1993). These
dimerisation domains have either been adapted from the Fos - Jun transcription
factors in the case of HLA-DR15 (Gauthier et al., 1998, Smith et al., 1998), HLA-
DQ2 (Quarsten et al., 2001) and I-Ag7 (Latek et al., 2000), or engineered acid - base
leucine zipper motifs (Chang et al., 1994, O'Shea et al., 1993) in the case of I-Au
(Anderton et al., 2001, Radu et al., 2000, Radu et al., 1998).
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Many researchers have, however, found the erratic virus production step
required in the baculovirus system too labour-intensive. Protein expression using
stably transfected Drosophila melanogaster S2 Schneider cells has been found to
provide equivalent protein yield with much less effort (Bunch et al., 1988, Cameron
et al., 2002, Ivey-Hoyle, 1991). This system was initially used to produce soluble
empty I-Ed by co-transfection of S2 cells with separate a and (3 chain constructs in
the expression vector pRmHa3. The I-Ed expressed in this system was free of bound
endogenous peptides, and up to 90% of the purified I-Ed could be homogenously
loaded with peptide resulting in functionally active pMHC complexes (Wallny et al.,
1995). However, it became apparent that not all MHC class II proteins could be
formed as easily using this system due to a failure of assembly of certain MHC class
II proteins and/or their tendency to aggregate despite the presence of a peptide
ligand. Leucine zipper motifs were used to improve this system. Using the Fos -
Jun leucine zipper domains, HLA-DR15 was initially expressed empty in the yeast
Pichia pastoris (Kalandadze et al., 1996) before being expressed in S2 cells using the
vector pRmHa3 with the MBP peptide 85-99 being covalently attached to the amino
terminus of the P chain by a linker peptide (Appel et al., 2000). This system has
recently been used to produce both HLA-DR2 and HLA-DR7 tetramers with a series
of covalently linked peptide ligands (Yang et al., 2002). Concurrently, acid-base
leucine zipper dimerisation domains have been used in the expression of soluble
empty I-Ad (Scott et al., 1996), as well as I-Ad covalently linked via the p chain
amino terminus to an ovalbumin peptide (Scott et al., 1998). With the success of this
modification, the group lead by William Kwok have successfully produced non-
peptide loaded tetramers of HLA-DQ6 (Kwok et al., 2000, Reichstetter et al., 2000)
and HLA-DR4 (Buckner et al., 2002, Gebe et al., 2001, Novak et al., 2001a, Novak
et al., 1999, Novak et al., 2001b). The tetramers formed were based on the MHC
class II heterodimer containing a BSP at the carboxy terminus of the P chain
resulting in the addition of a single biotin to each MHC class II monomer before
tetramerisation using avidin (Figure 1.7). The formation of such soluble, yet empty,
heterodimers opens the way for loading a variety of peptide ligands to the expressed
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Molecular model of the complete MHC class II tetramer taken from (Nepom et al., 2002).
Streptavidin (in blue) anchors the long, flexible linker arms that contain the leucine zipper
dimerisation domains. These linker arms form the anchors for the MHC class II units that are
recognized by the antigen-specific T cell receptor.
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MHC class II proteins without the added effort of genetically engineering individual
linked peptides.




Recombinant MHC class II
monomers
5.3.2 Novel MHC class II oligomer systems
Despite the success of the "classical" tetramer design based upon the avidin
biotin interaction (Figure 1.8), several groups have designed other strategies to
produce multivalent peptide/MHC complexes (reviewed in (Hugues et al., 2002)).
Indeed, some have suggested that the rigidity of the avidin-biotin scaffold in
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"standard" tetramers may impede the optimal interaction of these with TCRs
(Casares et al., 2001a).
Figure 1.8 - "Classical" tetramer design
MHC II a chain ►dp?
i~4
W^JVIHC II P chain
Biotin^_^^ v
Illustration of the "classical" tetramer design based on the archetypal MHC class 1 tetramer taken from
(Hugues et al., 2002). The MHC II a and p chains are non-covalently linked. The carboxy terminus
of the extracellular MHC II p chain is directly biotinylated without an intervening linker sequence.
The first multivalent peptide/MHC complex linked the immunoglobulin
heavy chain IgGl to the carboxy terminus of the extracellular portion ofMHC class I
H-2Kb resulting in a dimeric MHC class I complex (Porto et al., 1993). This
immunoglobulin scaffold was used in the formation of I-Ek, linking the a and
P chains to IgG light and heavy chains respectively (Figure 1,9a). The dimeric I-Ek
proteins were covalently linked to moth cytochrome C peptide (MCC 91-103) and
were expressed in a baculovirus system. The dimeric peptide-I-Ek complexes were
able to specifically bind to and activate their cognate antigen-specific T cell (Hamad
et al., 1998). Using a variation of the IgG scaffold idea, Casares et al have linked the
carboxy terminus of I-Ed p chain to the hinge region of murine IgG2a heavy chain
(Figure 1,9b). The influenza virus hemaglutinin peptide (HA110-120) was linked to
the amino terminus of the same I-Ed p chain. Both the I-Ed a and modified P chains
were expressed using a baculovirus system leading to the formation of dimeric I-Ed
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proteins. These proteins were noted to be conformationally correct and able to stain
HA antigen-specific T cells (Casares et al., 2001a, Casares et al., 1997), as well as
being able to alter T cell activation (Casares et al., 2002) and differentiation (Casares
et al., 1999). However, and once again, this scaffold idea could not be readily
extended to other MHC class II proteins without further modification. Malherbe et
al (Malherbe et al., 2000) modified the carboxy termini of I-Ad extracellular a and p
chains by adding acid and base leucine zipper sequences respectively, linking the
carboxy terminus of the resulting a chain to the Fc portion of murine IgG2a (Figure
1.9c). The amino terminus of the P chain was covalently linked to a Leishmania
LACK peptide antigen. The resulting dimer was expressed in Drosophila S2 cells
using the vector pRmHa3. The dimers were noted to bind LACK-specific T cells. A
similar system has been used to produce HLA-DR15 and HLA-DR4 (Appel et al.,
2000, Appel et al., 2001).
Figure 1.9 - Immunoglobulin scaffold based oligomers (Figure adapted from (Hugues et al.,
2002))
a)
rMHC II p chain
IgG heavy chain
*
MHC II a chain
IgG light chain
Illustration of the archetypal immunoglobulin-based scaffold used to both aid in the MHC class II ap
chain association, and also in the formation ofMHC class II dimers.
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.— Linked peptide
MHC II p chain
IgG heavy chain
Illustration of the modified immunoglobulin scaffold structure linking the carboxy-terminus of the
MHC Class II p chain to the hinge region of the IgG2a heavy chain.
c)
Linked peptide
/ / MHC II a chain
Leucine zipper dimerisation domain
IgG heavy chain
Illustration of the additional modifications of the immunoglobulin scaffold using leucine zipper
domains to aid ap chain association.
An innovative oligomerisation technique has been engineered by Cochran et
al (Cochran et al., 2000) using thiol-reactive maleimide groups linked to a defined
number of lysine residues spaced along a flexible non-repeating peptide backbone
containing glycine, serine and glutamic acid (Figure 1.10). HLA-DR1 was modified
by the addition of a cysteine residue at the carboxy terminus of the P chain before
being expressed in E.coli and folded in vitro. The refolded HLA-DR1 heterodimer
could then be formed into dimers, trimers and tetramers by chemical linkage to the
peptide backbone that also contained a fluorescent label. This system not only
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allowed assessment of antigen-specific T cells, but also the molecular requirements
in terms ofTCR binding for T cell activation.
Figure 1.10 - Peptide backbone oligomerisation (Figure adapted from (Hugues et al., 2002))
Fluoroclirome
Given the problem of the heterodimeric nature of MHC class II proteins,
methods are needed to improve chain pairing. The above has highlighted two
techniques, namely the addition of a molecular scaffold and the addition of leucine
zipper dimerisation domains, the latter possibly being more effective (Scott et al.,
1996). A novel way around the problem was first developed by Rhode et al (Rhode
et al., 1996) who linked the carboxy terminus of the I-Ad extracellular p chain to the
amino terminus of the I-Ad a chain by a 24 amino acid flexible linker. The construct
was expressed using a baculovirus system and found to be conformationally correct
as evidenced by antigen-specific T cell stimulation. This technique was extended by
Burrows et al (Burrows et al., 1998) who have constructed a two-domain single
chain MHC class II peptide, linking the pi domain directly to the al domain (Figure
1.11). The a2 and P2 domains of MHC class II appear to be involved in TCR
signalling through their interaction with CD4 (Cammarota et al., 1992, Huang et al.,
1997a, Konig, 2002, Konig et al., 1995). Studies have, however, shown that
although CD4 is required for T cell signalling it is not required for pMHC-TCR
binding stability (Boniface et al., 1998, Hamad et al., 1998, Konig, 2002, Radu et al.,
2000). This group has engineered these single chain MHC class II peptides for rat
RT1.B (Burrows et al., 2000a, Burrows et al., 1998, Burrows et al., 1999) and human
HLA-DR15 (Chang et al., 2001). These constructs were expressed in E.coli
inclusion bodies and required less complicated refolding compared to the
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heterodimeric constructs previously expressed in E.coli. Moreover, the constructs
could be covalently linked to antigenic peptides through the amino terminus of the
(31 domain, improving their stability. The constructs have been shown to be
functionally correct through antigen-specific T cell binding and inhibition, but have
not yet been oligomerised into an antigen-specific multimeric T cell staining reagent.
Figure 1.11 - Single chain MHC class II (Figure adapted from (Burrows et al., 1999))
MFIC II ai chain
6 Concluding Remarks
6.1 Utility of the tetramer approach
The above discussion highlights the various difficulties that are being
overcome from the seminal work on MHC class I multimers to the work currently in
progress on MHC class II multimers. MHC class I multimers are now readily
produced and have been successfully utilised in a number of studies to date. MHC
class II multimers have also been produced, but their synthesis has not been as
uniformly successful. Indeed, at the inception of this thesis few MHC class II
multimers had been described, and these were mainly produced using either the
bacterial expression systems previously used for MHC class I multimer production,
or the baculovirus system. Consistent production of MHC class II multimers only
began at the turn of the millennium, but multiple strategies were being used, with no
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one strategy being clearly pre-eminent. Nevertheless, the promising clinical utility of
this approach remains a major driving force to its continued development. Possible
uses include (Nepom et al., 2002):
• Ability to identify antigen-specific T cells
• Define intermediate phenotypes involved in disease progression
• Distinguish responder versus non-responder status for different
therapeutics
• Characterize clinical heterogeneity
• Mark T cells for studies of novel genes and molecular pathways
• Screen peptide libraries for epitope identification
6.2 Aims of the study
With the emerging developments in the MHC class II multimer approach to
characterising CD4+ T cells came the possibility of developing such a reagent to
study an archetypal human autoimmune disease, Goodpasture's disease. The
building blocks of MHC Class II tetramers are recombinant MHC Class II peptides
that have been modified to allow both expression in a soluble form and
multimerisation to form the final tetrameric units. These form the Tetramer Building
Blocks (TBB).
The aim of this project was to develop TBBs that could be used to examine
autoreactive T cells in patients and/or mice with Goodpasture's Disease and mice
with autoimmune anaemia. At the commencement of the study, the three most
promising techniques for TBB construction were taken as templates for further
development towards the formation of three MHC Class II multimers: I-Ed, HLA-
DR7 and HLA-DR15. HLA-DR7 and HLA-DR15 were chosen for their negative
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and positive associations respectively with Goodpasture's Disease, whilst I-Ed was
chosen for its association with autoimmune anaemia.
As a technology that, even now, is still in relatively early development, it was
recognised from the outset that the generation of TBBs would be a major challenge
in its self, and most likely the most that I could achieve in the time available. This
would leave others to evaluate these TBBs as agents for investigating the
autoimmune response in both Goodpasture's Disease and autoimmune anaemia.
6.3 Outline of approaches
The first approach built on work performed by Wallny et al (Wallny et al.,
1995), and employed an insect expression system based in Drosophila melanogaster
S2 cells (Ivey-Hoyle, 1991) (Figure 1.12a). The copper inducible vectors containing
the separate extracellular alpha and beta chains of the murine I-Ed were kindly
donated by Wallny et al. This group had successfully produced soluble I-Ed
heterodimers. The heterodimers formed were devoid of bound endogenous peptide,
and were capable of being extrinsically loaded with peptide following their
purification from the - induced supernatant. The heterodimers demonstrated
conformational change upon peptide binding and were noted to be functionally active
after this by antigen-specific T cell stimulation (Wallny et ah, 1995). The above
work had not made use of techniques to enhance the heterodimeric association of the
produced alpha and beta chains. Given the importance of peptide binding for the
correct association of native MHC Class II alpha and beta chains, the amino terminus
of the beta chain was engineered to contain a covalently attached peptide-binding
cassette based on the work of Kozono et al (Kozono et al., 1994). Such a construct
could, therefore, be formed with or without a covalently attached peptide. The latter
construct would not only allow ease of changing the associated peptide, but would
for example, allow for extrinsic loading of a panel of peptides to more rapidly probe
T cell epitopes (Kwok et al., 2001). The possibility of using this covalently attached
peptide-binding cassette was made available for all three approaches, although not
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necessarily utilised at all times. The plan was to use the "classical" tetramer
foundation of the avidin-biotin interaction, and so a site-specific biotinylation
sequence was engineered onto the carboxy-terminus of the I-Ed beta chain.
The second approach is an enhancement of the above system and employs
two leucine zipper domains at the carboxy terminus of the extracellular domains of
both alpha and beta chains (Figure 1.12b). These leucine zipper domains would be
intended to maintain the heterodimeric chain association of the alpha and beta chains
(Kalandadze et al., 1996, Scott et ah, 1996) with or without a covalently linked
peptide. Such an approach should also theoretically improve the yield of correctly
associated heterodimeric protein.
The final approach circumvents the heterodimeric association by hybridising
the al and (31 domains into a single chain construct that maintains the peptide -
binding groove in this cooperative unit (Braunstein et ah, 1990) (Figure 1.12c). This
hybrid molecule was initially developed by Burrows et al (Burrows et ah, 1998)
using rat RT1.B class II molecules with great success. This final approach was the
most innovative of the three and had not been used for MHC multimer formation.
Protein refolding techniques would have to be developed for these bacterially
expressed recombinant proteins.
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Figure 1.12 - Diagram of TBB Approaches
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1 Materials
1.1 General Chemicals
All materials, with the exception of those mentioned, were obtained from
either Sigma-Aldrich Company Limited, UK; Fisher Scientific, UK; BDH
Laboratory Supplies (VWR International); or Scientific Laboratory Supplies Ltd,
UK.
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1.2 Molecular biology additive stock solutions
The following stock solutions were formed and stored at -20°C:
Ampicillin 50mg/ml in dH?0
Carbenicillin (CNBioscience) 50mg/ml in dH^O
Chloramphenicol (Transgenomic Limited) 34mg/ml in 100% ethanol
IPTG (Transgenomic Limited) 1M in dFhO
Tetracycline (Transgenomic Limited) 12.5mg/ml in 50% ethanol in dF^O
X-gal (Transgenomic Limited) 2% solution in dimethylformamide
1.3 Tissue Culture
1.3.1 Plastics /Glassware
All materials, with the exception of those mentioned, were obtained from
either Nalge Nunc International (Denmark), Sarstedt Inc. (USA), or Techne
(Cambridge) Ltd (UK).
1.3.2 Media
All media, with the exception of those mentioned, were obtained from either
Invitrogen Life Technologies (Holland) or PAA Laboratories (UK).
1.3.3 Cell Lines
All cell lines, with the exception of those mentioned, were obtained from
either Invitrogen Life Technologies (Holland), or American Type Culture Collection
(Table 1).
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Table 1 - Cell lines
Cell Line Utility Source Reference
HL-60 Source of human c-myc
onco-protein as a
positive control.






















DA6.147 Source ofmurine IgGi
monoclonal antibody





(Guy et al., 1982)
DA6.231 Source ofmurine IgGi
monoclonal antibody
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2 Nucleic Acid Methods
2.1 Ligation of DNA fragment into a plasmid vector
The relevant plasmid and DNA insert were digested with the required
restriction enzymes (Promega Corporation) at 37°C for between 2-3 hours. The
optimal buffer for each enzyme combination was utilised for each restriction enzyme
digest.
The plasmid was dephosphorylated by incubating with Calf Intestinal
Alkaline phosphatase (CIP) in CIP buffer {Promega Corporation) for 1 hour at 37°C
as per the manufacturer's instructions. Dephosphorylation was terminated by
inactivating the enzyme through the addition of 0.5M EDTA and incubation at 65°C
for 20 minutes. The plasmid was then purified using the QIAEX II® protocol for
desalting and concentrating DNA solutions (Qiagen) as per the manufacturer's
instructions. This protocol is based on the adsorption of DNA to silica gel that is
then washed to remove impurities including salts. The adsorbed and purified DNA
can then be eluted using a low salt alkaline eluant such as lOmM Tris.Cl (pH 8.5).
The DNA insert was separated by agarose gel electrophoresis prior to
excising the relevant insert band and purifying using the QIAEX II® gel extraction
protocol (Qiagen) as per the manufacturer's instructions. This protocol utilises an
optimised buffer containing a high concentration of chaotrophic salt to disrupt the
hydrogen bonds within the agarose polymer, allowing solubilisation of gel slice. In
addition, the high salt concentration dissociates DNA binding proteins from the DNA
fragments, allowing the DNA to be adsorbed to a silica gel as above.
The concentration of the purified products was assessed roughly by agarose
gel electrophoresis using a 1:4 ratio of cut plasmid to cut insert.
The following ligation mixtures were prepared and incubated at 16°C
overnight in a thermal cycler (Genius - Techne (Cambridge) Ltd.): To lpl of cut
plasmid was added 0, 1,4, and 7pi of prepared insert prior to adding lpl ofT4 ligase
buffer {Promega Corporation) and lpl of T4 ligase {Promega Corporation). The
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mixture was adjusted to 10pi with sterile water. The ligated products could be
transformed into competent cells as noted below.
2.2 Making and transforming competent cells
The following protocol is based on the work of Hanahan (Hanahan, 1983)
and was adapted from Sambrook et al (Sambrook et al., 1989).
SOB/LB agar plates were prepared using 1.5% agar autoclaved in the
bacterial growth medium prior to pouring into 90mm plates (.Bibby Sterilin Ltd.).
Magnesium sulphate was added, as well as any antibiotics required, prior to pouring
the plates. Subcloning Efficiency™ DH5a™ E.coli {Life Technologies) were
streaked onto a prepared agar plate (without antibiotic) using a sterile applicator
(Nalge Nunc InternationalT) prior to incubating overnight in a 37°C incubator {Sanyo
Gallenkamp).
A 50ml baffled flask was sterilised by adding 50ml dH20 and boiling in a
microwave (Program 1050 - ProLine) for 3 minutes prior to discarding the water and
adding 50ml sterile complete SOB/LB medium. Using a sterile applicator,
approximately 20 bacterial colonies were taken and placed into the prepared flask
before incubating in an orbital shaker (Orbital Incubator - Sanyo Gallenkamp) at
37°C until the optical density at 550nm (OD550) was between 0.3-0.4 (Unicam UV1
- Thermo Spectronic, USA). The cell suspension was decanted into a pre-cooled
50ml Falcon tube prior to centrifuging at 2000# at 4°C for 10 minutes. The
supernatant was discarded prior to re-suspending in 10-15ml ice-cold transforming
buffer and leaving on ice for 10 minutes. The suspension was centrifuged as before
prior to re-suspending in 2-5ml ice-cold transforming buffer and adding 140pl of
DD solution, swirling immediately. The solution was incubated for 10 minutes prior
to adding a further 140pl of DD solution and swirling as before, incubating for a
further 20 minutes on ice.
Chapter 2 - Materials and Methods 53
Formation ofMHC Class II - Peptide Multimers
5pi of plasmid (1:10 dilution) or ligation mixture was added to a 1.5ml
epindorf tube prior to placing on ice. 50pi of the above cell suspension was added to
each epindorf tube prior to mixing and leaving on ice for 30 minutes. The bacteria
were heat shocked by placing into a 42°C water-bath for 90 seconds, then retuning to
ice for 2 minutes. 200pl of pre-warmed SOC medium (EKIT-B1 — ThermoHybaid
Ltd.) was then added to each epindorf prior to incubating at 37°C for 1 hour. The
cell suspension was spread onto dried SOB agar plates containing 100pg/ml
ampicillin, incubating inverted overnight in a 37°C incubator.
2.3 Small-scale preparation of plasmid DNA ("Mini-prep")
The success of plasmid ligation was assessed by performing small-scale DNA
preparations of a selected number of colonies from agar plates predicted to contain
the desired insert. These plates were those having the greatest colony count above
the background (cut plasmid alone) plate. The method of DNA preparation was
adapted from Sambrook et al (Sambrook et al., 1989).
Each of the selected colonies was taken from the agar plate using separate
sterile applicators and placed into 2ml of sterile bacterial medium containing
100pg/ml ampicillin in a 15ml Falcon tube. The tubes were placed in a 37°C orbital
shaker overnight at 200rpm. The following morning, 1.5ml of the cell suspension
was poured into a clean epindorf tube, with the remaining suspension being stored at
4°C. The epindorf tube was centrifuged at 18000g at room temperature (Sigma 1-15
- Sigma (Germany)) for 3 minutes prior to discarding the medium. The pellet was
re-suspended in 100pi of GTE by vigorous vortexing, adding 200pl of sodium
hydroxide/SDS solution to each suspension and mixing by inversion prior to
incubating on ice for 5 minutes. 150pl of ice-cold 3M/5M potassium acetate solution
was then added, mixing the resulting solution by gentle vortexing prior to incubating
on ice for a further 15 minutes. The solution was then centrifuged at 18000g at room
temperature for 5 minutes to remove cellular debris and precipitated proteins,
transferring the supernatant to a fresh epindorf tube. The supernatant was vortexed
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with 200pl of buffered phenol (Severn Biotech Ltd.) and centrifuged at 18000g for 2
minutes to remove any remaining protein. The upper phase of the resulting solution
was removed and the DNA precipitated by adding an equal volume of 100%
isopropanol and vortexing prior to centrifuging at 18000g for 5 minutes at room
temperature. The supernatant was aspirated and 1ml of 70% ethanol added prior to
centrifuging for 1 minute as above. The ethanol was then removed and the pellet
allowed to air-dry prior to re-dissolving in 50pl lOmM Tris.Cl pH8.5.
Once re-dissolved the DNA was assessed by performing a panel of restriction
enzyme digests in the presence of RNAse. The digests were assessed by agarose gel
electrophoresis. The DNA was stored at -20°C if required for further analysis at a
later point in time.
2.4 Larger scale DNA preparation ("Midi-prep")
Once colonies containing the correctly ligated DNA had been provisionally
established as above, further clarification and sequencing was performed on larger
scale and purer DNA preparations.
lOOpl of the stored bacterial suspension was inoculated into 50ml of bacterial
culture medium containing 100pg/ml ampicillin in a 250ml microwave-sterilised
baffled flask. The bacteria were allowed to grow overnight in a 37°C orbital shaker
at 250rpm prior to preparing the DNA using the QIAGEN® Plasmid Midi Kit
(QIAGEN) as per the manufacturer's instructions. This plasmid purification protocol
is based on a modified alkaline lysis procedure, binding the plasmid DNA to an
anion-exchange resin at a low-salt concentration. RNA, proteins, dyes and low
molecular weight impurities are removed by a medium-salt concentration buffer
prior to eluting the plasmid DNA in a high-salt buffer. The DNA is concentrated and
desalted by isopropanol precipitation. The DNA is precipitated by centrifugation at
15000g for 30 minutes at 4°C before washing in 70% ethanol. The washed DNA is
centrifuged at 15000g for 10 minutes at room temperature. The resulting DNA pellet
can either be stored at -20°C under ethanol in order to keep sterile, or re-dissolved in
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lOmM Tris.Cl pH8.5 for use in restriction digests to confirm or refute the presence of
the correct insert sequence prior to storing at -20°C.
2.5 Agarose gel electrophoresis
Agarose mini gels were formed to analyse the DNA products of PCR,
restriction enzyme digests or plasmid production. In general, 1.5% agarose gels were
formed using 0.5% TBE buffer by heating the agarose in the TBE buffer until it
dissolved to form a clear solution using a microwave. 5pi of 10mg/ml ethidium
bromide was added to each 50ml agarose gel prior to pouring into the mini gel
apparatus (Scie-Plas Ltd.) and allowing to solidify at room temperature. Once
solidified 50ml of 0.5% TBE buffer was poured over the gel and 5pi of a 1:10
dilution of Hae III digest DNA ladder (Kramel Biotech International) was loaded
into one well after mixing with a small drop of DNA loading buffer (roughly l/6th
volume).
Samples were loaded after mixing with a small amount of DNA loading
buffer as above. The gel was electrophoresed at 100V, 75mA for 30 minutes to
obtain adequate separation. The DNA bands were visualised under UV light.
2.6 Assessment of nucleic acid concentration
Assessment of DNA and RNA concentration was made
spectrophotometrically (Unicam UV1 — Thermo Spectronic, USA) after the nucleic
acid sample was diluted in Milli-Q H20 (Millipore UK Ltd). DNA solutions were
diluted at 1:800 in Milli-Q H20, whilst RNA solutions were diluted at 1:100. Milli-
Q H20 was used to zero the instrument before the ODs of the solutions were
analysed at 260nm (A26onm) and 280nm (A28onm). Actual nucleic acid concentrations
were then calculated as follows:
[RNA] = (A26onm x 40 x dilution factor) pg/ml
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[DNA] = (A260nm x 50 x dilution factor) pg/ml
The ratio of A26onm:A28onm should be roughly 1.8-2.0:1 indicating a low level
of protein contamination.
2.7 DNA Sequencing and sequence analysis
All DNA sequencing was performed by DNAShef at the Royal Infirmary of
Edinburgh using fluorescence-based dideoxy chain-termination cycle sequencing
(ABI Prism® BigDye™ Terminator -Applied Biosystems).
The sequencing data was viewed using Edit View vl.0.1 (Perkin-Elmer
Corp.). Sequences were compared using ClustalX (Thompson et al., 1997) and DNA
Stridervl.2 (C'EA, France).
2.8 Extraction of mRNA and RT-PCR
Extraction ofmRNA was carried out on Drosophila melanogaster S2 as well
as DR2Lum cells. All procedures were undertaken under RNase-free conditions at
all times. The cell suspension was centrifuged at 500# for 5 minutes at 15°C, before
removing the supernatant and re-suspending in 2ml of fresh medium. A cell count
was performed, with approximately lxlO7 cells being taken for mRNA extraction.
The extraction of mRNA was carried out using the QuickPrep™ Micro mRNA
Purification Kit (Amersham Pharmacia Biotech). The kit combines extraction of
RNA in a buffered solution containing guanidinium thiocyanate to ensure rapid
inactivation of endogenous RNases with separation of the poly(A)+ RNA using
oligo(dT) attached to cellulose. The separated poly(A)+ RNA is washed in high and
low salt buffers before eluting from the oligo(dT) cellulose. The separated poly(A)+
RNA is composed of both heterogeneous nuclear RNA (hnRNA) and mRNA. Once
eluted, the RNA was concentrated by precipitation using the supplied glycogen and
potassium acetate solutions combined with pre-chilled 95% ethanol at -20°C for 1
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hour. The precipitated RNA was then stored as a pellet under ethanol at -80°C
following centrifugation at 15000g at 4°C for 5 minutes.
RT-PCR was carried out using Ready-To-Go® RT-PCR beads (Amersham
Pharmacia Biotech) as per the manufacturer's two-step protocol using pd(N)6 as the
first-strand primer in a thermal cycler (Genius - Techne (Cambridge) Ltd.). Each
bead is optimised to allow cDNA synthesis and PCR to occur sequentially within the
same tube, and contains the correct quantities of Moloney Murine Leukemia Virus
(M-MuLV) reverse transcriptase and Taq DNA polymerase together with buffer,
MgCl2, nucleotides and RNAguard. For one bead reaction, lOpl ofRNA suspension
was used as the template RNA, with 5pl of 0.5pg/pl pd(N6) random primer being
used as the first strand primer. To this 25pi of MilliQ H2O was added and the bead
incubated at 42°C for 30 minutes prior to inactivating the reverse transcriptase by
heating to 95 °C for 5 minutes. The cDNA formed by this process was then amplified
by PCR using gene-specific primers. Where DNA contamination might affect the
interpretation of results, for example in the assessment of DNA transcription in
transfected S2 cells, DNase I pre-treatment of the RNA was used. This was
performed by incubating the RNA with RNase-free DNase I (Promega) in DNase
Buffer (xlO) for 1 hour at 37°C before using the resulting solution containing RNA
as the template for first-strand cDNA synthesis.
3 Hybridoma Cell Culture
3.1 Routine culture
All hybridoma cell lines were cultured in RPMI 1640 supplemented with a
final concentration of 2mM L-glutamine/100U/ml penicillin/0. lmg/ml streptomycin
and 10% heat-inactivated foetal calf serum. Cells were maintained at a concentration
of between 105 - 106 cells/ml by re-suspending in fresh media on passaging. Cells
were maintained at 37°C and 5% CO2 in a WTC Binder (Germany) incubator.
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L243 hybridoma cells were initially grown in Modified Dulbecco's medium
with 10% heat-inactivated foetal calf serum prior to gradually transferring to RPMI
1640 as above.
3.2 Cryopreservation
Flybridoma cells were cryopreserved at passaging. A 10ml cell suspension
was taken and centrifuged at 500g for 5 minutes at 20°C. The supernatant was
discarded to leave 1.5ml of conditioned medium. To this, an equal quantity of a 10%
DMSO in heat-inactivated foetal calf serum was added, thus re-suspending in a final
concentration of 5% DMSO. The resulting cell suspension was placed into a
cryovial prior to placing in Mr Frostie® (Nalge Nunc International), which was then
placed at -80°C (Sanyo Ultra Low) overnight. The cryovials were then transferred to
a liquid nitrogen store (Cryosystem 2000 - MVE Cryogenics, USA) for prolonged
storage.
3.3 Recovery of cells
Cryopreserved cells were defrosted rapidly by placing the cryovial in a 37°C
water-bath. Just prior to complete defrosting, the cryovial was sprayed with a 70%
ethanol solution and placed in a sterile safety cabinet. The cell suspension was
removed and 10ml of fresh medium added to the suspension. The suspension was
centrifuged at 500g for 5minutes at 20°C prior to discarding the supernatant and re-
suspending the cell pellet in lOmls fresh medium. The cell suspension was placed
into a sterile 25cm2 flask prior to maintaining as above. The cells were passaged
initially 48 hours later, using a 1:2 dilution with fresh medium, prior to following the
normal routine outlined above.
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3.4 Cell lysis
The required cell suspension (at least 107cells/ml) was initially centrifuged at
750g at 4°C for 5 minutes to pellet the cells, which could then be stored at -20°C
until required. To the cell pellet, 1ml of cell lysis solution was added, prior to
vortexing and placing on ice for at least 3hours. The suspension was then
centrifuged at 20000# for 30 minutes prior to removing the supernatant and storing
this at -20°C until required.
3.5 Antibody purification
Supernatant was collected from antibody-producing hybridoma cells when
they were passaged. The supernatant was centrifuged at 2000g for 5 minutes at 4°C
before decanting the cell-free supernatant into a sterile bottle containing a final
concentration of 0.1% sodium azide. The bottle was stored at 4°C until full, then
placed at -20°C for long-term storage.
When purifying, 11 of frozen supernatant was defrosted at room temperature
before precipitating the antibody with 40% ammonium sulphate at 4°C overnight
prior to centrifuging at 5500# for 30 minutes at 4°C. The pellet was dissolved in
PBS to 20% of the starting volume. The resulting solution was placed into prepared
Seamless Cellulose dialysis tubing and dialysed extensively at 4°C against sodium
phosphate loading buffer containing 0.05% sodium azide. The final solution was
filtered through a 0.45pm filter prior to storing at 4°C.
A 2ml anti-mouse IgG sepharose column was packed and equilibrated with
20 column volumes of sodium phosphate wash buffer using a Biocad 700E
Workstation. The antibody solution was then loaded at 2ml/minute onto the column
in 100ml aliquots, eluting each time with 10 column volumes of 0.1M glycine buffer
(pH2.5) containing 0.15M NaCl, collecting the eluate in a neutralising volume of 1M
sodium phosphate buffer pH8.0. The final eluate was then concentrated by loading
onto a 1.7ml Poros®A column (PerSeptive Biosystems) which had been equilibrated
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with sodium phosphate wash buffer as above, eluting with glycine buffer as above.
Sodium azide was added to the final eluate to a concentration of 0.1% prior to
aliquoting and storing at -20°C.
4 Insect Cell Culture and Protein Production Methods
4.1 Routine culture
Drosophila melanogaster Schneider 2 (S2) cells were used throughout this
study for the production ofMHC Class II heterodimers.
The S2 cells were grown in either serum supplemented media (Schneider's
Drosophila Medium), or serum-free media (Insect Express Sf9-S2). Serum
supplementation was carried out by the addition of 10% heat-inactivated insect-
qualified foetal calf serum. Penicillin and streptomycin were added to all media to
give a final concentration of 100U/ml and 0.1mg/ml respectively.
The S2 cell lines were passaged twice weekly by gently tapping the flask and
removing about 80% of the resulting cell suspension, prior to replacing with an equal
volume of fresh medium. Although transfected cell lines were maintained primarily
within the same flask, untransfected cells were transferred into a fresh flask at each
passage.
All insect cell work was carried out under sterile conditions in a Baker
Sterilgard Class II biological safety cabinet (Baker Corporation). This was cleaned
with a 2% Virkon (.Antec International Ltd.) solution before and after use.
Cell lines were maintained at 26°C either in tissue culture flasks within a
cooled incubator (LMS), or in magnetic spinner flasks maintained at 26°C within a
magnetic, thermostatically controlled water bath (MCS-104L and MWB-12L-
Techne).
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4.2 Cryopreservation
S2 cell lines were cryopreserved when required at passaging. A 10ml cell
suspension was taken and centrifuged at 500g for 5 minutes at 20°C (4K15 - Sigma
Laboratory Centrifuges). The supernatant was discarded to leave 1.5ml of
conditioned medium. To this, an equal quantity of a 15% DMSO solution was
added. This solution was formed in either heat-inactivated foetal calf serum or
serum-free medium, depending upon the growing medium. The resulting cell
suspension was placed into a cryovial prior to placing in Mr Frostie® as described
above.
4.3 Recovery of cells
Cryopreserved S2 cells were defrosted rapidly by placing the cryovial in a
37°C water-bath. Just prior to complete defrosting, the cryovial was sprayed with a
70% ethanol solution and placed in a sterile safety cabinet. The cell suspension was
removed and 10ml of fresh medium (serum-free or serum-supplemented as required)
was added to the suspension. The suspension was centrifuged at 500g for 5minutes
at 20°C prior to discarding the supernatant and re-suspending the cell pellet in 1 Omls
fresh medium. The cell suspension was placed into a sterile 25cm2 flask prior to
maintaining as above. The cells were passaged initially 48 hours later, using a 1:2
dilution with fresh medium, prior to following the normal routine outlined above.
4.4 Transfecting S2 cells
S2 cells were stably transfected as per manufacturer's protocol using calcium
phosphate (Drosophila Expression System Version A - Invitrogen Life
Technologies). S2 cells were initially seeded into six-well plates 24 hours prior to
transfection, with the plates being placed within a humidified box within the cooled
incubator. The ethanol covering the sterile DNA pellets was first removed before
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allowing the pellets to air-dry. The dried pellets were re-suspended in 20pi ofMilli-
Q H2O before assessing the DNA concentration as per Methods. Transfection was
carried out using a total of 19pg of DNA per transfection, with lpg being the
resistance vector. Therefore, where two DNA sequences require co-transfection, 9pg
of each sequence is transfected with the resistance vector. Selection was carried
using hygromycin-B at 500pg/ml, with selection being carried out within the six-well
plates for 4 weeks prior to transfer to larger culture flasks for continued selection. A
negative transfection control without DNA was used in parallel with a positive
transfection control. The latter was in the form of a previously successful plasmid
encoding for the a3(NCl) domain of Type IV collagen - pMT/BiP/V5IIis/A/P"
(Chopra, 1999). The vector encoding for hygromycin-B resistance, pCoHYGRO,
was kindly donated by Dr S. Chopra (Chopra, 1999).
4.5 Production of recombinant protein
Following at least 6 weeks of selection in serum-supplemented medium
containing 500pg/ml hygromycin-B, the stably transfected cells were transferred to
hygromycin-B-free serum-supplemented medium by using this medium on
passaging. The cells were then seeded either into tissue culture flasks or into spinner
flasks at a density of 2 x 106/ml and allowed to grow until a density of 4-6 xl06/ml
was reached. Cell viability was assessed by Trypan Blue exclusion using the
following formula:
Total viable cells 4- Total cell number x 100%
The cells were induced at this point with lOOmM 0.2pm filter-sterilised CuS04
solution to give a final concentration of ImM Cu2+. The supernatant was harvested
after 4-5 days or when the cell density had reached 10-20 x 106/ml. The supernatant
was harvested by centrifuging the cell suspension at 1500g for 5 minutes at 20°C
prior to removing the supernatant and processing as noted below.
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Cells were also transferred to serum-free medium after transferring to
hygromycin-B-ffee medium by a gentle weaning process involving reducing
quantities of serum-supplemented medium at each passage.
Growth in spinner flasks as suspension cultures was aided by the addition of
filter sterilised 10% Pluronic F-68 to the medium to give a final concentration of
0.1%. This surfactant helps reduce shear stress.
4.6 Purification of recombinant protein
The recombinant protein was precipitated by mixing with ammonium
sulphate at a final concentration of 40% w/v (Kuroda et al., 2000) at 4°C overnight.
The precipitated proteins were harvested by centrifugation at 5500g for 30 minutes at
4°C, re-suspending the precipitate in 20% of the initial volume of PBS (.Diagnostics
Scotland) with 0.05% sodium azide. The resuspended protein was then placed into a
prepared cellulose dialysis tube and dialysed extensively against PBS/0.05% sodium
azide at 4°C. The dialysis membrane was prepared by boiling in dH20 for 20
minutes three times. Once dialysed, the solution was filtered through a 0.45pm filter
prior to adding a 1:103 dilution of protease inhibitor cocktail (Cocktail for use in
purification of poly(Histidine)-tagged proteins). Dialysis should remove the copper
ions used to induce the cells that may interfere with the nickel chelation step below.
The solution was stored for a short period at 4°C prior to further purification.
Further purification was carried out by metal chelation affinity
chromatography using Poros®20MC medium (1.7ml bed volume) and a Biocad 700E
workstation (PerSeptive Biosystems Inc.). The column was stripped, regenerated and
loaded with nickel as per the manufacturer's instructions before being equilibrated in
the column wash buffer. The sample solution was mixed in a 50:50 ratio with the
column wash solution prior to loading onto the prepared Poros®20MC column at
3ml/minute. The column was washed for 10 column volumes in column wash buffer
prior to eluting with the column elution solution over 20 column volumes at
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3ml/minute. The eluate was then dialysed extensively into PBS containing 0.1%
sodium azide.
5 Bacterial Protein Production Methods
5.1 Transforming BL21 (DE3) Cells
BL21(DE3) (CN Bioscience) cells were transformed as per above method
using the single-chain constructs for HLA-DR15, HLA-DR7 or IEd (Figure 5.14)
ligated into pET25b (CN Bioscience) as per above method. The transformed bacteria
were plated onto LB agar plates containing 100pg/ml of carbenicillin prior to placing
in a 37°C incubator overnight.
5.2 Small scale protein production and analysis
Five single colonies from the above transformation were taken using a sterile
loop and placed into 10ml LB medium containing 200pg/ml carbenicillin allowing
the bacteria to grow at 37°C in an orbital shaker at 250rpm for up to 6 hours. The
bacterial suspension was centrifuged at 5000g at 4°C for 5minutes before re-
suspending the cell pellet in 20ml fresh LB medium containing 300pg/ml
carbenicillin and storing at 4°C for a maximum period of 72 hours.
500pi of the stored suspension was taken and placed in 10ml LB medium
containing 400pg/ml of carbenicillin before incubating in an orbital shaker at 37°C
and 250rpm. The optical density at 600nm (ODgoo) was measured and the cell
suspension was induced with 1M IPTG to give a final concentration of ImM once an
OD600 of 0.5 had been attained. The induced cells were kept in the orbital shaker at
37°C and 250rpm for 4 hours before centrifuging at 5000g for lOminutes at 4°C,
storing the cell pellet at -80°C overnight.
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The use of high concentrations of carbenicillin helps to prevent the
overgrowth of cells that have lost the transformed plasmid that might otherwise
occur due to bacterial p-lactamase production.
The stored pellets were defrosted at room temperature with 10ml PBS being
added to each pellet before sonicating for 60seconds with a 50% duty cycle on ice
(Ultrasonic Processor - Jenkons Scientific Ltd.). The suspension was centrifuged at
10000g for 20minutes at 4°C, discarding the supernatant before sonicating in a
further 10ml PBS as previously. After further centrifugation, the pellet was
resuspended in 1ml Inclusion body re-suspension solution by further sonication
followed by shaking on ice overnight. The suspension was centrifuged at 15000g for
20minutes at 4°C and the soluble fraction collected and analysed using SDS-PAGE
and Coomassie Brilliant Blue stain.
The monomeric scTBB proteins have the following predicted molecular




5.3 Cryopreservation of transformed cells
Once the colony having the greatest protein production had been identified
above, a glycerol stock was formed as follows:
The stored cell suspension was centrifuged at 5000g for 5 minutes at 4°C
resuspending the cell pellet in 10ml fresh LB containing 400pg/ml carbenicillin.
500p.l of the resulting suspension was taken and added to 10ml fresh LB containing
400pg/l carbenicillin and incubated at 37°C in an orbital shaker at 250rpm until an
OD600 of 0.5 had been attained. 4.5ml of the cell suspension was then added to 0.5ml
Chapter 2 - Materials and Methods 66
Formation ofMHC Class II - Peptide Multimers
of 80% glycerol in LB medium that had been previously sterilised by autoclaving.
Carbenicillin was added to the resulting mixture to give a final concentration of
100pg/ml. The resulting cell suspension was aliquoted into sterile cryovials before
snap freezing in an ethanol/dry ice bath and storing the frozen vials at -80°C.
In order to make use of this stored colony, a sterile applicator was scraped
over the glycerol surface before streaking across an LB-agar plate containing
200pg/ml of carbenicillin. The plate was incubated inverted overnight in a 37°C
incubator to allow bacterial growth. Single colonies were then assessed for protein
production as above before proceeding to large-scale protein production using the
colony with the highest protein yield.
5.4 Large scale production of recombinant protein
Once the colony with the highest protein yield had been chosen from the
small-scale preparation above, a larger scale culture of the bacterial colony was
made. The stored cell suspension was centrifuged at 50()0g for 5 minutes before
removing the supernatant and resuspending the cell pellet in 10ml of fresh LB
medium containing 400pg/ml carbenicillin by gentle vortexing. The resulting
suspension was then divided between two 11 samples of LB medium containing 300
pg/ml carbenicillin contained in 21 baffled flasks. The bacterial suspensions were
incubated at 37°C in an orbital shaker at 250rpm until the ODgoo was between 0.6
and 0.8. The cell suspension was induced with 1M IPTG to give a final
concentration of ImM, and the resulting suspension continued to be incubated in the
orbital shaker for 4 hours at 37°C. The cell suspensions were centrifuged at 5000g
for 10 minutes prior to discarding the supernatant and storing the pellet at -20°C until
required.
Once required, the pellet was defrosted and resuspended in 35ml ice-cold
PBS using an Ultra-Turrax T8 (IKA Labortechnik, Germany) prior to placing into
Oakridge tubes at -80°C for five hours. The suspension was defrosted prior to
sonicating on ice for 120 seconds using a 50% duty cycle. Lyoszyme was added at a
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final concentration of 0.2mg/ml prior to incubating at 4°C on a rolling platform for 1
hour. The aim of this step was to improve overall bacterial cell lysis efficiency. To
this suspension was added deoxycholic acid to a final concentration of 0.1%,
magnesium chloride to a final concentration of 2mM, and DNase I to a final
concentration of 2pg/ml prior to replacing on the roller platform at 4°C overnight.
This step was used to solubilise cellular membranes and destroy bacterial DNA so
aiding downstream purification. The suspension was then centrifuged at 20000g at
4°C for 10 minutes prior to discarding the supernatant and resuspending the pellet in
25ml ice cold PBS using an Ultraturex and sonication for 60s with a 50% duty cycle
before centrifuging once more as above. This was repeated three times. The pellet
was then resuspended in 25ml of a solution of 0.5% TritonXlOO and ImM EDTA
using the Ultraturex and sonication on ice as previous. This suspension was
incubated at 4°C on a roller platform for 30 minutes before centrifuging as above.
Finally, the pellet was resuspended in 30ml ice cold PBS using the Ultraturex and
sonication as previously, before centrifuging as above. This was also repeated three
times. Such washing has been shown to improve the purity of the final inclusion
body preparation (Fischer et al., 1992, Kuhelj et al., 1995). This final proteinaceous
pellet was resuspended in 10ml 6M Urea with 50mM HEPES pH 8.0 and 1M sodium
chloride using a combination of Ultraturex and sonication on ice as above. The
resulting suspension was incubated on a roller platform overnight at 4°C. This final
suspension was centrifuged at 20000g at 4°C for 15 minutes prior to removing and
storing the supernatant at 4°C, adding 0.25ml of a protease inhibitor cocktail adapted
for nickel-chelation chromatography.
The above inclusion body isolation technique was based on a documented
method (Sambrook et al., 1989), with adaptations based on a combination of other
methodologies following various trial isolation attempts (Altman et al., 1991, Altman
et al., 1993, Fischer et al., 1992, Frayser et al., 1999, Rudolph, 1996, Rudolph and
Lilie, 1996).
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5.5 Purification and refolding of recombinant protein
A 1.7ml POROS®20MC perfusion chromatography® column was packed
using the POROS® Self Pack® packing device on a Biocad 700E (.PerSeptive
Biosystems Inc.) as per manufacturer's instructions. The packed column was initially
stripped and regenerated as per the manufacturer's instructions prior to saturating the
column with nickel ions. The nickel ions were loaded using 400ml of the nickel
loading buffer past over the column at 3ml/minute using a Biocad 700E, removing
any unbound nickel using 10 column volumes of 0.5M sodium chloride. The
prepared column was equilibrated in 20 column volumes of the wash solution for
single chain. The protein suspension was passed through a 0.45pm filter before
loading onto the equilibrated column at 3ml/minute in 5ml aliquots, each aliquot
being separated by a 10 column volume wash step using the wash solution for single
chain. The column was eluted using 10 column volumes of the elution solution for
single chain. The eluted protein solution was stored at 4°C after adding 0.25ml of
Bacterial Protease Inhibitor Cocktail.
Based on the work of several authors (Burrows et al., 1998, Frayser et al.,
1999, Rudolph, 1996, Stockel et al., 1997), slow refolding of the purified single
chain protein construct was undertaken using serial dialysis at 4°C. A Seamless
Cellulose dialysis membrane was prepared by boiling three times for 20 minutes
each time in Milli-Q water. 20ml aliquots of the purified single chain protein
construct were placed into the prepared membrane before dialyzing at 4°C against 21
of a solution containing 6M Urea, 150mM NaCl, 5mM reduced glutathione, 0.5%
NP40, and 0.1% sodium azide in 20mM ethanolamine pHlO. Dialysis was continued
for 48 hours, changing the dialysate after 24 hours for a fresh solution. Dialysis was
then continued in 48-hour stages using 21 of the following solutions:
• 150mM NaCl with 5mM reduced glutathione, 0.5% NP40, and 0.1%
sodium azide in 20mM ethanolamine pHIO
• 150mM NaCl with 5mM reduced glutathione, and 0.1 % sodium azide
in 20mM ethanolamine at pHIO
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• 150mM NaCl with 5mM reduced glutathione, 0.5mM oxidised
glutathione and 0.1% sodium azide in 20mM ethanolamine at pHIO
• PBS with 0.1% sodium azide
• PBS with 0.05% sodium azide
Once in PBS the refolded single chain construct was removed from the dialysis
membrane and stored at 4°C with 0.25ml of Bacterial Protease Inhibitor Cocktail.
6 Cell Lysate Preparation
6.1 A20/HL60/BE1 Cell lysate
A20/HL60/BE1 cells were cultured in RPMI until at least 107 cells were
available for lysis. The cell suspension was centrifuged at 2000g for 5 minutes at
5°C before discarding the media and resuspending the cell pellet by vortexing in 1ml
PBS containing 2% NP40 and 75pi of Protease Inhibitor Cocktail (for mammalian
cell extracts - Sigma-Aldrich Company Limited). The cells were vortexed frequently
over a 1-hour period of storage on ice. The cell suspension was centrifuged at 3000g
for 5 minutes at 0°C and the supernatant harvested. The supernatant was stored at -
20°C until required.
6.2 Balb/c spleen lysate
The Balb/c spleen lysate was prepared using two methods. Initial work used
a method adapted from Marrack et al (Marrack et al., 1993). The spleen was
removed from a freshly killed Balb/c mouse and crushed between two frosted slides,
placing the contents into 1ml PBS containing 2% NP40 and Protease Inhibitor
Cocktail (for mammalian cell extracts - Sigma-Aldrich Company Limited) at 1ml per
20g wet weight of tissue. The spleen extract was sonicated on ice for 30 seconds
three times 1 hour apart before centrifuging at 18000g at 0°C for 30 minutes. The
resulting mixture was sonicated on ice before centrifuging as above. The supernatant
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was removed and 200jllI sterile water added to lyse any remaining red cells before
centrifuging at 20000g for 10 minutes at 0°C. The supernatant containing the cell
membrane suspension was removed and stored at -20°C until needed. Later work
used an adaptation of this method in order to improve yield. The spleen pulp was
initially homogenised using a Teflon-coated glass homogeniser on ice in the presence
of the Protease Inhibitor Cocktail. The resulting suspension was centrifuged at 500g
for 10 minutes at 4°C to remove nuclei and organelles. The supernatant was
removed and centrifuged at lOOOOOg for 2 hours at 4°C in a Beckman T70i
ultracentrifuge {Beckman Coulter (UK) Ltd.) in order to pellet the membranes. The
resulting pellet was resuspended in ice-cold PBS, 1% NP40, 0.05% Sodium azide,
and Protease Inhibitor Cocktail before storing at -20°C until required.
7 Protein Identification Methods
7.1 SDS-PAGE
SDS-PAGE gels were prepared in the usual manner as laid out in Sambrook
et al (Sambrook et al., 1989). Once set, the gels were placed into an electrophoresis
tank before being loaded with samples. Samples were mixed in a 50:50 ratio with
SDS sample buffer prior to running at 120V, 20mA (per gel) for 1.5hours (Consort
E834). 10pi ofPerfect Protein™ Markers (CN Bioscience) was loaded in one well of
each gel.
7.2 Western Blot
Proteins from the above gels were transferred onto a nitrocellulose membrane
{Schleicher & SchuelT) by blotting at 30V, 40mA in a wet blotting tank overnight.
This enabled further analysis by antibody probing of the resulting membrane.
All procedures were carried out at room temperature. The membrane was
initially stained with Ponceau S working solution for approximately 10 minutes prior
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to developing the stain with three washes in 1% acetic acid solution. The stained
marker lane was then excised from the membrane prior to blocking the membrane in
a solution of 0.5% TWEEN 20 in PBS for 30 minutes. The nitrocellulose was then
washed for 5 minutes (x3) in a solution of 0.1% TWEEN 20 in PBS, before exposing
the membrane to the primary antibody diluted to the desired concentration in 0.1%
TWEEN 20/PBS for 2 hours at room temperature on a rocking platform. The
nitrocellulose was then washed in 0.1% TWEEN 20/PBS as before prior to exposing
the membrane to the secondary antibody diluted in 0.1% TWEEN 20/PBS for 2
hours at room temperature.
At this juncture, two separate approaches were taken depending upon the
nature of the proteins being assessed:
In the majority of cases, particularly for bacterially derived proteins, a two-
layer approach was taken whereby the secondary antibody was conjugated to alkaline
phosphatase. Following exposure to the secondary antibody, the membrane was
washed with 0.1% TWEEN/PBS as previously prior to washing with alkaline
phosphatase buffer for 5 minutes. Detection was carried out by adding solutions of
both NBT and BCIP in a 1:400 dilution in alkaline phosphatase buffer. The colour
was allowed to develop prior to stopping the reaction by washing in dFEO, allowing
the membrane to air dry.
The alternative approach utilised a three-layer approach whereby the
secondary antibody was conjugated to biotin (.Diagnostics Scotland) with a tertiary
layer composed of streptavidin-peroxidase (Diagnostics Scotland). Detection was
carried out by adding either Sigma Fast ™ 3,3'-Diaminobenzidine hydrochloride or
3-amino-9-ethylcarbazole as per the manufacturer's instructions.
See Table 2 for complete list of antibodies used.
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Table 2 - Antibodies used
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7.3 Coomassie Brilliant Blue
Proteins from the above gels were also stained overnight using GelCode®
Blue Stain Reagent (.Perbio Science) as per the manufacturer's instructions. Although
utilising the colloidal properties of Coomassie G-250, this system was not only more
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convenient to use, but also yielded clearer results due to reduced background
staining.
7.4 Silver Stain
For greater sensitivity in protein detection, a silver stain was adapted from
Sambrook et al (Sambrook et al., 1989). All procedures were carried out at room
temperature. The proteins were fixed by incubating overnight in five gel volumes of
a solution of 30% ethanol, 10% glacial acetic acid and 60% Milli-Q water. The
fixative solution was discarded and the gel washed twice in 10 gel volumes of 30%
ethanol for 30 minutes each time. The gel was then washed three times in Milli-Q
water for 10 minutes each time. The water was discarded and five gel volumes of
freshly prepared 0.1% silver nitrate was added for 30 minutes. The gel was washed
rapidly in Milli-Q water prior to developing in five gel volumes of a freshly prepared
solution of 2.5% sodium carbonate and 0.02% formaldehyde in Milli-Q water. The
developing reaction was quenched by washing the gel in 1% acetic acid prior to
washing in dH20.
All solutions were prepared using Milli-Q water in clean glass containers to
reduce leaching from plastics. A rocking platform was used throughout to circulate
the solutions around the gel, and all incubations were performed at room
temperature.
7.5 Drying SDS-PAGE gels
SDS-PAGE gels were dried using a gel drying kit (Promega Corporation)
following the manufacturer's instructions. In essence, the SDS-PAGE gels are
washed in dH20 prior to placing between 2 sheets of Gel Drying Film that had been
moistened in a solution of 40% methanol, 10% glycerol and 7.5% acetic acid. The
films are clamped between two drying frames and allowed to dry at room
temperature for 48hrs.
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7.6 Immunoprecipitation
The immunoprecipitation method was adapted from that laid out in Sambrook
et al (Sambrook et ah, 1989). The antigen/antibody mixture volume was adjusted
using NET-gel buffer before incubating at 4°C on a rocking platform for 5 - 6 hours.
The Protein A-sepharose was equilibrated in NET-gel buffer prior to adding lOOpl of
the suspension to the antigen/antibody mixture and continuing to incubate overnight.
The Protein A-sepharose mixture was passed through a Mobicol® 1ml microcolumn
(MoBiTec GmbH) with a 10pm pore filter to collect the sepharose beads. The beads
were then washed twice with NET-gel buffer at room temperature for 20 minutes
each time before washing once with lOmM Tris.Cl (pH 7.5)/0.1% NP40 for 30
minutes at room temperature. The beads were dried by centrifuging the column at
2000g at room temperature for 5 minutes. The antibody/antigen were eluted from the
protein A-sepharose by incubating with lOOpl lOOmM glycine (pH 2.95) / 0.15M
NaCl for 2 minutes at room temperature prior to centrifuging at 2000g for 10 minutes
at room temperature. The eluate was collected in a microcentrifuge tube containing a
neutralising quantity of 1M Tris (pH 8.0). The eluate was stored at -20°C until
analysis.
7.7 Cytospin
Cytospins were prepared from cell suspensions of both induced and non-
induced Drosophila S2 cells. lOOpl of cell suspension was taken and centrifuged at
300g for 3 minutes onto Superfrost Plus® (BDH Laboratory Supplies) slides using a
Shandon Cytospin 2® cytocentrifuge (Thermo Shandon Inc.). The slides were
allowed to air-dry for 10 minutes prior to fixing in a solution of 90% chemically dry
acetone and 10% methanol for 10 minutes at room temperature. The now fixed
slides were then allowed to air-dry at room temperature before being stored at room
temperature for a maximum of 48 hours. Slides were also stored at -20°C following
the initial 10 minute period of air-drying at room temperature.
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The fixed cells were first demarcated by encircling using an ImmEdge Pen®
{Vector Laboratories Inc.). In order to stain the fixed cells, the slides were first
washed in PBS +/- 0.1% saponin for two 5-minute washes at room temperature
before blocking for non-specific protein binding. Blocking was achieved by
sequentially washing with a solution of 1% BSA in PBS +/- 0.1% saponin for 30
minutes at room temperature followed by 1% serum (homologous to the secondary
antibody to be applied) in PBS +/- 0.1% saponin for 30 minutes at room temperature.
The slides were then washed twice for 5 minutes in PBS +/- 0.1% saponin prior to
incubating flat with a 1:50 dilution of the primary antibody in PBS +/- 0.1% saponin
for 1 hour at room temperature. The slides were then washed twice for 5 minutes in
PBS +/- 0.1% saponin before incubating flat, hidden from light and at room
temperature, with a 1:50 dilution of the relevant FITC-conjugated secondary
antibody in PBS +/- 0.1% saponin. The slides were then washed 3 times for 5
minutes in PBS +/- 0.1% saponin prior to air-drying at room temperature. The
stained slides were mounted in VectorShield with DAPI® (Vector Laboratories Inc.)
under a coverslip before sealing with clear nail varnish.
The stained slides were viewed using an Axiovert SI00® microscope {Carl
Zeis) with a CoolSNAP ® camera {PhotoMetrics) and Openlab 3.0® software
{Improvision). In general, exposure times were as follows:
DAPI - 0.03s at x63(oil-immersion) and 1.00s at x32
FITC - 1.50s at x63(oil-immersion) and 8.00s at x32
The photographs were collated using Adobe® Photoshop® 6.0 {Adobe Systems Inc.),
overlaying the FITC image onto the DAPI background image set at 45% opacity.
See Appendix 3 for list of solutions used.
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Chapter 3
Results (I)
Formation of Soluble Recombinant l-Ed Heterodimers
Suitable for Tetramer formation
1 Introduction
Preliminary investigations were undertaken using murine I-Ed for two main
reasons. First, there was the prospect of undertaking interesting experiments aimed
at studying important questions in collaboration with Dr R.N. Barker's group at the
University of Aberdeen. Second, constructs and a working expression system were
available locally that required relatively minor degrees of alteration to allow their
theoretical viability.
Dr Barker's group have been investigating spontaneous autoimmune
haemolytic anaemia (AIHA) that occurs in NZB mice. The target antigen for this is
known to be the Band 3 anion channel protein found on red blood cells, and the
process is known to be I-Ed restricted (Elson and Barker, 2000, Perry et al., 1996).
Therefore, this collaboration would enable any I-Ed tetramer constructs to be tested
in vivo within a working disease model, and would form the basis for the
development of human MF1C class II tetramer work within a developing disease
model ofGoodpasture's Disease.
Soluble recombinant I-Ed devoid of its transmembrane domains (I-Edt) had
been successfully produced using insect cell expression systems. Kozono et al
(Kozono et al., 1994) had used a baculovirus based system to form soluble murine
MHC class II proteins (I-Edk and I-Ad) with covalently bound peptides, whilst
Wallny et al (Wallny et al., 1995) had used the simpler Drosophila melanogaster
Schneider cell expression system to form soluble I-Edt devoid of associated peptide.
Given the success of the latter system as well as its relative ease of use, the
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Drosophila melanogaster Schneider line 2 (S2) cell expression system was chosen.
The rapidity of selection using hygromycin B and the ease of expression using the
inducible metallothionein promoter adds to the systems favourability. Moreover, the
cell lines are capable of growth in serum-free medium without a significant loss of
protein expression, and in large-scale reactors so improving production and
purification steps. The majority of proteins produced to date using this system have
been functionally indistinguishable from their native counterparts, and have not
required further refolding (Ivey-Hoyle, 1991).
2 Construction of Recombinant l-EdtPCBirA
2.1 The l-Ed(3tBirA construct
Wallny et al (Wallny et ah, 1995) had demonstrated the functionality of the
expressed I-Edt in terms of peptide binding and T cell activation. They had
exogenously loaded the soluble recombinant I-Edt proteins and used the resulting
complexes to coat ELISA plates and show T cell activation by the formed
complexes. Adapting this established functional system for TBB formation required
modification of the construct (Figure 3.1). The necessary adaptations to I-Edt had
largely been completed when I joined the laboratory and these will be briefly
described here because my work built upon these constructs in general, specifically
pRmHa3 I-Ed(3tBirA. Wallny et al (Wallny et al., 1995 15) kindly donated the
constructs pRmHa-3 I-Edat and I-Ed(3t. Two modifications to the I-Edpt were
undertaken to enable its further use in tetramer formation:
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Figure 3.1 - I-E construct comparison
a) Natural murine I-E
I-E P cDNA
Leader |pquence
T ransmjempra jte fflomains
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c) Planned recombinant murine I-EdtBirA and I-EdtBand3
vi"fTk
Peptide binding cassette I-E ptBirA cDNA:
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Predicted molecular weights:
I-EdptBirA - 24.8 kD
I-EdptBirABand3 - 27.6 kD
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The first modification was the addition of the BirA biotinylation consensus
sequence to the carboxy terminus of the extracellular I-Ed beta chain. This consensus
sequence results in the covalent attachment of biotin, through the action of the E.coli
biotin holoenzyme synthetase BirA, to a unique lysine residue (K) within the 13
amino acid consensus sequence domain (LxxILDAQKMVWx) (Beckett et ah, 1999,
Schatz, 1993). The consensus sequence used is the same as that used by Altman et al
(Altman et al., 1996) and is based upon the work of Schatz (Schatz, 1993). The
addition of this sequence to the carboxy terminus of I-Edpt permits enzymatic site-
specific biotinylation of the recombinant I-Ed beta chain. Such single-site
biotinylation is important in order to ensure that later mixing with avidin results in
four recombinant I-EdtBirA molecules being bound to each avidin molecule so
forming a tetramer without interfering with T cell TCR binding. This modification
was performed using the two oligonucleotides BirAl and BirA2 (See Appendix 1)
that were annealed to create the BirA adapter sequence. This sequence was inserted
into the Kpni/BamHI site ofpUC19, so forming pUC19BirA.
The second modification was the addition of a covalently linked peptide-
binding domain to the amino terminus of the I-Ed beta chain following on from the
work of Kozono et al (Kozono et al., 1994). This would allow relatively easy
insertion of cDNA encoding different peptides into the recombinant I-EdtBirA. This
involved the insertion of an Xhol restriction site between the leader sequence and the
start of the pi domain of I-Edpt (vide infra). The insertion of this site involved the
separate PCR amplification of the I-Edpt leader sequence using the oligonucleotide
pair IE1 and IE2 (See Appendix 1) and the I-Edpt sequence itself using
oligonucleotide pair IE3 and IE4 (See Appendix 1). This amplification introduces an
EcoRI site 5" of the leader sequence, an Xhol site 3" of the leader sequence and 5' of
the I-Edpt sequence, and a Kpnl Site 3" of the I-Edpt sequence. These two separate
products were combined using the intervening Xhol site prior to expanding with the
two outside oligonucleotides IE1 and IE4. This final product was inserted into
pUC19BirA using the EcoRI and Kpnl restriction sites so forming pUC19-I-
EdptBirA (Figure 3.2)
Chapter 3 - Results (I) 82
Formation ofMHC Class II - Peptide Multimers
Figure 3.2 - Nucleotide and amino acid Sequences of I-EdptBirA
a) Nucleotide sequence:
1 GAATTCGAGC TCCTGCAGCA TGGTGTGGCT CCCCAGAGTT CCCTGTGTGG
EcoRI START LEADER SEQUENCE
51 CAGCTGTGAT CCTGTTGCTG ACAGTGCTGA GCCCTCCAGT GGCTTTGGTC
101 AGAGACACTC GAGGCCCACG GTTTTTGGAA TACGTTACAT CTGAGTGTCA
Xhol
151 TTTCTACAAC GGGACGCAGC ACGTGCGGTT TCTGGAGAGA TTCATCTACA
201 ACCGGGAGGA GAACCTGCGC TTCGACAGCG ACGTGGGCGA GTACCGCGCG
251 GTGACAGAGC TGGGGCGGCC AGACGCCGAG AACTGGAACA GCCAGCCGGA
301 GATCCTGGAG GATGCGCGGG CCTCGGTGGA CACGTACTGC AGACACAACT
351 ATGAGATCTC GGATAAATTC CTTGTGCGGC GGAGAGTTGA GCCTACGGTG
401 ACTGTGTACC CCACAAAGAC GCAGCCCCTG GAACACCACA ACCTCCTGGT
451 CTGCTCTGTG AGTGACTTCT ACCCTGGCAA CATTGAAGTC AGATGGTTCC
501 GGAATGGCAA GGAGGAGGAA ACAGGAATTG TGTCCACGGG CCTGGTCCGA
551 AATGGAGACT GGACCTTCCA GACACTGGTG ATGCTGGAGA CGGTTCCTCA
601 GAGTGGAGAG GTTTACACCT GCCAGGTGGA GCATCCCAGC CTGACCGACC
651 CTGTCACGGT CGAGTGGAAA GCACAGTCCA CATCTAGGGG TACCGCTAGC
Kpnl
701 GGCGGTGGAC TGCATCATAT TCTGGATGCA CAGAAAATGG TGTGGAATCA
751 TCGTTAAGGA TCC Bii A SEQUENCE
STOP BamHI
b) Protein sequence:
1 RDTRG PRFLE YVTSE CHFYN GTQHV RFLER FIYNR EENLR
Peptide cassette link
41 FDSDV GEYRA VTELG RPDAE NWNSQ PEILE DARAS VDTYC
81 RHNYE ISDKF LVRRR VEPTV TVYPT KTQPL EHHNL LVCSV
121 SDFYP GNIEV RWFRN GKEEE TGIVS TGLVR NGDWT FQTLV
161 MLETV PQSGE VYTCQ VEHPS LTDPV TVEWK AQSTS RGTAS
201 GGGLH HILDA QKMVW NHR
BirA Sequence
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Once formed in pUC19, the I-EdptBirA construct was sequenced to confirm its
accuracy before cloning into the expression vector pRmHa-3 using the EcoRI and
BamHI restriction sites. Based on the murine model of AIHA, the linked peptide
chosen was a Band 3 peptide previously shown to stimulate a vigorous T cell
response.
The pRmHa3-I-Edat construct required no modification from that described
by Wallny et al (Wallny et al., 1995).
2.2 The Peptide binding cassette construct
Peptide binding is an important component in the maintenance ofME1C Class
II heterodimeric stability and association (Germain and Hendrix, 1991). Therefore, a
peptide-binding cassette was constructed in order to enable different peptides to be
covalently linked to the N-terminus of I-EdptBirA. In order to allow relatively easy
insertion of cDNA encoding these different peptides we designed a cassette
containing two insertion sites suitable to accept adapters for the desired peptides.
The covalently linked peptides should thus occupy the peptide-binding groove of I-
EdptBirA, improving overall peptide-binding groove occupancy and stability. The
peptide-binding cassette was modelled on the successful construct described by
Kappler and Marrack's group (Kozono et al., 1995, Kozono et al., 1994, Liu et al.,
1997).
The cassette was generated by annealing the oligonucleotides PCTop and
PCBottom (See Appendix 1) to generate a double-stranded adapter cDNA which was
cloned into the XhoEBglll sites of pUC19, forming pUC19pepcas. This plasmid was
used to assemble and sequence the cDNAs encoding the desired peptide inserted into
the cassette using the Bglll site. The complete cassette could then be excised using
Xhol/Sall prior to insertion into the Xhol site of I-EdptBirA (Figure 3.3). The
correct insertion of the cassette would require clarification through restriction
enzyme digestion. Once the recombinant peptide had been formed linked to the I-
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EdptBirA construct, the linked peptide could, if desired, be released from its covalent
linkage by thrombin enzymatic cleavage.
Figure 3.3 - The peptide-binding cassette
a) Nucleic acid sequence:
ctg cag etc gag ggg aga tct gga ggt tea eta gtg cca egg ggc tct gga ggc ggtcga egg tac c
III / I
PstI Xnol Bglll Sail Kpnl
b) Amino acid sequence:
G*R S G 6 S ivmfl S G G G
t
Thrombin cleavage site
Linker peptide Linker peptide
The diagram shows the nucleic acid sequence of the planned peptide-binding cassette, including its
intrinsic unique restriction enzyme sites. The expected amino acid of the cassette is outlined, and the
site of peptide linkage is asterisked.
I felt that it was necessary to assess the accuracy of the DNA sequences of I-
Edat and I-EdptBirA within the pRmHa3 vector, particularly with respect to the
reading frame of the sequences, prior to assessing the presence of inducible protein.
Samples of both pRmHa3-IEdat and pRmEIa3-IEdptBirA were sequenced using the
metallothionein promoter oligonucleotide (pMT) as the sequencing primer. Analysis
of the DNA sequences revealed that they were correct and in frame.
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3 Expression of Recombinant l-EdtBirA - Preliminary work
3.1 Transfection and selection of S2 cells
Drosophila melanogaster S2 cells were transfected by calcium phosphate
precipitation with a mixture of lpg pCoHYGRO (Hygromycin-resistance vector),
9pg I-Edat, and 9pg of either I-EdptBirA or I-EdptPCBirA-Band3. Selection with
Elygromycin-B was continued for a minimum of six weeks. Induction was
performed with ImM copper sulphate. Initial protein induction was carried out in
the presence of Hygromycin-B, although the later work was carried out in its
absence.
The selection of the Hygromycin-B concentration used was based upon an
assessment of the concentration of Hygromycin-B needed to kill untransfected S2
cells whilst allowing the survival of transfected cells. Two six well plates were taken
and each seeded with either a cell suspension of untransfected S2 cells or S2 cells
transfected with the pCoHYGRO vector. Hygromycin-B was then added to the
medium in each of the two plates in increasing concentrations per well (300, 500,
600, 700, 800 and 1000pg/ml), before incubating the plates in the cooled incubator at
25°C. After 72 hours incubation all of the transfected cells were found to be viable,
however, the untransfected cells were only viable at the lowest Hygromycin-B
concentration. After a further 72 hours, none of the untransfected cells were viable,
whilst all of the transfected cells remained viable. Following from this brief
experiment a concentration of 500pg/ml ofHygromycin-B was used as the selection
concentration for all further experiments.
3.2 Assessment of l-Ed controls using monoclonal antibodies
In order to assess the formation of recombinant heterodimeric I-Ed using the
Drosophila expression system, positive controls needed to be established and
antigen-specific monoclonal antibodies needed to be evaluated.
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Two different protein controls were formed: an A20 cell lysate and a Balb/c
spleen preparation. Each of these was assessed by Western blotting using the
monoclonal antibodies 14-4-4S and 2G9 (Figure 3.4 & Figure 3.5).
2G9 identifies the I-EdaP heterodimeric band at approximately 50kD, as well
as the monomeric a band at approximately 25kD, within both the Balb/c spleen and
the A20 cell lysates (Becker et ah, 1992). 14-4-4S does not appear to bind to I-Ed as
well as 2G9 during Western blotting. The 14-4-4S antibody normally binds to a
conformational epitope formed by both I-Ed a and P chains, which is altered during
SDS-PAGE (Ozato and Sachs, 1982). However, the antibody does appear to bind
weakly to I-EdaP heterodimeric band and an I-Ed monomer band within the A20
lysate. Later work suggests that 14-4-4S may be specific to an I-Ed a-chain epitope
(Spencer et ah, 1993, Spencer and Kubo, 1989).
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Lane 1 - Perfect Protein® marker
Lane 2 - Stained with 14-4-4S
Lane 3 - Stained with 2G9
Lane 4 - Stained with anti-mouse IgG alone
>- - Positive band
A20 cell lysate samples were separated by SDS-PAGE and transferred onto nitrocellulose by Western
blotting. The nitrocellulose was probed using both I-A/l-E - specific monoclonal antibodies. A faint
band at about 25kD is identified by both monoclonal antibodies, and represents the separate I-Eda
chain. This is more clearly defined with 2G9. A faint band is also seen at 50kD with both
monoclonal antibodies representing the heterodimeric I-Ed. No non-specific staining is seen with
secondary antibody alone.
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Lane 1 - Perfect Protein® markers
Lane 2 - Stained with 2G9
Lane 3 - Stained with 14-4-4S
>- - Positive band
Balb/c spleen lysate samples were separated by SDS-PAGE and transferred onto nitrocellulose by
Western blotting. The nitrocellulose was probed using both I-A/I-E - specific monoclonal antibodies.
A definite band at about 50kD is identified by 2G9 representing the heterodimeric 1-Edap. Fainter
bands are seen at about 25kD that represent the monomeric a chain of I-Ed. No definite staining is
seen with 14-4-4S.
4 Characterisation of Expression of Recombinant l-Ed
4.1 Assessment of transcription
DNA transcription was assessed in duplicate using RT-PCR of extracted
mRNA from both induced (ImM CuSO.4) and non-induced S2 cells (Figure 3.6).
The following primer pairs were used for gene-specific amplification following
cDNA synthesis:
• For IEdat - SC3 and SCm4 (See Appendix 2)
• For IEdptBirA - IE1 and IE4 (See Appendix 1)
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Figure 3.6 - I-Ed transcription assessed by RT-PCR











Lane 1 - Hae III DNA digest ladder
Lane 2 - I-EdtBirA - non-induced S2 cells
Lane 3 - I-EdtBirA - induced S2 cells
Lane 4 - I-EdtBirA - non-induced S2 cells (Reverse transcriptase inactivated)
Lane 5 - I-EdtBirA - induced S2 cells (Reverse transcriptase inactivated)
Lane 6 - I-EdtBand3 - non-induced S2 cells
Lane 7 - I-EdtBand3 - induced S2 cells
Lane 8 - I-EdtBand3 - non-induced S2 cells (Reverse transcriptase inactivated)
Lane 9 - I-EdtBand3 - induced S2 cells (Reverse transcriptase inactivated)
Lane 10 - pRmHa3-I-Edat plasmid
- Positive bands
- Primer dimers/trimers
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b) Transcription of I-Ed p-chain assessed by RT-PCR
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Lane 1 - Hae III DNA digest ladder
Lane 2 - I-EdtBirA - non-induced S2 cells
Lane 3 - I-EdtBirA - induced S2 cells
Lane 4 - I-EdtBand3 - non-induced S2 cells
Lane 5 - I-EdtBand3 - induced S2 cells
Lane 6 - pRmHa3-I-EdptBirA plasmid
Lane 7 -pRmHa3-I-EdptPCBirABand3 plasmid
CZ> - Postive bands
mRNA was extracted and treated with RNase-free DNase I (Promega Corporation, USA) prior to first
strand synthesis to reduce DNA cross-contamination. A concurrent control was also performed as per
manufacturer's instructions to assess DNA cross-contamination by inactivating the M-MuLV reverse
transcriptase. Separate micro-tubes were used for cDNA synthesis intended for assessment of IEd
alpha chain and beta chain mRNA using gene-specific primers. First strand cDNA was generated by
M-MuLV reverse transcriptase and PCR was used to amplify the cDNA using the gene specific
primers (32 cycles, denature at 95°C for 30 seconds and anneal at 55°C for 30seconds). Positive
controls for the PCR step were formed using the plasmids pRmHa3-IEdat, pRmHa3-
IEd|3tBirA and pRmHa3-IEdptPCBirABand3. The PCR products were analysed by agarose gel
electrophoresis. The above is a representative gel from three experiments.
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RT-PCR shows the production of the I-Edpt chain mRNA only in the induced
cells (Figure 3.6b). In terms of the I-Edat chain, it would appear that some mRNA is
present in the uninduced cells, although this is increased upon induction (Figure
3.6a). This does not appear to be secondary to DNA contamination as there are no
bands in the negative control lanes. The above experiment indicates that DNA
transcription of pRmHa3-IEdat, pRmHa3-IEdptBirA and pRmFIa3-
IEdptPCBirABand3 plasmids was taking place upon induction of the cells with
copper.
4.2 Assessment of protein production within induced S2 cell
supernatant
Preliminary work using S2 cells stably transfected with pRmHa3 -human a3
Type (IV) collagen NCI domain had shown protein production after 2 days of copper
induction, continuing for at least 16 days. S2 cells stably transfected with pRmHa3-
IEda and pRmHa3-IEdptBirA (+/- covalently linked Band3 peptide) were induced
using ImM copper sulphate for 10 days. The supernatant from the induced cells was
analysed by Western blot probed with I-A/Ed specific monoclonal antibody 2G9
(Figure 3.7). No identifiable I-EdtBirA was detected in this preliminary induction
using ImM copper ions in the presence of Hygromycin-B. The possibility of low-
level production was assessed by repeating the above induction. S2 cells stably
transfected pRmHa3-IEda and pRmHa3-IEd(3tBirA were induced as above and a
larger volume of cell supernatant concentrated by immunoprecipitation using the 14-
4-4S monoclonal antibody (Figure 3.8). This revealed faint bands at around 30kD in
lanes 1 and 2, at a similar level to the bands seen in the control lane 3. The predicted
molecular weights of I-EdptBirA, I-Edat and native 1-Eda and I-Edp being 24.8kD,
20.4kD, and about 34kD and 29kD respectively. No similar bands are seen in the
antibody alone lane (Lane 4). The dual banding may represent differential I-
Edat and pt chain SDS-PAGE mobilities. 2G9 certainly competes with the I-Ap
chain specific monoclonal antibody MK-D6 (Ruberti et al., 1992), although the paper
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describing the development of 2G9 implies recognition of the I-A/I-Ea chain rather
than a conformational epitope per se (Becker et ah, 1992). The yield of I-EdtBirA,
therefore, appears to be at a low level using the current induction regimen, although
the formed protein appears to be "conformationally correct" given its
immunoprecipitation using 14-4-4S. However, the disparity between the expected
molecular weights of the immunoprecipitated proteins and their apparent weights is
difficult to explain other than to consider the result a spurious one.
Figure 3.7 - Assessment of I-EdtBirA production by stably transfected S2 cells
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Lane 1 - Perfect Protein® marker
Lane 2 - Supernatant from untransfected S2 cells
Lane 3 - Supernatant from S2 cells transfected with human a3(IV) collagen
Lane 4 - Supernatant from S2 cells transfected with I-EdtBand3
Lane 5 - Supernatant from S2 cells transfected with I-EdtBirA
Lane 6 - Supernatant from S2 cells transfected with murine a3(IY) collagen
Lane 7 & 8 - Supernatant from S2 cells transfected with human a5(IV) collagen
Lane 9 - Concentrated recombinant I-Edt from I-Edt transfected S2 cell supernatant
2G9 immunoblot of supernatant taken from induced S2 cells transfected with constructs coding for
one of five different protein sequences. The only positive band seen is in the positive control Lane 9.
This is representative of five separate protein induction experiments.
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, Lane 1 - Immunoprecipitate of I-E tBirA sample 1
50kD - Lane 2 - Immunoprecipitate of I-EdtBirA sample 2
35kD -
'H f £ Lane 3 - Immunoprecipitate ofBalb/c spleen
25kD - Lane 4 - 14-4-4S monoclonal antibody sample
>• - Positive band
15kD -
S2 cells stably transfected with pRmHa3-IEd|3tBirA and pRmHa3-IEdat were induced using ImM
copper sulphate. The supernatant was harvested after 72 hours by centrifuging the cell suspension at
500g for 5minutes at 15°C. 40ml of supernatant was immunoprecipitated using the 14-4-4S
monoclonal antibody. Balb/c spleen was used as the positive antigen control. The elution was
performed using lOOpl SDS gel-loading buffer (containing DTT). The immunoprecipitates were
separated by SDS-PAGE gel electrophoresis before a Western blot was performed using 2G9 as
previous.
The results indicated possible expression of soluble I-EdtBirA complexes that
bound 14-4-4S, but at much lower levels than expected from previous reports
{Wallny, 1995 #15}. Possible causes for the disappointing results could have
included the concentration of copper used at induction, the length of the induction
period, as well as the presence of hygromycin at induction. These factors were
separately assessed on at least two occasions each, but the results remained
disappointingly unchanged, with a consistent lack of identifiable I-EdtBirA protein in
induced S2 cell supernatants. Although previous work using pRmHa3-human a3
Type (IV) collagen NCI domain had shown variations in expressed protein
production between stably transformed cell populations, this could not be a feasible
explanation for the consistent lack of identifiable I-EdtBirA protein. Therefore, the
possibility of intracellular sequestration of the induced protein due to poor secretion
was investigated.
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4.3 Assessment of protein production within induced S2 cells
In order to investigate the possible sequestration of proteins within induced
cells, cytospins of both the induced and non-induced S2 cells were made. The
cytospins were stained using either 2G9 (Figure 3.9) or 1444S.
Figure 3.9 - Cytospin of S2 cells transfected with I-EdtBirA (+/- Band3) stained using 2G9
a) Induced S2 cells with I-EdtBirA (No saponin used) - X400 magnification
b) Induced S2 cells with I-EdtBirA (Saponin used) - X400 magnification
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c) Uninduced S2 cells with I-EdtBirA (Saponin used) - X630 magnification
d) Induced S2 cells with I-EdtBirABand3 (No saponin used) - X400 magnification
e) Induced S2 cells with I-EdtBirABand3 (Saponin used) - X400 magnification
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f) Uninduced S2 cells with I-EdtBirABand3 (Saponin used) - X630 magnification
The S2 cells were washed and probed in the presence and absence of saponin. Saponin was utilised in
order to permeabilise the S2 cell membranes and allow intracellular protein identification. 2G9 was
used at a 1:50 dilution for 2 hours at room temperature before washing and developing using FITC-
conjugated goat-anti-rat IgG at a 1:50 dilution for 1 hour at room temperature. Uninduced S2 cells
were used as negative controls for the primary antibody, whilst the secondary antibody alone was used
to assess for non-specific staining. The above are representative cytospins from three experiments.
The cytospins stained with 2G9 reveal low-level I-EdtBirABand3 and I-
EdtBirA protein production. The staining pattern appears to be cytoplasmic, whether
with or without saponin, indicating that the cytospin process may have permeabilised
the cells. There is no clear indication of excessive intracellular protein sequestration
(Figure 3.9). Non-specific staining is not seen in the secondary antibody alone
control slides, and there is no evidence of protein production in the uninduced cells.
There does not appear to be any subjective difference between transfectants carrying
the linked Band 3 peptide and those simply carrying the empty peptide-binding
cassette. Similar results were seen when using 14-4-4S. These results are in keeping
with the findings of both supernatant immunoprecipitation and RT-PCR of probable
low-level protein production.
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5 Discussion
Attempts at producing the modified murine I-EdtBirA +/- linked Band3
peptide resulted in poor protein yield. Although nucleic acid work had shown the
accuracy of the DNA sequences and their transcription on copper induction,
translational problems appear to have occurred preventing significant protein
production. The system was tested in the absence of selection agent to minimise
cellular toxicity at induction with no real difference in outcome. Certainly
difficulties had been experienced with yield by other groups using eukaryotic
expression of 'empty' MHC Class II molecules (McMichael and Kelleher, 1999),
and this had led to the use of covalently linked peptide to the amino terminus of the
pi chain of MHC Class II molecules using a flexible linker (Crawford et ah, 1998,
Kozono et ah, 1994). One drawback to this approach is that separate constructs
would have to be engineered for each peptide being analysed. However, the
presence of covalently linked peptide did not appear to improve protein production in
my system, highlighting that such modifications are not always successful. It is
possible that the relatively minor modifications to the I-Edpt resulted in a reduction
of expression efficiency, however the reasons for this remain unclear.
It was clear that changes to the construct and/or expression system would be
necessary to obtain sufficient protein to form tetramers. I considered exploring
further the reasons for the poor yield, but reports from other groups clearly indicated
that efficient production required careful enhancement of a,p association either
through non-covalent or covalent binding. Two techniques were beginning to
emerge in the literature:
Work by Cosson et al (Cosson and Bonifacino, 1992) identified the
importance of the transmembrane domains ofMHC Class II molecules in facilitating
their heterodimeric association, although not necessarily their peptide-binding
ability. The importance of chain pairing is further highlighted by reports that
separate MHC Class II chains may bind peptide (Dornmair and McConnell, 1990,
Rothenhausler et al., 1990), and indeed that this binding may induce antigen-specific
apoptosis of T cells (Nag et al., 1996). Acid-base leucine zipper dimerisation
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domains had been successfully used to replace the transmembrane domains and lead
to the production of recombinant soluble MHC Class II heterodimers (Novak et al.,
1999, Radu et al., 1998, Scott et al., 1998). Following discussions with Dr E. Sally
Ward's group, they made their acid-base leucine zipper motif available to me for
furthermodification to enable its use in my constructs (See Chapter 4).
The second technique used bacterial expression to improve yield, and
radically altered the way in which the heterodimeric peptide-binding domain of
MHC Class II was formed. Burrows et al (Burrows et al., 1998, Burrows et al.,
1999) had developed a single chain construct linking the rat RT1.B Pi to the oq
domain in such a way that they could be refolded into an active and functional
peptide binding domain (See Chapter 5).
As both techniques were evolving and not yet of proven utility, I decided to
utilise both in a twin-pronged attack on the generation of murine and human MHC
Class II multimers.
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Chapter 4
Results (II)
Formation of Leucine Zipper-associated Recombinant
Heterodimeric HLA-DR Tetramer Building Blocks
1 Introduction
I decided to adapt a technique that has been successfully used by other groups
to facilitate the heterodimeric pairing between two protein chains. The leucine
zipper motif mediates dimerization of a number of different proteins, classically
DNA-binding proteins. The motif is a sequence of leucine residues spaced every
seventh amino acid residue along an alpha helix, and as a result, all the leucine
residues of the motif are placed along one side of the alpha helix. According to the
zipper model, the leucine side chains extending from the leucine repeats are able to
interdigitate with the leucine side chains of a second polypeptide chain that contains
the same motif. Therefore, the hydrophobic surfaces of two leucine repeating
sequences of the protein molecules interact to form homo or heterodimers
(Landschulz et al., 1988). Based on the Fos-Jun leucine zipper interaction O'Shea et
al (O'Shea et al., 1993) engineered an acid-base leucine zipper coiled-coil structure
that had additional unfavourable electrostatic interactions in the homodimeric state,
so further favouring heterodimeric association. This strategy was used to enhance
the heterodimeric pairing of a TCR a and p chain (Chang et al., 1994), and was
developed further by Dr E. Sally Ward's group to improve the heterodimeric
association and stability of recombinant I-Au and I-Aq expressed using the
baculovirus insect cell expression system (Radu et al., 1998). Dr W. Kwok's group
also developed the same strategy for the formation of recombinant HLA-DR4 using
the Drosophila S2 expression system (Novak et al., 1999).
Other groups have successfully used such a chain-pairing strategy. Scott et al
(Scott et al., 1996, Scott et al., 1998) used leucine zippers to improve the yield and
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stability of 'empty' functional IAd expressed in Drosophila melanogaster SC2 cells
using the pRmHa3 vector. Wucherpfennig's group have used the Fos/Jun
transcription factor leucine zipper motifs to aid in the formation of secreted HLA-
DR2 using both a yeast (Kalandadze et al., 1996) and a baculovirus expression
system (Gauthier et al., 1998, Smith et al., 1998).
Following a presentation by Dr Radu (Radu, 1999), I approached his group
regarding the use of their acid-base leucine zipper construct in my own work. As we
were working on different disease models, Dr Ward kindly donated cDNA encoding
the zipper motifs. This chapter describes my design, production and characterisation
of HLA-DR15 and HLA-DR7 heterodimers utilising acid-base leucine zippers to
promote heterodimer formation.
2 Design of Acid-Base Leucine Zipper-associated HLA-DR15
and HLA-DR7 Molecules
The aim of this strategy is to promote both the association and stability of the
HLA-DR ap heterodimeric complex by replacing the transmembrane domains of the
a and p chains with acidic and basic leucine zipper sequences respectively. The use
of these zipper motifs would fix the alignment of the alpha and beta chains, so
correct design was imperative. Therefore, I modelled my construct design on that
successfully used by Dr Ward's group (Radu et al., 1998) by aligning the sequence
of the I-Aq molecule they adapted with the sequences of HLA-DR15 and DR7 using
Clustal X (Thompson et al., 1997). The alignments shown in Figure 4.1 identified
the positions in the sequence of HLA-DRa and p where insertion of the leucine
zipper sequences would most closely resemble the successful construct produced by
Dr Ward's group.
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Figure 4.1 - Alignment of I-A and HLA-DR peptide sequences
Alignment of MHC Class II alpha chain peptide sequences
I-Aq alpha chain - I E A D H V- -E L T E T - Linker sequence
HLA-DRA*0101 - IEEKHV—ETTEN - Transmembrane
Alignment of MHC Class II beta chain peptide sequences
I-Aq beta chain - HFVAQL--ESALSK - Linker sequence
HLA-DRB1*1501 - R F L W Q P—E S A Q S K - Transmembrane
HLA-DRB1*0701 - R F L W Q G—E S A Q S K - Transmembrane
The sequences for I-Aq were provided with the constructs donated by Dr Ward's
group (C.G. Radu, personal communication). The HLA-DR sequences were
obtained from the GenBank sequence database. The figure shows extracts of the
alignments taken at the commencement of the I-Aq alpha and beta sequences and the
junction site with the transmembrane domain.
The design features of the construct were (Figure 4.2):
a) An acidic and basic leucine zipper sequence at the carboxy terminus of the
extracellular alpha and beta chain domains respectively to enhance
heterodimer formation and the yield of conformationally correct HLA-DR
molecules.
b) A polyhistidine tail at the carboxy terminus of the alpha chain acidic leucine
zipper to aid identification of the alpha chain and protein purification by
metal chelation chromatography (Kuroda et al., 2000, Scott et al., 1998).
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c) A human c-myc tag at the carboxy terminus of the beta chain basic leucine
zipper to aid beta chain identification.
d) A linker sequence between the a and (3 chains and their relevant tail sections
that not only allows for greater flexibility of the final heterodimer, but also
contains a thrombin cleavage site which can be used to release each chain
from its tail. The flexibility afforded by these linker sequences may allow or
even facilitate clustering of the MHC - peptide - TCR complex on the
surface of an antigen-specific T cell. Such flexibility might also compensate
for any errors in chain alignment.
e) A site-specific biotinylation sequence at the carboxy terminus of the beta
chain construct. This sequence would permit site-specific biotinylation of the
beta chain and enable multimerisation of the resulting a(3 heterodimer using
the avidin-biotin interaction as per "classical" tetramer design.
f) No covalently attached peptide was specified in order to allow different
peptides to be associated. This would enable various reagents to be formed in
order to analyse T cells (Kwok et al., 2001, Novak et ah, 2001a). Provision
was made for later insertion of covalently attached peptide should problems
arise with poor heterodimeric association, yield, or peptide loading by the
introduction of the peptide-binding cassette described previously via the
preserved Xhol site at the N-terminus of the (3 chains (Figure 4.3).
Construction of the design involved the following:
a) Formation of the extracellular portions of HLA-DRA1*0101, HLA-
DRB1*1501, and HLA-DRB1*0701 using PCR based upon the alignment
above.
b) Ligation of the above sequences into a modified pUC19 vector containing the
murine I-Ed signal sequence (Figure 3.2). The murine signal sequence was
used for logistical reasons as it was readily available and was known to be
functionally successful (see Results (I)).
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c) Excision of acidic and basic zipper and associated sequences from the I-Aq
constructs provided by Dr Ward's group and ligation of these 3' of the above.
d) Transfer of the above to the expression vector pRmHa3
Figure 4.2 - HLA-DR zipper-associated construct
Start codon \




Acid leucine zipper motif
His-Tagsite [
\j Xhol site for optional
: peptide binding cassette
| Linker containing thrombin
j cleavage site
] ••••'"! Base leucine zippermotif
r ni ■■
i myc-Tagsite |
I BirA site i
i Kindly donated by I
j Dr Ward's group i
Chapter 4 - Results (II) 104
Formation ofMHC Class II - Peptide Multimers
3 Construction of Leucine Zipper Associated HLA-DRa
Chain
3.1 Construction of extracellular alpha chain
The extracellular HLA-DRA1*0101 cDNA sequence was obtained by RT-
PCR ofmRNA from DR2Lum cells extracted using the QuickPrep™ Micro mRNA
purification kit (Amersham Pharmacia Biotech). RT-PCR was performed using
Ready-To-Go® RT-PCR beads (Amersham Pharmacia Biotech). The cDNA formed
by this process was then amplified by PCR using the oligonucleotide primers
zipDRAL2 and zipDRAR (Appendix 1). The PCR was carried out over 30 cycles
(Denature at 95 °C for 1 minute, anneal at 56°C for 1 minute, extend at 72°C for 90
seconds). The 603bp DNA product was separated by agarose gel electrophoresis and
purified using the QIAEX II® gel extraction protocol. This DNA product was then
restricted with Sail and BamHI, and ligated into the pUC19-I-EdptBirA restricted
with Xhol and BamEfi. This resulted in the DNA product being ligated in-frame
with the murine I-Ed start codon and leader sequence, with the loss of the I-EdpBirA
sequence including its Xhol site (Figure 4.3).
The ligated construct was transformed into DF15 E.coli and the transformants
were tested for the presence of the expected DNA using a panel of restriction enzyme
digests. DNA sequencing using the using pUC19 primer 'M13 forward' was used to
confirm the identity of the transformant containing the desired plasmid sequence -
WSA1 (Figure 4.4). This part of the construct was relatively straight forward to
produce, only requiring two attempts for a successful outcome.
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Figure 4.3 - Construction ofHLA-DRA with acidic leucine zipper
Formation of WSA1:
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Figure 4.4 -WSA1 nucleotide sequence
1 GAATTCGAGC TCCTGCAGCA TGGTGTGGCT CCCCAGAGTT CCCTGTGTGG
EcoRI START
51 CAGCTGTGAT CCTGTTGCTG ACAGTGCTGA GCCCTCCAGT GGCTTTGGTC
101 AGAGACACTC GACATGTGAT CATCCAGGCC GAGTTCTATC TGAATCCTGA
151 CCAATCAGGC GAGTTTATGT TTGACTTTGA TGGTGATGAG ATTTTCCATG
201 TGGATATGGC AAAGAAGGAG ACGGTCTGGC GGCTTGAAGA ATTTGGACGA
251 TTTGCCAGCT TTGAGGCTCA AGGTGCATTG GCCAACATAG CTGTGGACAA
301 AGCCAACCTG GAAATCATGA CAAAGCGCTC CAACTATACT CCGATCACCA
351 ATGTACCTCC AGAGGTAACT GTGCTCACGA ACAGCCCTGT GGAACTGAGA
401 GAGCCCAACG TCCTCATCTG TTTCATCGAC AAGTTCACCC CACCAGTGGT
451 CAATGTCACG TGGCTTCGAA ATGGAAAACC TGTCACCACA GGAGTGTCAG
501 AGACAGTCTT CCTGCCCAGG GAAGACCACC TTTTCCGCAA GTTCCACTAT
551 CTCCCCTTCC
. TGCCCTCAAC TGAGGACGTT TACGACTGCA GGGTGGAGCA
601 CTGGGGCTTG GATGAGCCTC TTCTCAAGCA CTGGGAGTTT GATGCTCCAA
651 GCCCTCTCCC AGAGACTACA GAGAACTCGT CACTCGAGAG ATCT ATCC
Xhol BglllBamHI
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3.2 Addition of acid leucine zipper to extracellular alpha chain
The acid leucine zipper and polyhistidine tag sequence was excised from the
vector provided by Dr Ward's group (pBlueBac4.5 with I-AqAlpha (Radu et al.,
1998)) by restricting with Xhol and Bglll. Concomitantly, WSA1 was restricted
with Xho I and Bgl II and dephosphorylated prior to ligation with the above. The
ligated construct was then transformed into DH5 E.coli and the transformants were
tested for the presence of the expected DNA using restriction enzyme digestion.
DNA sequencing with the pUC19 primer 'Ml3 reverse' was used to confirm the
identity of the transformant containing the desired plasmid sequence - WSA2.
Sequencing showed three base changes compared to the expected sequence resulting
in a single conservative amino acid change of a threonine to a serine near the
beginning of the acid leucine zipper motif and far removed from the peptide-binding
groove (Figure 4.5). This part of the construct was relatively straight forward to
produce, only requiring two attempts for a successful outcome.
Figure 4.5 - Acid leucine zipper and polyhistidine sequence ofWSA2
651 GCCCTCTCCC AGAGACTACA GAGAACTCGT CACTCGAGCT GGTGCCGCGC
Terminal WSAI sequence Xhol
701 GGAACGACTA CAGCTCCATC AGCTCAGCTC GAAAAAGAGC TCCAGGCCCT
751 GGAGAAGGAA AATGCACAGC TGGAATGGGA GTTGCAAGCA CTGGAAAAGG
801 AACTGGCTCA GCATCACCAT CACCATCACT AGAGATCTGG ATCC
Bglll BamHl
Key:
C - No amino acid change resulting
A - Leads to Ser rather than Thr
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3.3 Transfer of a-chain construct to pRmHa3 expression vector
The a-chain construct (HLA-DRAz) was excised from WSA2 using BamHI
and EcoRI, and ligated into pRmHa3-I-Edat (see Chapter 4) restricted with the same
enzyme pair. The ligated construct was then transformed into DH5 E.coli and the
transformants tested for the presence of the expected DNA using a panel of
restriction enzyme digests. This part of the construct was straight forward to
produce, only requiring one attempt for a successful outcome. DNA was purified
from a "midi-prep" of the transformant containing the expected DNA bands. This
DNA was used for transfecting D.melanogaster S2 cells (vide infra). The expected
translated protein sequence is seen in Figure 4.6.
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4 Construction of Leucine Zipper Linked HLA-DRp Chains
4.1 Construction of extracellular beta chains
The extracellular HLA-DRB1*1501 cDNA sequence was obtained by RT-
PCR of mRNA from DR2Lum cells as noted above. The cDNA formed by this
process was then amplified by PCR using the oligonucleotide primers zipDRBL and
zipDRBR (Appendix 1) in the same manner as their a-chain counterparts noted
above. The 615bp DNA product was separated by agarose gel electrophoresis and
purified using the QIAEX II® gel extraction protocol. This DNA product was then
restricted with Xhol and Hindlll, and ligated into the vector pUC19-I-EdtBirA
restricted with the same enzyme pair. This resulted in the DNA product being
ligated in-frame with the murine I-Ed start codon and leader sequence. The ligated
construct was transformed into DH5 E.coli and the transformants were tested for the
presence of the expected DNA using a panel of restriction enzyme digests. DNA
sequencing using the using pUC19 primer 'M13 forward' was used to confirm the
integrity of the transformant containing the desired plasmid sequence - WSB1-15
(Figure 4.7).
The extracellular HLA-DRB1*0701 DNA sequence was obtained by PCR
using the oligonucleotide primers zipDRBL and zipDRBR on HLA-DR7 cDNA
cloned from E1LA-DR7 positive B cells by Mrs D. Wojtacha. This template was
shown by DNA sequencing to contain exon 2 of HLA-DRB 1*0701. The PCR was
carried out over 30 cycles (Denature at 95°C for 1 minute, anneal at 55°C for 90
seconds, extend at 72°C for 90 seconds). The single 615bp DNA product was
separated by agarose gel electrophoresis and purified using the QIAEX II® gel
extraction protocol. This DNA product was then restricted with Xhol and Hindlll,
and ligated into the vector pUC19-I-EdtBirA as above. DNA sequencing using the
using pUC19 primer 'Ml3 forward' was used to confirm the identity of the
transformant containing the desired plasmid sequence - WSB1-7 (Figure 4.8).
This section of construct formation was relatively straight forward, only
requiring two attempts for a successful outcome in each case.
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Figure 4.7 - Construction of DRB with zipper
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TGAACGGCCA GGAAGAGAAG GCTGGGATGG TGTCCACAGG CCTGATCCAG
G G
AATGGAGACT GGACCTTCCA GACCCTGGTG ATGCTGGAAA CAGTTCCTCG
AAGTGGAGAG GTTTACACCT GCCAAGTGGA GCACCCAAGC GTGACAAGCC
G -A T TG
CTCTCACAGT GGAATGGAGA GCACGGTCTG AATCTGCACA GAGCAAGTCG
TCAGTCGACG GATCC
Sail BamHI
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4.2 Addition of basic leucine zipper to extracellular beta chains
The basic leucine zipper sequence with its c-myc tag and BirA site-specific
biotinylation sequence was excised from the vector provided by Dr Ward's group
(pBlueBac4.5 with I-AqBeta (Radu et al., 1998)) by restricting with Sail and BamHI.
Concomitantly the WSB1 vectors were restricted with same enzyme pair and
dephosphorylated prior to ligation with the above. The ligated constructs were then
transformed into DFI5 E.coli and the transformants tested for the presence of the
expected DNA using restriction enzyme digestion. DNA sequencing with 'Ml3
reverse' was used to confirm the identity of the transformants containing the desired
plasmid sequences - WSB2-07 and WSB2-15 (Figure 4.9). The sequencing showed
no changes from the expected. This part of the construction process was relatively
straight forward, only requiring one attempt for a successful outcome.
Figure 4.9 - Basic leucine zipper, c-myc tag and BirA sequence for WSB2
AATCTGCACA GAGCAAGTCG TCAGTCGACC TGGTTCCGCG
Sail
C'GGATCGACT ACAGCTCCAT CAGCTCAGTT GAAAAAGAAA
TTGCAAGCAC TGAAGAAAAA GAACGCTCAG CTGAAGTGGA
AACTTCAAGC CCTCAAGAAG AAACTCGCCC AGGTCACCGT
CTCCTCAGAA CAAAAACTCA TCTCAGAAGA GGATCTGAAT
AGTGGCGGTG GCCCAGGTGG CCTGGTTTCT ATCTTCGAAG
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4.3 Transfer of p-chain constructs to pRmHa3 expression vector
The p-chain constructs (HLA-DRB15z and HLA-DRB7z) were separately
transferred to the vector pRmHa3-I-Edat as noted for the a-chain constructs. The
ligated constructs were then transformed into DH5 E.coli and the transformants
tested for the presence of the expected DNA using a panel of restriction enzyme
digests. DNA was purified from a "midi-prep" of the transformant containing the
expected DNA bands. The restriction enzyme digests of the pRmHa3-DRpi5z
transformant were found to contain all the expected DNA bands, whilst that of
pRmHa3-DRp7z was less clear. Sequencing performed using the pMT promoter
primer later revealed that both vectors contained the expected sequence. This DNA
was used for transfecting D.melanogaster S2 cells vide infra. The expected
translated peptide sequences are seen in Figure 4.10.
Figure 4.10 - HLA-DRB15z and -DR7z peptide sequences
15 1 DTRGP RFLWQ PKREC HFFNG TERVR FLDRY FYNQE




ESVRF DSDVG EFRAV TELGR PDAEY WNSQK DILEQ
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GMVST GLIQN GDWTF QTLVM LETVP RSGEV YTCQV
07 -V '
15 EHPSV TSPLT VEWRA RSESA QSKSS VD RGSTT
07 176 M
Linker Thrombin site
15/07 211 APSAQ LKKKL QALKK KNAQL KWKLQ ALKKK LAQVT
Linker Base zipper sequence
15/07 246 VSSEQ KLISE EDLNS GGGPG GLVSI FEAQK IEWH
c-myc Tag Linker BirA sequence
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5 Expression of Leucine Zipper-Associated Heterodimeric
HLA-DR15 Construct
5.1 Establishment of stable S2 cell transfectants
S2 cells were stably transfected with pRmHa3-DRAz and pRmHa3-DRB15z
by calcium phosphate precipitation as per Methods. Selection was carried out using
Hygromycin-B for at least eight weeks before induction was attempted. Prior to
induction the medium was changed in order to remove the Flygromycin-B in order to
improve the protein production as noted previously (W. Kwok, personal
communication).
Appropriate transcription of pRmHa3-DRAz and pRmHa3-DRB15z was
tested in duplicate by RT-PCR ofmRNA extracted from stable transfectants with or
without prior induction with copper sulphate. The following gene-specific primer
pairs were used:
• For DRAz - zipDRAL2 and zipDRAR (Appendix 1)
• For DRB15z - zipDRBL and zipDRBR (Appendix 1)
The resulting DNA was analysed by agarose gel electrophoresis. As shown in
Figure 4.11, the relevant mRNA is only expressed upon induction of the transfected
S2 cells for both the DRAz and DRB15z chains. There is no DNA contamination
using the methods outlined as seen by the lack of bands in the negative control wells.
The untransfected S2 cells do not have the relevant DNA transcript upon induction.
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mRNA from S2 cells stably transfected with pRmHa3-DRAz and pRmHa3-DRB15z or pRmHa3-
DRB7z was extracted and treated with RNase-ffee DNase 1 (Promega Corporation, USA) prior to first
strand synthesis to reduce DNA cross-contamination. A concurrent control was also performed as per
manufacturer's instructions to assess DNA cross-contamination by inactivating the M-MuLV reverse
transcriptase. Separate micro-tubes were used for cDNA synthesis intended for assessment of alpha
chain and beta chain mRNA using gene-specific primers. First strand cDNA was generated by M-
MuLV reverse transcriptase and PCR was used to amplify the cDNA using the gene specific primers.
Positive controls for the PCR step were formed using the plasmids pRmHa3-DRAz, pRmHa3-
DRB15z and pRmHa3-DRB7z. The PCR products were analysed by agarose gel electrophoresis.
The above is a representative gel from three experiments.
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5.2 Characterisation of HLA-DR15LZ in post-induction
supernatant
The assessment of protein production within post-induction supernatant
utilised five monoclonal antibodies: L243; 9E10; DA6.231; DA6.147; and anti-His
tag.
The binding pattern of each of these monoclonal antibodies is depicted in Figure
4.12.
Figure 4.12 - Monoclonal antibody binding to HLA-DR constructs
L243
HLA-DRLZ a chain predicted MW 27.5kD
HLA-DR15LZ (3 chain predicted MW 31.4kD
HLA-DR7LZ (3 chain predicted MW 31.3kD
: Anti-His Tag I1
Small-scale assessment of protein production was initially performed in
25cm2 flasks using 20ml of medium. Induction was carried out using ImM copper
sulphate, collecting the supernatant after 96hours. The pre-induction viable cell
count was 5.9 x 106 cells/ml (85% viability), whilst the post-induction cell count was
8.7 x 106 cells/ml (73% viability). The cell suspension was centrifuged at 2000# for
10 minutes at 4°C before collecting the supernatant (Figure 4.13).
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Figure 4.13 - HLA-DR15LZ & HLA-DR7LZ supernatant assessment
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Lane 1 - Perfect Protein™ markers
Lane 2 - IEdtBirA supernatant
Lane 3 - HLA-DR15LZ supernatant
Lane 4 - HLA-DR7LZ supernatant
Lane 5 - HL60 cell lysate
Lane 6 - BE1 cell lysate
Lane 7 - Human spleen lysate
Lane 8 - a3 type IV collagen
- Positive band
S2 cells transfected with I-Ed, HLA-DR15LZ, and HLA-DR7LZ were induced using ImM copper
sulphate. 20pi samples of the post-induction supernatants were separated by SDS-PAGE and electro-
blotted onto nitrocellulose. Concurrently 20pl of the following positive control preparations were also
separated: HL60 cell lysate (c-myc control); BE1 cell lysate (HLA-DR control); a human spleen
lysate, prepared as per Balb/c spleen (HLA-DR control); and a sample of a His-tag labelled human a3
type IV collagen kindly provided by Dr J. Zou (University of Edinburgh). The preparation of these is
outlined in Chapter 2. The nitrocellulose membranes were then separately probed with the following
monoclonal antibodies: 9E10 (A), DA6.231 (B), and anti-His tag (C). The blots were developed
using the three-layer approach and Sigma Fast ™ 3,3-Diaminobenzidine hydrochloride. The above is
representative of four protein induction experiments.
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The presence of both the HLA-DR15p and a chains within the induced
supernatant is clearly seen in Lane 3 of the above immunoblots at approximately the
expected size of 31kD and 28kD respectively. The bands identified within the blots
are seen to be at that expected of a single monomeric chain rather than at that of the
heterodimerically associated ap dimer. This would suggest either that the chains are
already dissociated within the supernatant, or that the conditions within the gel have
resulted in their dissociation. Further assessment showed that the latter is the most
likely explanation, in keeping with the findings of Kwok et al (personal
communication), as noted below. Having shown the presence of the separate a and
P chains within the induced supernatant, further assessment of their association and
functionality is required. Larger scale production of induced supernatant was carried
in spinner flasks in order to obtain sufficient material for further analysis. Neither
the a or p chain were detectable within the induced supernatant of S2 cells
transfected with the HLA-DR7 construct vide infra. The monoclonal antibodies used
were seen to correctly identify the relevant positive controls.
5.3 Characterisation of cell-associated HLA-DR15LZ protein
The presence of cell-associated protein was assessed using cytospins from
the above experiment (Figure 4.14).
Figure 4.14 - Assessment of cell-associated HLA-DR15LZ TBB
a) Stained with DA6.231 (Saponin used) - X400 magnification
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b) Stained with anti-His Tag (Saponin used) - X 400 magnification
c) Stained with L243 (Saponin used) - X 400 magnification
d) Stained with secondary antibody alone (Saponin used) - X 400 magnification
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e) Stained with L243 - Oil Immersion magnification
Saponin used Saponin not used
Cell suspensions from induced and non-induced transfected S2 cell cultures used in (Figure 4.13)
were used to form cytospins. The cytospins were probed using the beta chain-specific monoclonal
antibody DA6.231, the alpha chain-specific anti-His tag monoclonal antibody, and the conformational
sensitive L243 monoclonal antibody only in the case of induced cells. Controls for non-specific
staining with the secondary antibody alone were also prepared. Saponin was used to enhance
intracellular penetration of the antibodies. Uninduced S2 cells were used as negative controls for the
primary antibody, whilst the secondary antibody alone was used to assess for non-specific staining.
The above is representative of three cytospins.
The presence of the separate HLA-DRa and HLA-DRP15 chains is seen within the
induced S2 cells (Figure 4.14a&b), but not the non-induced cells (Figure 4.14a&b
inset). Indeed, conformationally correct heterodimeric HLA-DR15LZ also appears
to be present associated with these cells (Figure 4.14c). The staining seen certainly
does not appear to be non-specific as there is no fluorescence seen using the
secondary antibody alone (Figure 4.14d). Saponin was used in the hope that it would
help to differentiate between intracellular and cell surface protein. The results with
and without saponin appear to be similar (Figure 4.14e), and would either indicate
that induced proteins can be found both within cells and surface associated, or that in
preparing the cells the membrane is sufficiently damaged to negate any
differentiation that saponin could make.
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5.4 Utility of serum-free medium
Growth in serum-free media would ease further purification of recombinant
proteins by minimising contamination by serum proteins. However, it was important
to assess whether the successfully transfected S2 cells were able to grow in this
medium, and whether protein production was still feasible. Therefore, HLA-
DR15LZ transfected S2 cells were sequentially adapted to serum-free growth over a
series of five passages. Once growing in serum-free medium, a test induction using
ImM copper sulphate was performed (Figure 4.15).














Lane 1 - Perfect Protein® markers; Lane 2 - Standard media; Lane 3 - Serum-free media
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Post-induction supernatant was collected after 5 days. The pre-induction viable cell count was 2.5 x
106 cells/ml (91% viability), whilst the post-induction cell count was 2.4 x 106 cells/ml (59%
viability). The cell suspension was centrifuged at 2000g for 10 minutes at 4°C. 20pl samples of the
post-induction supernatant were separated by SDS-PAGE and electro-blotted onto nitrocellulose. The
blots were probed with anti-His Tag and 9E10 monoclonal antibodies, developing the blot using the
three-layer approach utilising Sigma Fast ™ 3,3'-Diaminobenzidine hydrochloride. The above is
representative of 3 protein induction experiments.
The blots clearly show the presence of both the DRa band (Figure 4.15a) and the
DR(3 band (Figure 4.15b) at their expected size (28kD and 31kD respectively).
However, the amount of protein induced using the serum-free media (Lane 3) is
substantially less than that from the serum-containing media (Lane 2) in Figure 4.15.
This would be in keeping with the poorer cell growth noted in the serum-free media.
One possible solution to this would be the addition of a reduced amount of serum, eg
1%, that would improve cell growth without hindering downstream purification
(Malherbe et al., 2000). One intriguing finding is the presence of a higher weight
band that represents heterodimeric HLA-DR15aP units that have remained
associated through their leucine zipper motifs. This may have been masked by the
heavy albumin band present in serum-supplemented medium.
The functional heterodimeric nature of the induced protein under these
conditions was assessed in parallel with that of the induced protein in serum-based
medium below (See Chapter 6).
5.5 Assessment of heterodimeric nature of induced protein
For the recombinant HLA-DR15 a and (3 proteins to be functionally useful as
tetramer building blocks (TBB) they must be in a heterodimeric association.
Although heterodimeric association was seen, the majority of the proteins were
separate a and p chains as expected in SDS-PAGE (Kwok et al, personal
communication). Therefore, to determine the proportion of induced protein
occurring as ap heterodimer complexes in post-induction supernatant I used two
different techniques. In the first, the p chain-specific monoclonal antibody DA6.231
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was used to precipitate the HLA-DR15LZ p chain and the precipitate probed for
HLA-DR15LZ a chain co-precipitation (Figure 4.16). In the second, the HLA-
DR15LZ a chain was immobilised via the His tag using nickel-chelation
chromatography, and the immobilised protein examined for HLA-DR15LZ P chains
(Figure 4.17).
Figure 4.16-Western blot stained with DA6.147 following DA6.231 immunoprecipitation
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Lane 1 - Perfect Protein markers®
Lane 2 - Untransfected S2 cell supernatant
Lane 3 - HLA-DR15LZ supernatant
Lane 4 - I-EdtBirA supernatant
Lane 5 - BE1 cell lysate
\ 7 - a-chain band
Immunoprecipitation was carried out using 12ml of the following copper-induced supernatants: S2
cells transfected with HLA-DR15LZ construct grown in serum-containing medium; S2 cells
transfected with the I-EdtBirA grown in serum-containing medium (this was used as a negative
control); and untransfected S2 cells grown in serum-containing medium (this was used as a further
negative control). To each of the above 10ml of DA6.231 hybridoma supernatant was added, and the
resulting solution made up to 30ml with NET-gel buffer. 1ml of BE1 lysate was used as a positive
control for HLA-DR immunoprecipitation. The immunoprecipitation was performed as per Methods.
The eluates were separated by SDS-PAGE gel electrophoresis, before electro-blotting onto
nitrocellulose overnight. The nitrocellulose membrane was probed with the DA6.147 (HLA-DRa
chain-specific monoclonal antibody) monoclonal antibody. The blot was developed using the three-
layer approach with Sigma Fast ™ 3,3'-Diaminobenzidine hydrochloride.
Immunoprecipitation of the DR[3 chain with the DRp chain-specific
monoclonal antibody DA6.231 brought down DRa chains detected with the DRa
chain-specific monoclonal antibody DA6.147. This is consistent with the S2 cell
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supernatants containing ocP heterodimeric complexes sufficiently stably associated to
persist through immunoprecipitation.
In order to further assess the proportion of HLA-DR15LZ p chain that was
associated with a chain as against free, I took advantage of the His-tag at the carboxy
terminus of the a chain to extract all the free a chains as well as those in ap
heterodimers by metal chelation chromatography of the induced supernatant. This
would also allow an assessment of the utility of the method in the purification of
HLA-DR15LZ. 30ml of copper-induced supernatant from S2 cells transfected with
HLA-DR15LZ construct grown in serum-containing medium was precipitated with
ammonium sulphate, dissolving the precipitated protein in PBS/0.05% sodium azide.
This step not only concentrates the protein, but also allows for removal of copper
ions that may interfere with the nickel-histidine interaction. A small-scale nickel
affinity column was prepared using a 3ml bed-volume of iminodiacetic acid -
Sepharose 6B Fastflow® beads formed in an Econo-Pac® disposable chromatography
column (BioRad Laboratories). A small-scale nickel-affinity chromatography
purification was carried out (Figure 4.17).
After passage over the nickel-IDA column, there were no detectable
recombinant protein losses seen by the lack of either detectable HLA-DRa or HLA-
DRp chains in the column post-load or wash steps. This would indicate that the vast
majority of P chains were associated with a chains, and that any protein losses are
small. The P chains were recovered with the a chains upon elution of the nickel-
IDA column with EDTA. The recombinant protein also appears to be concentrated
by the elution process (as seen in Lanes 8 of Figure 4.17). The presence of
detectable HLA-DRP in the eluate (Lane 8 of Figure 4.17a) indicates that HLA-
DR15LZ TBB can withstand ammonium sulphate precipitation and that nickel-
chelation chromatography could be used in larger-scale purification. Furthermore,
this finding confirms the heterodimeric association of the recombinant HLA-
DR15LZ TBB.
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Figure 4.17 - Metal chelation extraction of a chain pulls down P chain
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Lane 1 - Perfect Protein®markers Lane 6 - Column wash 3
Lane 2 - Column pre-load Lane 7 - Column eluate 1
Lane 3 - Column post-load Lane 8 - Column eluate 2
Lane 4 - Column wash 1 Lane 9 - Column eluate 3
Lane 5 - Column wash 2 Lane 10 - Column eluate 4
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The small IDA column was equilibrated in 80ml of PBS by gravity flow before stripping the column
of any bound metal ions using 20ml PBS/1 OOmM EDTA. The stripped column was equilibrated with
130ml PBS before loading with nickel ions using 20ml 0.1M nickel chloride/1OmM sodium acetate
pH 5.0. The column was equilibrated using 30ml PBS and 50ml PBS/1OmM imidazole to remove any
unbound nickel ions from the column. 10ml of the crude protein solution prepared above with lOmM
imidazole added was loaded onto the column by gravity flow, collecting the resulting post-load.
Unbound protein was removed by washing the column using 3 x 10ml PBS/1OmM imidazole,
collecting the three wash steps separately. The bound protein was eluted from the column using 4 x
2.5ml PBS/1OOmM EDTA, with the elution solution being mixed with the column beads and left at
room temperature for 10 minutes prior to collecting each eluate separately. The column was washed
and regenerated using PBS/1 OOmM EDTA prior to storing under 30% ethanol at 4°C. lOpl samples
of each fraction were taken and separated by SDS-PAGE electrophoresis. The separated proteins
were electro-blotted onto nitrocellulose overnight. The nitrocellulose membranes were probed
separately using 9E10 and anti-His tag monoclonal antibodies. The membranes were developed using
the three-layer approach with 3-amino-9-ethylcarbazole. The above is representative of two small
scale metal chelation experiments.
5.6 Assessment of large-scale production of HLA-DR15LZ TBB
Given the successful small-scale production and purification ofHLA-DR15LZ
TBB, larger scale production was attempted using spinner flasks. Serum-
supplemented media was initially tried and, although HLA-DR15LZ TBB was
successfully produced, the yield was not as good as predicted due to poor cell growth
within the spinner flasks. Despite the poor yield, the possibility of large-scale
production was proven. The ammonium sulphate precipitation step was seen to
concentrate the protein produced to a small extent, raising the issue of protein losses
at this stage of the preparation (Figure 4.18). This suggestion was not bom out on
further analysis (Figure 4.20). Large-scale nickel-chelation chromatography was
also performed using a Biocad 700E® workstation (PerSeptive Biosystems Inc.)
(Figure 4.19). Unfortunately, the column did not appear to completely bind all the
recombinant protein at the first pass. Therefore, this post-load was loaded onto the
column once more, and a further assessment made (Figure 4.20). This second
passage appeared to minimise the protein losses. Furthermore, minimal losses were
noted at the ammonium sulphate precipitation step, as there was no detectable protein
in the non-precipitated supernatant (Lane 2 of Figure 4.20). However, this does not
take into account any irretrievably aggregated protein.
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Lane 1 - Perfect Protein® marker
Lane 2 - Ammonium sulphate concentrate
Lane 3 - Post-induction supernatant
15kD -
20pl samples of post-induction supernatant from HLA-DR15LZ transfected S2 cells before and after
ammonium sulphate precipitation were separated by SDS-PAGE. The gels were electro-blotted prior
to probing with DA6.231 (P-chain specific) monoclonal antibody. The membranes were developed
using the three-layer approach with Sigma Fast ™ 3,3'-Diaminobenzidine hydrochloride.
Figure 4.19 - Protein losses using a Poros® MC column
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Lane 1 - Perfect Protein® marker
Lane 2 - MC column eluate
Lane 3 - MC column post-load
Lane 4 - MC column pre-load
Nickel-chelation affinity chromatography purification was carried out using a 1.7ml bed volume
column packed with Poros®20MC medium and a Biocad 700E workstation (PerSeptive Biosystems
Inc.). 20|xl samples of the pre-load, post-load and eluate were separated by SDS-PAGE and electro-
blotted onto nitrocellulose. The membrane was probed with 9E10 (anti-c-myc tag, P-chain specific)
monoclonal antibody and developed using the three layer approach with Sigma Fast TM 3,3'-
Diaminobenzidine hydrochloride. The above was replicated on two occasions.
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Figure 4.20 - Final purification of HLA-DR15LZ TBB
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Lane 1 - Perfect Protein® marker
Lane 2 - Ammonium sulphate precipitate supernatant
Lane 3 - MC column pre-load
Lane 4 - MC column eluate
Lane 5 - MC column post-load
The post-load from the initial loading of the Poros® MC column was loaded again onto the prepared
column and affinity purification carried out. 20pl samples were taken from the pre-load, post-load
and eluate of this experiment and separated by SDS-PAGE. In conjunction with this, a 20pi sample
from the supernatant overlying the ammonium sulphate precipitate was also separated on the same
gel. The gel was electro-blotted onto nitrocellulose before probing with 9E10 (anti-c-myc tag, (3-chain
specific) monoclonal antibody. The membranes were developed using the three-layer approach with
3-amino-9-ethylcarbazole.
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6 Expression of Leucine Zipper-Associated Heterodimeric
HLA-DR7 Construct
6.1 Establishment of stable S2 cell transfectants
S2 cells were stably transfected with pRmHa3-DRla and pRmHa3-DR7p by
calcium phosphate precipitation in parallel with the HLA-DR15 transfection above.
Appropriate transcription of pRmHa3-DRAz and pRmHa3-DRB7z was tested in
duplicate by RT-PCR as for pRmHa3-DRB15z above using the same gene-specific
primer pairs. The resulting DNA was analysed by agarose gel electrophoresis
(Figure 4.11). Unlike the HLA-DR15LZ transfected S2 cells, it would appear that
mRNA is transcribed in both un-induced and copper-induced cells transfected with
the HLA-DR7LZ construct. This finding is somewhat difficult to explain given that
both constructs are contained within the same vector, and indeed the HLA-DRAz
vector is identical in both cases. This phenomenon is not due to contamination by
genomic DNA, as the negative control lanes contain no nucleotide bands.
6.2 Assessment of protein production
A small-scale induction was carried out using ImM copper sulphate,
collecting the induced supernatant after 96hours. The pre-induction viable cell count
was 3 x 106 cells/ml (83% viability), whilst the post-induction cell count was 15.7 x
106 cells/ml (90% viability). The supernatant was collected and samples analysed
(Figure 4.13). No detectable HLA-DR7LZ a-chain or P-chain were identified on the
Western blot. Therefore, although transfection was apparently successful in terms of
cell selection and DNA transcription, there appeared to be a translational or post-
translational problem. To define this further, cytospins were formed as above in
order that cell-associated proteins could be identified. Once again, no specific
proteins were detectable (Figure 4.21). Furthermore, these cytospins show a lack of
significant non-specific binding by the primary antibodies to the cell preparations.
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Figure 4.21 - Assessment of cell-associated HLA-DR7LZ TBB
a) Stained with DA6.231 (Saponin used) - X40 magnification
b) Stained with anti-His Tag (Saponin used) - X 40 magnification
c) Stained with L243 (Saponin used) - X 40 magnification
As Figure 4.14
Chapter 4 - Results (II) 131
Formation ofMHC Class II - Peptide Multimers
One possible factor was that ofDNA quantity and quality. With this in mind,
a further transfection was carried out using double and treble the standard DNA
quantities previously used. Selection was carried out as per Methods. Only those
cells transfected with double the standard DNA quantities survived the selection
process. A small-scale induction was carried out as above, collecting the induced
supernatant after 7 days (Figure 4.22). A faint band was detectable using 9E10 in the
HLA-DR7LZ supernatant as well as the serum-free supernatant from the FILA-
DR15LZ-transfected S2 cells. This band was at the expected molecular size for the
P-chain. This result may suggest that the possible problem was related RNA
translation factors such as RNA 'hairpins'. Supplementary transfections will need to
be carried out in order to assess the HLA-DR7LZ construct further.






Lane 1 - Perfect Protein® marker
Lane 2 - HLA-DR7LZ Post-induction supernatant
Lane 3 - F1LA-DR15LZ Post-induction supernatant









A 20fxl sample of the HLA-DR7LZ post-induction supernatant was separated using SDS-PAGE prior
to electro-blotting onto nitrocellulose overnight. Post-induction supernatant from HLA-DR15LZ
transfected cells grown in serum-free medium was used as a positive control for the Western blot.
The nitrocellulose membrane was probed with 9E10 (anti-c-myc tag, P-chain specific) monoclonal
antibody and developed using the three-layer approach with 3-amino-9-ethylcarbazole.
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7 Discussion
In this chapter, I have described the successful construction of the nucleic
acid sequences for both HLA-DR15LZ TBB and HLA-DR7LZ TBB. HLA-DR15LZ
TBB has been successfully expressed in Drosophila S2 cells and has been shown to
assemble as a,p heterodimers in solution having the correct protein tags attached.
Moreover, the protein expressed has been easily identified using standard SDS-
PAGE techniques indicating that the yield using this system is consistently greater
than that previously, found using the initial I-Ed construct (Chapter 3). The
heterodimeric nature of the HLA-DR15LZ TBB protein in both liquid phase and
cell-associated forms has been established, with provisional purification techniques
also being confirmed in the form of nickel-chelation chromatography. Indeed, the
functional heterodimeric nature of HLA-DR15LZ TBB has been alluded to through
the finding of L243 antibody staining in both solution and the cell-associated phase.
In an attempt to minimise extraneous protein contamination, serum-free medium was
used with a degree of success. Indeed, one viable option would be to use serum-free
media supplemented with a small amount of serum in order to improve yield whilst
still minimising extraneous protein contamination (Malherbe et al., 2000).
The HLA-DR15LZ TBB formed appears to be in a consistently stable
heterodimeric state as evidenced by the data above. This together with the
conformational integrity of the recombinant protein, alluded to by L243 monoclonal
antibody binding, would indicate that the HLA-DR15LZ TBB is also likely to be
functionally correct. The lack of covalently bound peptide allows for greater
flexibility in peptide loading, with the leucine zipper domains providing the
necessary stability as suggested in the literature, notably by William Kwok's group
(Mallone and Nepom, 2004). Certainly, the consistency of recombinant protein
production using the Drosophila S2 cell system highlights its ease of use compared
to the baculovirus based system that has been previously used to form recombinant
HLA-DR15 (Gauthier et al., 1998, Smith et al., 1998). Furthermore, the
polyhistidine tag allows for ease of purification without any apparent loss of
conformational integrity, as has been found by other groups (Kuroda et al., 2000). A
further purification step using antibody-based affinity chromatography remains a
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possibility using the L243 monoclonal antibody. The main problems were faced
upon increasing the scale of production.
Large-scale production of HLA-DR15LZ TBB was initiated although with
limited success in terms of protein yield. The problems encountered are easily
surmountable in terms of improved cell growth through the use of different flasks
such as bubbling spinner flasks (Kuroda et al., 2000), or roller flasks (Appel et al.,
2000). The ammonium sulphate concentration step, although cumbersome, is
effective, and has been used by other groups for the same purpose (Kuroda et al.,
2000). However, it maybe worth trying to load the post-induction supernatant
directly onto the nickel-loaded column as has been used in small-scale production by
other groups (Kuroda et al., 2000) in order to assess whether the copper ions in the
large-scale supernatant do actually affect protein binding to the affinity column.
Should there be no effect, it would be then reasonable to omit the extra step of
ammonium sulphate precipitation with its attendant risks of protein losses. The
purification step using nickel chelation was successful, but column losses required
multiple loading and elution steps. In order to circumvent this a larger column could
be used and/or the column resin could also be changed. The resin used at present is
based on the tridentate iminodiacetic acid (IDA). Nickel may be released from its
interaction with this resin during chromatography, so reducing the resin binding
capacity. The quadridentate resin nitrilotriacetic acid (NTA) has improved nickel ion
retention and is therefore potentially a more stable adsorbent, with improved binding
capacity (Hochuli et al., 1987). Using this resin may mean an alteration to the
automation process as the NTA columns currently available are for use in low
pressure systems and not HPLC systems such as the Biocad 700E® workstation
(.PerSeptive Biosystems Inc.).
Despite the success of the HLA-DR15LZ TBB expression, difficulty was
experienced in expressing HLA-DR7LZ TBB. Analysis of these difficulties
indicated that the problem was likely to be at the RNA translation stage of the HLA-
DRB7z construct. Should further work using HLA-DR15LZ TBB prove successful,
these problems may be remediable, allowing the formation and assessment of HLA-
DR7LZ TBB.
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Chapter 5
Results (III)
Formation of Recombinant MHC Class II Single-chain
constructs
1 Introduction
Bacterial expression was developed in parallel with the insect cell expression
system outlined in the previous chapter. The impetus behind this diversification was
the anticipated problem with the eukaryotic expression system in terms of protein
yield. This problem was realised in the initial attempts to form I-EdtBirA as noted in
Chapter 4. Although Drosophila S2 cell expression leads to the formation of
secreted and essentially correctly folded protein, the yield of this can be quite low
and appears to depend upon the protein being expressed (Ivey-Hoyle, 1991, Stern
and Wiley, 1992, Wallny et al., 1995).
Altman et al (Altaian et al., 1993) were one of the first groups to demonstrate
production and in vitro refolding ofMHC class II proteins produced in E.coli. This
group also demonstrated that glycosylation of MHC class II proteins is not an
absolute requirement for functional TCR recognition. Refolding was performed in
the presence an excess of antigenic peptide. Other groups have since used bacterial
expression to produce functional HLA-DR molecules with and without antigenic
peptide in the refolding solution. There appears to be a consensus that the former
leads to a greater refolding yield (Arimilli et al., 1995, Stockel et al., 1994) in
keeping with earlier work suggesting the importance of peptide in stabilising the
correct conformation of MHC Class II (Sadegh-Nasseri and Germain, 1991).
However, refolding naturally expressed a and P chains into functional class II
molecules has proven a difficult and inefficient process, particularly in the absence of
antigenic peptide (Frayser et al., 1999, McMichael and Kelleher, 1999). Although
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the leucine zipper approach could have been tried to enhance yields from prokaryotic
expression, I felt that the problems previously encountered with bacterial expression
of MHC class II (See Introduction) warranted a different strategy. It is striking that
MHC class I, where the peptide-binding domain is formed within the same
polypeptide chain by an intramolecular disulphide bond between the al and a2
domains of that chain, folds much more efficiently into a functional unit following
bacterial expression. Therefore, an attractive strategy for the formation of
recombinant MHC class II proteins using a bacterial expression system was the
formation of MHC class II a-|3 chain fusion proteins. The attractions of such a
strategy would include the inherently correct ratio of a and P chains covalently
bound together in a similar manner to the MHC class I peptide-binding domain.
Furthermore, the nature of the construct would allow the use of a single plasmid
within the context of a simpler expression system as compared to the Drosophila S2
system outlined in the previous chapter.
Fusion protein approaches have been used successfully to circumvent the
problems of heterodimeric association and improve functional yield for both MHC
class I and II proteins. Kourilsky's group at the Pasteur Institute engineered a
recombinant single-chain murine MHC Class I molecule by linking the carboxy-
terminus of the murine H-2Kd ectodomain to the amino terminus of murine
microglobulin through a 15 amino acid linker. This construct was expressed in a
eukaryotic system and found to bind synthetic peptides with the same specificity as
the native molecule, and trigger antigen-specific T cells (Abastado et al., 1995,
Mottez et al., 1991). Moreover, this group used the immobilised construct to
successfully enrich for antigen-specific T cells (Bousso et al., 1997). Denkberg et al
adapted this approach by linking the amino terminus of HLA-A2 to the carboxy
terminus of human p2-microglobulin, adding the peptide sequence for site-specific
biotinylation by BirA biotin ligase to the carboxy terminus of HLA-A2. This
construct was expressed using a bacterial expression system and, after peptide
loading and biotinylation, was tetramerised using phycoerythrin-conjugated
streptavidin. These MHC Class I tetramers were able to stain antigen-specific CD8+
T cell lines (Denkberg et al., 2000). The fusion protein approach has also been used
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to form a functional murine MHC Class II I-Ad construct where the carboxy terminus
of the I-Ad P2 domain is linked by a 24 amino acid linker to the amino terminus of
the I-Ad a-chain extracellular domain. The construct was expressed using a
baculovirus expression system in Sf9 insect cells and found to be functionally correct
in terms of both peptide binding and antigen-specific T cell activation (Rhode et al.,
1996). As predicted, the functional protein yield and heterodimeric association was
greatly improved using this method of enforced chain association. A similar
construct has been successfully produced for HLA-DR1 (Zhu et al., 1997).
Taking this fusion protein approach one step further, Burrows et al (Burrows
et al., 1998) were the first to engineer a functional fusion protein consisting of solely
of the peptide binding 'superdomain'. They linked the carboxy terminus of the Pi
domain to the amino terminus of the ai domain of rat RT1.B MHC Class II. The
construct was produced in a bacterial expression system and was found to be
functionally correct in terms of peptide binding following in vitro refolding. The
peptide-loaded construct was found to bind antigen-specific T cells in vitro and lead
to antigen-specific inhibition of T cells both in vitro and in vivo. Given the
effectiveness of this approach, I used it as the template in designing both murine and
human two-domain single-chain MHC Class II constructs (scTBB - single-chain
Tetramer Building Blocks).
2 Construction of Single-chain MHC Class II Molecules
2.1 Design
In order to generate single-chain murine I-Ed and human HLA-DR molecules
we examined the alignment of these with rat RT1.B in relation to the x-ray
crystallographic structure of HLA-DR1 (Stern et al., 1994). This analysis suggested
that a short linker sequence could be used to join the pi and al domains of both
murine I-Ed and human HLA-DR in an analogous manner to that successfully used to
form the RT1.B fusion protein. Using Burrows' RT1.B peptide sequence (Burrows
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et al., 1998) and the published sequences for I-Ed, HLA-DRB1*1501 and HLA-
DRB1*0701, an alignment of the relevant sequences was made using ClustalX
(Thompson et al., 1997) (Figure 5.1).
Figure 5.1 - Alignment ofHLA-DR, IEd and RTB
Alignment of MHC Class II chains with RT1B sequence
RT1B (Pi) TSLRRL GGQD DIEADH (ax)
I-Ed (Pi) LVRRRV GAQD AIKEEH (aQ
HLA-DR (Pi) TVQRRV GAQD AIKEEH (ax)
Alignments of HLA-DRA1*0101 and I-Ed a-chain with rat RT1B a-chain, and of
HLA-DRB 1*0701, HLA-DRB1*1501 and I-Ed p-chain with rat RT1B p-chain in the
vicinity of the linker used to fuse the rat ai and Pi domains (GGQD) in the construct
made by Burrows et al (Burrows et al., 1998) were performed with the aid of the
Clustal X software package (Thompson et al., 1997). The sequences for RT1B were
taken from the two-domain single-chain construct of Burrows et al (Burrows et al.,
1998). The HLA-DR and I-Ed sequences were obtained from the SWISS-PROT
sequence database. A similar short amino acid linker sequence (GAQD) was
engineered into our two-domain construct to link the Pi and ai domains.
Having identified how HLA-DR and I-Ed a and p chains could be joined in a
similar manner to the recombinant RT1B construct, oligonucleotides were designed
to add suitable restriction and junctional sites to the 5" and 3' ends of the Pi and oq
domains by PCR. Each Pi and ai domain was then joined together by overlap
extension PCR (Horton et al., 1990) prior to ligating into pUC19I-EdptBirA
containing in frame the cDNA sequence encoding the BirA biotinylation consensus
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sequence (Figure 5.2). The option to covalently link a peptide to the amino-terminus
of the construct was generated by the insertion of an Xhol into the construct at a
suitable location to be compatible with the peptide-binding cassette strategy
discussed in Chapter 3 (Figure 3.3).
The major risk in adopting this approach was its extreme novelty. At the
time, it had only been shown to work for RT1B. Although RT1B had refolded
readily into a functional protein, it was anticipated that this could be a major obstacle
in adaptation to FILA-DR15, F1LA-DR7 and I-Ed. The protein formed would need to
be purified from other bacterial proteins, although the bacterial inclusion bodies in
which the protein is expected to accumulate are primarily composed of the expressed
protein. The protein would also require in vitro refolding which presents its own set
of challenges (Lilie et al., 1998).
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2.2 Formation of murine single-chain MHC Class II construct
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The first stage in the formation of this construct was the expansion of the I-Ed
a,] and pi domains using PCR. Vectors pRmHa3-I-EdptBirA and pRmHa3-I-Edat
were used as the source of I-EdPi and I-Edai respectively. PCR was set up using the
following oligonucleotide primer pairs (Appendix 2):
For I-Edai domain - SC3 and SCm4
For I-Edp, domain - SCI and SCmH2
The PCR was carried out over 25 cycles (Denature at 95 °C for 1 minute, anneal at
52°C for 1 minute, and extend at 72°C for 90 seconds). A single well-defined 300bp
product was purified from each reaction mixture.
The aj and Pi PCR products were heated, annealed and any aiPi pairings
extended using DNA polymerase. Unsatisfactory results were obtained on five
occasions before the relative quantities of the two PCR products were carefully
adjusted to 1:1 comparing the concentrations by sequential dilution and densitometry
of the agarose gel separated PCR products. The yield of the 600bp aiPi pairing was
very low at this stage, and PCR using the terminal primer pair (SCI and SCm4) was
employed to generate sufficient DNA for purification from an agarose gel (Horton et
al., 1990) (Figure 5.3). Once the relative concentrations of the two PCR products
had been adjusted, a successful outcome was achieved on the second attempt.
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Two cycles of overlap extension PCR were carried out following an initial denature step at 94.5°C for
5 minutes. Each cycle consisted of the following: denature at 94.5°C for 1 minute, anneal at 60°C for
2 minutes, and extend at 72°C for 5 minutes. The annealed and extended product then underwent a
further 26 cycles of PCR using the primers SCI and SCm4 (Denature at 94.5°C for 20 seconds, anneal
at 60°C for 1 minute, and extend at 72°C for 1 minute). The defined band of approximately 600bp was
excised as indicated. The PCR regimen was based upon the work of Burrows et al (Burrows et al.,
1998).
Next, the 600bp I-EdPiai fusion product was restricted with EcoRI and Kpnl
and cloned into pUC19-I-EdptBirA (See Chapter 3 figure 3.2). Transformants were
tested for the presence of the expected DNA using a panel of restriction enzyme
digests. One transformant was found to contain the expected DNA bands and was
sequenced using the 'Ml3' primers. This part of the construction process required
five attempts for a successful outcome. The sequencing revealed four base pair
changes from the expected sequence. These changes are due to degeneracy in
oligonucleotide primers SCI and SCmH2 and likely variations of the I-Ed sequence
given that none had translational effects (Mengle-Gaw et al., 1984) (Figure 5.4).
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Figure 5.4 - IEdsc DNA sequence
1 GAATTCCATG GGCTCTCGAG GCCCACGGTT TCTGGAATAC GTTACATCTG
EcoRI Xhol ^
^51 AGTGTCATTT CTACAACGGG ACGCAGCACG TACGGTTTCT GGAGAGATTC
101 ATCTACAACC GGGAGGAGAA CCTGCGCTTC GACAGCGACG TGGGCGAGTA
151 CCGCGCGGTG ACAGAGCTGG GGCGGCCAGA CGCCGAGAAC TGGAACAGCC
201 AGCCGGAGAT CCTGGAGGAT GCGCGGGCCT CGGTGGACAC GTACTGCAGA
t
251 CACAACTATG AGATCTCGGA TAAATTCCTT GTGCGGCGGC GAGTCGGAGC
^ SacI
(301 TCAAGACGCT ATCAAAGAGG AACACACCAT CATCCAGGCA GAGTTCTATC
t
351 TTTTACCAGA CAAACGTGGA GAGTTTATGT TTGACTTTGA CGGCGATGAG
401 ATTTTCCATG TAGACATTGA AAAGTCAGAG ACCATCTGGA GACTTGAAGA
aH
451 ATTTGCAAAG TTTGCCAGCT TTGAGGCTCA GGGTGCACTG GCTAATATAG
501 CTGTGGACAA AGCTAACCTG GATGTCATGA AAGAGCGTTC CAACAACACT
551 CCAGATGCCA ACGGTACCGC TAGCGGCGGT GGACTGCATC ATATTCTGG?
Kpnl
601 TGCACAGAAA ATGGTGTGGA . ATCATCGTTA AGGATCC
BamHI BirA
KEY:
★ - Sites of base pair changes
C - Changes secondary to oligonucleotide primer degeneracy
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2.3 Formation of HLA-DR15(31a1 DNA fusion construct
The formation of the HLA-DR15Piai DNA fusion construct was performed
in parallel with the formation of the I-EdPiai fusion DNA construct above. HLA-
DR15Pi and HLA-DRai domains were amplified from full length cDNAs for HLA-
DRB1*1501 and HLA-DRA1*0101 kindly donated by Dr K. Dornmair (Stockel et
ah, 1994). PCR amplification was performed using the following oligonucleotide
primer pairs (Appendix 2):
For DRcci domain - SC3 and SC4
For DRP, domain - SCI and SCH2
PCR was carried out as for the I-EdPia[ fusion DNA construct above. Both
PCR reactions yielded the approximate 300bp products as expected. This part of the
construct formation was straightforward requiring only one attempt for a successful
outcome. Attempts to join the products by overlap extension PCR yielded the
expected approximate 600bp product, but this, on two separate occasions, was
determined to have a sequence unacceptably altered by presumed PCR errors.
Therefore, a two-stage approach sequentially ligating the ai and Pi sequences into
pUC19-I-EdptBirA was employed (See Figure 5.5).
First the 300bp product of the amplification of the ai domain of HLA-
DRAI *0101 was restricted using SacI and Kpnl and cloned into pUC19BirA.
Transformants were tested for the presence of the expected DNA using a panel of
restriction enzyme digests. One transformant was found to contain the expected
DNA bands. This required two attempts for a successful outcome. The DNA from
this transformant was sequenced and revealed two base pair changes within the
expected sequence that are likely to be variations of the HLA-DRal sequence or as a
result of degeneracy within the oligonucleotide primer SC3 and are without
translational effects (Figure 5.6).
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Figure 5.5 - Outline of human single-chain formation
OHgo SC1 Oligo SC3
PCR
Ligate 2 Ligate 1
V p.ut.l t......
.Cut.2.../
Ec^r | §4^ '-Ed beta sequence j^KpriNf^BirA
I pUC19-l-EdptBirA [
NB: Restriction enzyme sites of importance marked
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Figure 5.6-Sequence of HLA-DRal DNA
1 GAGCTCAAGA CGCTATCAAA GAGGAACATG TGATCATCCA GGCCGAGTTC
SacI A
51 TATCTGAATC CTGACCAATC AGGCGAGTTT ATGTTTGACT TTGATGGTGA
101 TGAGATTTTC CATGTGGATA TGGCAAAGAA GGAGACGGTC TGGCGGCTTG








Sites of base pair changes
G - Change as a result of SC3 degeneracy
Next, the 300bp products of the amplification of the pi domains from HLA-
DRB1*1501 and HLA-DRB1*0701 using the oligonucleotide primers SCI and
SCH2 (Appendix 2) were purified from agarose gels. The right hand oligonucleotide
primer (SCH2) was modified to be specific for the human DRp sequences in
response to the problems encountered above. Each purified pi domain fragment was
restricted with SacI and EcoRI prior to ligating into pUC19aiBirA. The ligated
constructs were transformed into DH5 E.coli. Transformants were tested for the
presence of the expected DNA using a panel of restriction enzyme digests. Two
transformants for each of HLA-DR7 and -DR15 single-chain constructs were
sequenced using the 'Ml3' primers. Only one of the transformants for each
construct was found to contain the correct DNA sequence (Figure 5.7). This part of
construct formation also required two attempts for a successful outcome. The HLA-
DR15sc construct was noted to a have a single base pair change compared to the
expected sequence that is as a result of degenerate base in the oligonucleotide primer
SCI. This is without translational effect.
Chapter 5 - Results (III) 147
Formation ofMHC Class II - Peptide Multimers
Figure 5.7 - Sequence for HLA-DR7sc and DR15sc
Start pi sequence
★












15 41 CCTAAGAGGG AGTGTCATTT CTTCAATGGG ACGGAGCGGG
7 GG TATA C
15 81 TGCGGTTCCT GGACAGATAC TTCTATAACC AGGAGGAGTC
15 121 CGTGCGCTTC GACAGCGACG TGGGGGAGTT CCGGGCGGTG
7 A
15 161 ACGGAGCTGG GGCGGCCTGA CGCTGAGTAC TGGAACAGCC
15 201 AGAAGGACAT CCTGGAGCAG GCGCGGGCCG CGGTGGACAC
7 G_c AG G_c A
15 241 CTACTGCAGA CACAACTACG GGGTTGTGGA GAGCTTCACA
7 -GTG Linker__GT—
r- al sequence
15 GTGCAGCGGC GAGTCGGAGC TCAAGACGCT ATCAAAGAGG
7 281
SacI
15 321 AACATGTGAT CATCCAGGCC GAGTTCTATC TGAATCCTGA
CCAATCAGGC GAGTTTATGT TTGACTTTGA TGGTGATGAG
ATTTTCCATG TGGATATGGC AAAGAAGGAG ACGGTCTGGC
GGCTTGAAGA ATTTGGACGA TTTGCCAGCT TTGAGGCTCA
AGGTGCATTG GCCAACATAG CTGTGGACAA AGCCAACCTG






15 atggtacc Start of BirA sequence -=
7 561
Kpnl
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3 Expression of Single-chain Tetramer Building Blocks in
E.Coli
3.1 Selection of expression vector
A T7-based vector was desirable to achieve high level expression in E.coli
(Studier and Moffatt, 1986). The pET prokaryotic expression system (CN
Biosciences (UK) Ltd.) was utilised because of its range of vector-host combinations
and its proven efficiency by Burrows et al. Expression was piloted using the I-Edsc
construct ligated into pET14b as this vector/construct combination was readily
available in the laboratory and mirrored the successful expression of RT1.B single-
chain fusion protein by Burrows et al (Burrows et al., 1998, Burrows et al., 1999).
The pilot study demonstrated I-Edsc expression, but purification and identification
was initially hampered by the absence of a tag that was identifiable on the denatured
single-chain fusion protein. To gain suitable tags, initial expression ofHLA-DR15sc
was attempted using the expression vector pETBlue2 that had both HSV® and His®
tags. Frustratingly, this proved a very unsatisfactory choice of vector, probably as a
result of secondary structure formation in the mRNA (Dr B. Morris, Senior Scientist,
Novagen® product applications - personal communication). A third T7 vector,
pET25b, containing both C-terminal HSV® and His® tags was identified and HLA-
DR15sc inserted using a different ligation strategy. HLA-DR15sc and HLA-DR7sc
expression using pET25b proved efficient for both HLA-DR single-chain fusion
proteins.
3.2 Expression of I-Edsc TBB using the pET14b vector
The I-Edsc TBB construct was formed before either of the HLA-DRsc TBB
constructs and was thought suitable to pilot single-chain fusion protein expression
because a monoclonal antibody (2G9 (Becker et al., 1992)) was available capable of
recognising I-Ed on a Western blot. The I-Ed(3iaiBirA construct was cloned into
pET14b using the Ncol and BamHI cloning sites which had the consequence of
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cutting out the His-Tag® sequence inherent in the pET14b vector. Transformants
were identified by restriction enzyme digests and the purified plasmid transformed
into the bacterial expression host BL21(DE3), a strain of E.coli that contains the T7
RNA polymerase gene required for high efficiency expression.
An assessment of protein production was made by inducing 2ml cultures of I-
Edsc pET14b BL21(DE3) and analysing the cultures in order to detect expression of
I-Edsc TBB (Figure 5.8). The I-Edsc TBB product was found to be confined to
inclusion bodies, from which it could be solubilised using urea
(AmershamBiosciences, 1997, Williams et al., 1982). There was minimal loss
during cell lysis as indicated by the presence of a small amount of 2G9 positive
staining in Lane 3 of Figure 5.8b. This figure also shows that a proportion of the I-
Edsc TBB bound the I-Ed-specific monoclonal antibody 2G9.
Following the detection of I-Edsc TBB within induced I-Edsc pET14b
BL21(DE3), the experiment was adjusted in order to test the impact on expression of
various parameters. It was found that the highest level of expression was achieved
by:
• Selecting the colony to be used in large-scale induction from a subjective
assessment ofprotein production in small-scale culture.
• Use of LB medium which was found to be the most versatile and effective
medium.
• Use of carbenicillin as opposed to amoxicillin in order to reduce bacterial
overgrowth.
• Use of ImM IPTG for induction over 4 hours once the OD600 was between
0.6 and 0.8.
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b) 2G9-probed Western blot
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Lane 1 - Perfect Protein® markers
Lane 2 - Bacterial supernatant
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Lane 4 - Wash I
Lane 5 - Wash II
Lane 6 -Wash III
Lane 7 - Urea extract I
Lane 8 - Urea extract II
> — I-Edsc TBB protein
2ml cultures of I-Edsc pET14b BL21(DE3) were induced using IPTG. The presence of I-Edsc TBB
was assessed at each stage of the purification process of the induced bacterial culture by taking
samples and separating these by SDS-PAGE. The gels were analysed using both Coomassie staining
and Western blotting in parallel. The Western blot was probed using 2G9. This is representative of
three protein induction experiments.
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3.3 Pilot study purification of l-Edsc TBB
The I-Edsc TBB extracted from inclusion bodies contained considerable
quantities of contaminating proteins and so required further purification. Ion-
exchange chromatography was used initially as described by Burrows el al (Burrows
et al., 1999). The pi of the extracted IEdsc TBB was first roughly measured as being
about pH5 (Figure 5.9). The results suggested that anion exchange resins should
bind the fusion protein in buffers more alkaline than pH5, and cation exchange resins
in buffers more acidic than pH5. I chose anion exchange using basic buffers as these
were noted to improve the functional purification of the rat single-chain fusion
protein (Burrows et al., 1999).
Figure 5.9 - pi of I-EdscTBB
T— CM CO IO CO r- CO
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Lane 1 - Perfect Protein® markers
Lane 2 - pH4 elution
Lane 3 - pH5 elution
Lane 4 - pH6 (acetate buffer) elution
Lane 5 - pH6 (Tris buffer) elution
Lane 6 - pH7 elution
Lane 7 - pH8 elution
Lane 8 - Urea extract of I-Edsc TBB
The pi of the extracted I-Edsc TBB was first roughly calculated by equilibrating samples of the protein
extract in a series of buffer solutions of 8M urea with either 50mM Tris.CI (pH6, 7, 8 &9) or 50mM
sodium acetate (pH4, 5 & 6). The above samples were combined with S-Sepharose Fast cation
exchange beads equilibrated with the appropriate buffer. The beads were washed twice with the
appropriate buffer before eluting any bound protein using an elution buffer (8M urea, 0.25M sodium
chloride & 50mM Tris.CI pHIO). The eluates were separated by SDS-PAGE gel electrophoresis
before transferring onto nitrocellulose by Western blotting. The resulting blot was probed with 2G9
monoclonal antibody using the two-layer approach. The IEdsc TBB protein appears to have bound S-
Sepharose at pH5 but not pH6 suggesting a pi of about 5. This is in agreement with the theoretical pi
of the construct using the ExPASy Compute pI/MW tool (http://us.expasy.org/tools/pi_tool.html)
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Anion exchange chromatography was performed using Poros® 20HQ medium
(Figure 5.10).
Figure 5.10 - Anion exchange of IEdsc TBB
Fractions 1- 4 collected
Time (mins.)
A 4.6mm diameter/50mm length chromatography column was packed with Poros® 20HQ medium
(PerSeptive Biosystems Inc.) forming a 0.8ml bed volume as per manufacturer's instructions. The
column was first equilibrated with 20 column volumes of 6M urea/50mM Tris.Cl pH8.5. The
previously extracted IEdsc TBB solution was filtered through a 0.45pm filter before loading onto the
prepared column in 10ml aliquots per separation. The loaded column was washed with 10 column
volumes of the above equilibration buffer, before adding increasing salt concentrations to the
equilibration buffer in 10 column volume steps at 0.2M, 0.5M, 1M and 2M sodium chloride. 10ml
fractions were collected at each step. The separation process was carried out using a Biocad 700E
{PerSeptive Biosystems Inc.). The separation process was repeated ten times with identical
chromatograms.
The chromatogram highlights the problems encountered during the purification
process. Although three distinct elution peaks are seen only the first contains the
IEdsc TBB, while the other two higher optical density peaks do not appear to contain
any protein Figure 5.1 la. These later peaks are only seen after loading the extracted
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IEdsc TBB, and were not present during "dummy" separations using buffers alone. It
was also noted that the column used was unable to accommodate more than 10ml of
crude extract without increasing post-load losses. These later peaks may well,
therefore, represent impurities which led to column "fouling" and a loss of column
efficiency. This is a well recognised problem encountered with inclusion body
purification due to hydrophobic lipoprotein contaminants, particularly with anion
resins (AmershamPharmaciaBiotech, 2001).
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Key:
Lane 1 - Perfect Protein markers
Lane 2 - Pre-load
Lane 3 - Post-load
Lane 4 - Peak 1 from 2nd separation
Lane 5 - Peak 1 from 9th separation
Lane 6 - Peak 2 from 2nd separation
Lane 7 - Peak 2 from 9th separation
Lane 8 - Peak 3 from 2nd separation
Lane 9 - Peak 3 from 9th separation
- I-Edsc TBB band
Samples from each stage of the anion exchange separation were taken and separated by SDS-PAGE
using two gels in parallel. One gel was stained with Coomassie Blue, whilst the other was electro-
blotted onto nitrocellulose overnight and probed with 2G9 monoclonal antibody. Separations 2 and 9
were used as representative samples of the ten separations performed.
Figure 5.11 shows the loss of the majority of impurities upon passage through the
anion column (compare pre-load lane with peak 1 lanes in Figure 5.1 la). Moreover,
although there are two further peaks on the chromatogram, these do not stain positive
using Coomassie Blue stain. This would tend to suggest that these latter peaks are
formed by either non-proteinaceous material or small amounts of high molecular
weight protein-containing contaminants that have been diluted in the separation
process. The reduced intensity of the I-Edsc TBB in the eluates reflects at least three¬
fold dilution of the crude I-Edsc TBB preparation demonstrated by the reduced 2G9
stain in the eluate lane (Figure 5.1 lb).
The difficulties encountered with this particular expression system made its
further development for the human single-chain fusion proteins unattractive.
Chapter 5 - Results (III) 155
Formation ofMHC Class II - Peptide Multimers
3.4 Expression of single-chain proteins using the pET25b vector
3.4.1 Cloning ofsingle-chain proteins into pET25b vector
In order to overcome the purification difficulties, a different pET vector was
utilised that would place both an HSV-Tag® and a His-Tag® at the C-terminus of the
single-chain fusion protein. Tagging would not only enhance recombinant protein
identification, but would also allow alternative purification strategies to be used.
These issues are of particular relevance to the two human HLA-DR single-chain
constructs that currently do not have a monoclonal antibody akin to 2G9 with which
to identify them in their unfolded form. pET25b was chosen as the vector for its
HSV-Tag® and His-Tag® as well as its T7 promoter. However, cloning of the single-
chain constructs into pET25b in order to utilise the C-terminal tags was not
straightforward because of unsuitable restriction enzyme sites and the presence of a
stop-codon after the C-terminal BirA sequence within the single-chain constructs
(See Figure 5.4 & Figure 5.7). A two-step strategy was adopted that first cloned in a
modified BirA sequence before cloning in the separate single-chain construct
sequences.
The first stage in this process was the adaptation of the BirA DNA sequence.
The BirA DNA sequence was excised from the vector pUC19I-EdptBirA (See
Chapter 3) using the restriction enzyme PvuII. The DNA fragment of interest was
initially excised in order to reduce any non-specific binding of the rather long
oligonucleotide primers. The excised and purified DNA sequence was expanded and
modified using the oligonucleotide primer pair SC25L2 and SC25R2 (See Appendix
2). Thirty cycles of PCR were carried out (denature at 95°C for 60 seconds, anneal
at 52°C for 30 seconds, and extend at 72°C for 60 seconds). The resulting DNA
fragment was purified by agarose gel electrophoresis and restricted with Ndel and
Xbal before cloning into the pET25b vector restricted with Ndel and Nhel and
dephosphorylated (Figure 5.12a). This part of the construct formation was difficult,
requiring six attempts to achieve a successful outcome. Transformants were assessed
by restriction enzyme digests. A plasmid from a suitable transformant was
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sequenced using the 'T7 promoter' primer and shown to have the expected sequence
(Figure 5.13). This modified vector was named pET25b (BirA).
Figure 5.12 - Outline of pET25b-BirA scTBB formation

















b) Insertion of scTBB into pET25b-BirA
pET25b
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Figure 5.13 - Sequence pET25b(BirA) using T7 promoter primer
1 CATATGTCTC GAGGGGTACC AGCGGCGGTG GACTGCATCA
Ndel Xhol Kpnl
41 ^ATTCTGGAT GCACAGAAAA TGGTGTGGAA TCATCG^TCC
BirA Sequence




The above shows the nucleic acid sequence of the modified vector, pET25b(BirA). The His and HSV
tags are in frame with the 'stop' codon. Important restriction enzyme sites are also marked.
3.4.2 Cloning of scTBB sequences into pET25b(BirA)
Having formed the pET25b(BirA) vector the DNA sequences for the three
single-chain fusion protein constructs (HLA-DR15sc, HLA-DR7sc and I-Edsc) could
be cloned into the vector. Each of the three scTBB DNA sequences were cloned into
the Xhol/Kpnl site in pET25b(BirA) (Figure 5.12b). Transformants were assessed
by restriction enzyme digests and a plasmid from a suitable transformant sequenced
for each of the three cloned constructs using the 'T7 promoter' primer. This part of
the construct formation only required one attempt for a successful outcome. The
sequence of pET25b-IEdsc contained two base pair changes, that of pET25b-
HLADR15sc contained a single base pair change, whilst pET25b-HLADR7sc
matched the expected sequence (Figure 5.14). In the case of I-Edsc, these base pair
changes may represent primer degeneracy, whilst for HLA-DR15sc the changes may
represent variations of the nucleotide sequence as none were predicted to result in
any amino acid changes. Translations of the DNA sequences of the three scTBB
proteins are shown in Figure 5.15.
Chapter 5 - Results (III) 158
Formation ofMHC Class II - Peptide Multimers
Figure 5.14 - Nucleotide sequences of pET25b-IEdsc TBB, -DR15sc TBB & -DR7sc TBB
scTBB(IEd) CATATGTCTC GAGGCCCACG GTTTTTGGAA TACGTTACAT





CTGAGTGTCA TTTCTACAAC GGGACGCAGC ACGTGCGGTT
scTBB(DR15) GG T T G— GG
scTBB(DR7) A-A T G— GG A
scTBB(IEd) TCTGGAGAGA TTCATCTACA ACCGGGAGGA GAACCTGCGC
scTBB(DR15)
81
111011111o -A-T T- —A 1 i-3a i 01 i i i i
scTBB(DR7) C A C—T T- —A i i-3 b-3 1 O 1 1 1 1 1
scTBB(IEd)
121
TTCGACAGCG ACGTGGGCGA GTACCGCGCG GTGACAGAGC
scTBB(DR15) G- 1110111EH11 G
scTBB(DR7) G— G G
scTBB(IEd)
161
TGGGGCGGCC AGACGCCGAG AACTGGAACA GCCAGCCGGA
scTBB(DR15) T T T AA
scTBB(DR7) -A T-T TC AA
scTBB(lEd)
201
GATCCTGGAG GATGCGCGGG CCTCGGTGGA CACGTACTGC
scTBB(DR15) c C-G —G —c
scTBB(DR7) c —CAG G-CA CGTG
scTBB(IEd)
241
AGACACAACT ATGAGATCTC GGATAAATTC CTTGTGCGGC
scTBB(DR15) -C-G-G-TGT G-GC ACA A—
scTBB(DR7) . -C-G-G-TGG T—G-GC ACA A—
scTBB(lEd)
281
GGCaGAGTCGG AGCTCAAGAC GCTATCAAAG AGGAACACAC
scTBB(DR15) —c -A TGT
scTBB(DR7) —c -A TGT
scTBB(IEd)
321
CATCATCCAG GCAgGAGTTCT ATCTTTTACC AGACAAACGT
scTBB(DR15) G —c GAAT— T C-TCA
scTBB(DR7) G —c GAAT— T C-TCA
scTBB(IEd)
361





ATGTAGACAT TGAAAAGTCA GAGACCATCT GGAGACTTGA
scTBB(DR15) G—T— G-C AAG GG —C-G
scTBB(DR7) G—T— G-C AAG GG — C-G
scTBB(lEd)
441
AGAATTTGCA AAGTTTGCCA GCTTTGAGGC TCAGGGTGCA
scTBB(DR15) G- CGA —A'
scTBB(DR7) G- CGA A
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ATGGTGTGGA ATCATCGTTC CTCTAGCCAG CCAGAACTCG





Ag - A is determined base sequence & G is the expected base sequence.
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tsggg LHHIL DAQKM VWNHR sssqp
BirA sequence
ELAPE DPEDV EHHHH HH
HSV Tag His Tag
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3.4.3 Assessment of recombinant scTBB protein production
Sequenced plasmids (pET25b(BirA)-DR15sc TBB, -DR7sc TBB and -I-Edsc TBB)
were transformed into the bacterial expression host BL21(DE3) E.coli. Cultures
were induced and analysed as previously (Figure 5.16, Figure 5.17, and Figure 5.18).
A protein of the predicted 26kD size was identified in all transformed colonies using
the Coomassie stain. Immunoblotting identified DR15sc TBB as having a
polyhistidine tag as expected. The additional bands seen in the anti-His Tag
immunoblots may represent dimers (50kD bands) and breakdown products of the
scTBB as the untransformed control colony had few polyhistidine tagged elements
identified. Of note is the high expression and greater purity of the single-chain
fusion proteins using this vector in comparison to pET14b, particularly the two
human HLA-DR proteins.
Figure 5.16 - IEdsc TBB peptide production
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Key:
Lane 1 - Perfect Protein marker
Lane 2 - I-Edsc colony 1
Lane 3 - I-Edsc colony 2
Lane 4 - I-Edsc colony 3
Lane 5 - Untransformed control colony
< - I-Edsc
The above shows test cultures of three pET25b BL21(DE3) I-Edsc colonies induced using IPTG. The
crude urea-extracted inclusion body preparation was separated by SDS-PAGE. The gel was analysed
using Coomassie staining. A band of the expected size is seen in each of the three test colonies but
not in the untransformed control colony. This is representative of three protein induction experiments.
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Figure 5.17 - DR7sc TBB peptide production
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Lane 1 - Perfect Protein marker
Lane 2 - DR7sc colony 1
Lane 3 - DR7sc colony 2
Lane 4 - DR7sc colony 3
Lane 5 - Untransformed control colony
< -HLA-DR7sc
Legend as Figure 5.16
Figure 5.18 - DR15sc TBB peptide production
a) Coomassie blue stain
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Lane 1 - Perfect Protein marker
Lane 2 - DR15sc colony 1
Lane 3 - DR15sc colony 2
Lane 4 - DR15sc colony 3
Lane 5 - Untransformed control colony
< -HLA-DR15sc
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b) Anti-His tag immunoblot
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Key:
Lane 1 - Perfect Protein marker
Lane 2 - DR15sc colony 1
Lane 3 - DR15sc colony 2
Lane 4 - DR15sc colony 3
Lane 5 - Untransformed control colony
< -HLA-DR15sc
The above shows test cultures of three pET25b BL21(DE3) DR15sc colonies induced using IPTG.
The crude urea-extracted inclusion body preparations were separated by SDS-PAGE. The gels were
analysed using Coomassie staining, or electroblotted onto nitrocellulose overnight prior to probing
with anti-His tag monoclonal antibody and developing using the two-layer approach. A band of the
expected size is seen in each of the three test colonies but not in the untransformed control colony.
The higher weight band identified using the monoclonal antibody may represent dimerization of the
DR15sc TBB. This is representative of three protein induction experiments.
Having now established that all three scTBB constructs could be induced using this
expression system, the next step involved the assessment ofpurification strategies.
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4 Purification of scTBB proteins
4.1 Assessment of nickel chelation chromatography
The above series of results show that proteins of the expected size are being
produced with the expected His-Tag® sequence. The next stage was to utilise this
His-Tag® as a means of purification. A pilot purification was undertaken using
HLA-DR7scTBB as this protein had been the first to be successfully expressed.
A large-scale protein induction was performed utilising the bacterial clone
identified in the small-scale induction above as producing the highest protein yield.
5ml of the chosen bacterial colony suspension was taken and placed in 100ml of LB
medium containing 200pg/ml carbenicillin in a 250ml baffled flask. The resulting
suspension was incubated at 37°C, induced using IPTG and processed as per
Methods. In this pilot purification, the inclusion body pellet was solubilised using
6M guanidine hydrochloride (GnHCl) buffered with 50mM Tris.Cl pFI 7.5. The
resulting suspension was filtered through a 0.45pm filter before storing at 4°C
overnight. Subsequent inclusion body preparations were successfully solubilised
using the inclusion body re-suspension solution which utilises 6M urea and a HEPES
buffer (vide infra). The HLA-DR7scTBB suspension was purified using a 3ml bed-
volume Iminodiacetic acid (IDA)-Sepharose 6B Fastflow® column (Figure 5.19).
The nickel chelation column results in loss of low molecular weight contaminants,
although their absence from the post-load is difficult to explain other than for a
dilutional effect or breakdown. There are some losses during the purification
process, but the majority of the HLA-DR7sc TBB protein is eluted from the nickel
column, although still having some impurities. There is a higher weight band seen in
all the gels (at around 50kD) which may represent dimerization of the HLA-DR7sc
TBB protein through intermolecular disulphide bond formation.
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Figure 5.19 - His-Tag® purification of DR7sc TBB
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Lane 1 - Perfect Protein marker
Lane 2 - Column pre-load
Lane 3 - Column post-load
Lane 4 - Column wash
Lane 5 - First column eluate
Lane 6 - Second column eluate
Lane 7 - Third column eluate
Lane 8 - Fourth column eluate
A 3ml bed-volume IDA-Sepharose 6B Fastflow® column was formed in an Econo-Pac® disposable
chromatography column (Bio-Rad Laboratories Inc.). The prepared column was washed twice with
20ml of 50mM Tris.Cl pH7.5 before loading with nickel ions. 30ml of column metal ion loading
solution was passed over the column before washing twice with 20ml 50mM Tris.Cl pH7.5 and three
times with 10ml 6M GnHCl/50mM Tris.Cl pH 7.5/1OmM imidazole. The imidazole was added in an
attempt to prevent non-specific low-level interactions between non-His Tag® histidine containing
peptides and the nickel loaded column during purification. 1ml of HLA-DR7scTBB suspension was
loaded onto the prepared column after adding lOmM imidazole to the suspension. The column was
washed three times with 10ml 6M GnHCl/50mM Tris.Cl pH 7.5/10mM imidazole, before eluting the
column four times with 10ml 6M GnHCl/50mM Tris.Cl pH 7.5/1OOmM EDTA. In order to assess the
above purification samples from each stage were precipitated using four volumes of 100% ethanol at -
20°C for 72 hours. The precipitated solutions were centrifuged at 20000g for 30minutes at 4°C,
suspending the precipitated protein in 8M urea/20mM ethanolamine pH10/PMSF/ EDTA. Samples
were separated by SDS-PAGE gel electrophoresis before staining with Coomassie Blue. The majority
of impurities appear to have been removed during this purification. This is representative of two
purification experiments.
One way of improving separation and reducing non-specific protein binding
to the nickel-loaded column would be to increase the imidazole concentration in the
loading and wash buffers. However, this may result in increased losses, and so a
pilot study was carried out to determine the optimum imidazole concentration
(Figure 5.20).
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Figure 5.20 - Assessment of imidazole concentration for His-Tag purification
a) Column post-load b) Column wash
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Lane 1 - Column pre-load Lane 6 - 3OmM imidazole
Lane 2 - Perfect Protein marker Lane 7 - 50mM imidazole
Lane 3 - OmM imidazole Lane 8 - 75mM imidazole
Lane 4 - lOmM imidazole Lane 9-1OOmM imidazole
Lane 5 - 20mM imidazole Lane 10 - 200mM imidazole
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Eight 60ql bed-volume IDA-Sepharose 6B Fastflow® columns were formed using Mobicol® Iml
microcolumns (MoBiTec GmbH) with a 10pm pore filter to collect the sepharose beads. These
columns were each loaded with 1ml of column metal ion loading solution before being equilibrated
with 300pl of one of eight wash buffers. The buffers were composed of 6M GnHCl/O.lM Tris.Cl
pH7.5 and one of eight imidazole concentrations (OmM, lOmM, 20mM, 30mM, 50mM, 75mM,
lOOmM, and 200mM). 20pl ofHLA-DR7sc TBB inclusion body solution was added to each column
together with 80pl of the relevant wash buffer. The columns were mixed for 1.5hours at room
temperature before collecting the post-load by centrifuging each column at 18000g for 30 seconds into
a microfuge tube. The columns were washed twice with lOOpl of the relevant wash buffer before
eluting with lOOpl of 6M GnHCl/O.lM Tris.Cl pH8/100mM EDTA. The wash steps and eluates were
collected by centrifugation as above. Each sample collected was precipitated with four volumes of
100% ethanol at -20°C overnight. The precipitates were collected and re-suspended in 8M
urea/20mM ethanolamine pH10/PMSF/ EDTA before separating by SDS-PAGE gel electrophoresis
and staining with Coomassie Blue.
As can be seen in Figure 5.20a&b the increasing imidazole concentrations resulted in
increasing post-load losses particularly evident beyond 50mM imidazole, with
increasing losses during the column wash step beyond 20mM imidazole. Moreover,
there would appear to be little to gain in terms of eluate purity by altering the
imidazole concentration (Figure 5.20c). On balance, I decided to continue to use
lOmM imidazole in order to achieve the optimum balance between the reduction of
non-specific binding and increasing protein losses.
As a result of the difficulty in directly analysing the GnHCl prepared
samples, I used 6M urea as the chaotroph in later inclusion body preparations
together with 1M NaCl to maintain the ionic strength of the buffer and reduce non¬
specific column interactions. Large-scale purification used Poros® MC medium
(PerSeptive Biosystems) packed into a HPLC column. Having reviewed the
manufacturer's literature regarding the Poros® MC medium, I opted to use HEPES
buffer rather than Tris, as there is a theoretical weakening ofmetal ion binding to the
Poros® MC medium in the presence ofprimary amines as found in Tris buffer.
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4.2 Assessment of scTBB refolding
The incorporation of the recombinant scTBBs into insoluble bacterial
inclusion bodies simplifies the preliminary isolation steps as seen above. However,
the difficulties encountered during purification are shifted downstream in terms of
functionally correct protein refolding and disulphide bond formation.
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Lane 4 - HLA-DR15sc (26.4kD)
SDS-PAGE separation of urea-extract of inclusion body preparation from each of the three fusion-
protein constructs. One gel is stained with Coomassie Blue, whilst the other was electro-blotted onto
nitrocellulose before probing with anti-His tag monoclonal antibody and developing using the two-
layer approach. The variable mobility of the three constructs is seen. There is also a variable
proportion of each construct dimerised. The expected molecular weight of each construct is shown in
brackets. This is representative of the SDS-PAGE separation of four separate inclusion body
preparations.
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The scTBBs are very similar in their amino acid sequences and predicted
molecular weights, but their SDS-PAGE gel mobilities are very different as
demonstrated in Figure 5.21. The proportion of each scTBB at an apparently dimeric
mobility is also very different, being greater for FILA-DR15sc. Furthermore, the
greater frequency of protein fragments within the HLA-DR15sc separation possibly
suggests a more disorganised refolding permitting greater cleavage by proteases.
This dimerization is probably occurring through interchain disulphide bond
formation given the presence of two cysteine residues within the Pi domain of each
scTBB protein. Nonetheless, this was a surprising finding given that Burrows et al
did not seem to experience this dimerization with either of their two constructs
(Burrows et al., 1999, Chang et al., 2001). Therefore, although there is a large
degree of similarity in the primary structure of the three scTBB proteins, the degree
of dimerization and SDS-PAGE gel mobility is seen to vary between them indicating
differences in secondary and tertiary structure.
I performed pilot studies to ascertain the optimum folding regimen for the
scTBBs formed. ElLA-DR15sc was used as the pilot refolding target given its
apparently greater dimeric constitution. Monomer formation in the absence of
reducing conditions was used as a surrogate marker for correct refolding . The initial
refolding strategy was based upon that of Burrows et al (Burrows et al., 1999)
(Figure 5.22). The aliquot removed after the addition ofDTT showed a considerable
reduction in the content of the 55kD band compared with that pre-treatment
(compare lanes 2 and 3 in Figure 5.22) confirming that the band was due to dimer
formation as a result of inter-chain disulphide bonds. Unfortunately, considerable
dimer reformation occurred following the removal of the DTT (lane 4 Figure 5.22).
The majority of dimers could be broken by the addition of DTT (compare lanes 2-4
and 5-7 Figure 5.22). This result suggested that refolding should be undertaken with
more dilute protein solutions to reduce inter-chain disulphide bond formation, and
use a glutathione reoxidation system to facilitate disulphide bond shuffling during
refolding (Altman et al., 1993, Frayser et al., 1999, Rudolph and Lilie, 1996). A
subsequent pilot study was performed using this system (Figure 5.23).
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Figure 5.22 - DR15sc TBB refolding without redox shuffle (anti-HSV Tag)
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Lane 1 - Perfect Protein® markers < - Monomer scTBB
Lane 2 & 5 - Urea sample -/+ DTT reduction < - Dimeric scTBB
Lane 3 & 6 - DTT sample -/+ DTT reduction
Lane 4 & 7- PBS sample -/+ DTT reduction
A 6ml sample of His-Tag® purified HLA-DR15sc in its elution buffer was placed into prepared
Seamless Cellulose® dialysis tubing and dialysed against 5x400ml 6M urea/20mM ethanolamine
pHIO at 4°C over a 48hour period ('urea sample')- This was primarily performed to remove the
nickel ions from the purified protein which may prevent cysteine residue oxidation during
downstream renaturation (Rudolph and Lilie, 1996). Following this DTT was added to a final
concentration of 50mM and the resulting solution placed at 37°C for 1 hour in order to reduce any
disulphide bonds (Fischer et al., 1992) ('DTT sample'). The protein solution was then dialysed
against 2 x 1120mM ethanolamine pHIO at 4°C for 72hours and finally 3x11 PBS/0.05% sodium azide
at 4°C over 24hours ('PBS sample'). lOpl samples of each stage was taken and separated by SDS-
PAGE gel electrophoresis before and after further reduction with lOOmM DTT at 95°C for 10
minutes. The SDS-PAGE gel was electro-blotted onto nitrocellulose before being probed with anti-
HSV Tag monoclonal antibody and developed using the two layer technique.
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Figure 5.23 - Refolding scTBB(DR15) using redox shuffle
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Lane 1 - Perfect Protein® marker
Lane 2 - Pre-refolding
Lane 3 - Urea & reduced glutathione
Lane 4 - Ethanolamine & reduced glutathione
Lane 5 - Ethanolamine & oxidised glutathione
Lane 6 - PBS
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A 15ml sample of His-Tag® purified scTBB(DR15) in its elution buffer was first dialysed into 6M
urea/20mM ethanolamine pHIO as above. To this lOmM reduced glutathione was added and the
resulting solution gently mixed at 4°C overnight. This solution was then dialysed against 21 20mM
ethanolamine pH10/10mM reduced glutathione at 4°C overnight. Such slow dialysis should reduce
the urea concentration gradually and so theoretically reducing the risk of aggregation (Rudolph, 1996,
Rudolph and Lilie, 1996). Following this step, the solution was removed from the dialysis tubing and
oxidised glutathione added to a final concentration of ImM together with sodium azide to a final
concentration of 0.05%. The resulting solution was gently mixed at 4°C for 48hours before dialysing
against 2x41 PBS/0.05% sodium azide at 4°C for a further 48hours. The final refolded solution was
removed from the dialysis tubing and 0.1ml of Protease Inhibitor Cocktail for Bacterial Cell extracts
(Sigma-Aldrich Inc.) added before storing the solution at 4°C. Samples taken over the refolding
process were taken and separated by SDS-PAGE gel electrophoresis. One gel was stained with
Coomassie Blue whilst two were electro-blotted onto nitrocellulose overnight. The blots were probed
with anti-His-Tag® and anti-HSV-Tag® monoclonal antibodies
This refolding strategy resulted in a greater proportion of the HLA-
DR15scTBB protein remaining in monomeric form at the end of the refolding
process, although dilution of the protein had also occurred. The amount of protein
remaining in the dimeric state was minimised through this refolding process. The
dilution process itself may well have had a beneficial effect on the refolding-
aggregation equilibrium. The dual band seen at around 25kD (Figure 5.23a&b) may
represent the HLA-DR15scTBB protein with either altered mobility or relative
biotinylation.
The refolding strategy was also successfully used for both IEdscTBB and
HLA-DR7scTBB. Further refolding attempts resulted in minor additions to the
refolding solutions. NP40 was used in the initial stages of the refolding process as a
non-ionic detergent in an attempt to reduce aggregation further (Labeta et al., 1988,
Stockel et al., 1997). In order to reduce ionic variation over the refolding process,
the salt concentration was kept constant at 150mM NaCl.
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5 Discussion
In this chapter, I have described the successful construction of three two-
domain MHC Class II fusion proteins. The initial construction work was performed
using murine I-Ed through overlap-extension PCR, but this could not be extrapolated
for use with either HLA-DR7 or HLA-DR15. Their construction required a
successful revision of the previous method. Incorporation into a viable bacterial
expression system ultimately yielded abundant fusion proteins.
The pET14b vector system was initially utilised due to its availability in the
laboratory and its similarity to the pET21d vector used by Burrows el al (Burrows et
al., 1998). The murine construct I-EdscTBB was successfully ligated into this
expression vector, and the recombinant fusion protein found to be produced in
bacterial inclusion bodies. Unfortunately, further development of this system was
hindered because of a number of factors including poor yield and difficulties with
downstream purification using anion exchange chromatography that proved more
troublesome than encountered by other groups (Burrows et al., 1998, Burrows et al.,
1999, Chang et al., 2001). The main problem with this technique was that of non-
proteinaceous column fouling that could not be removed by thorough washing of the
inclusion bodies prior to their re-suspension. This resulted in a marked reduction in
column capacity and increased dilution of the resulting purified I-EdscTBB protein.
In order to open up other purification avenues, as well as improve the chances of
incorporating the human scTBB constructs into a bacterial expression vector, a
different pET vector was sought.
The vector pET25b was chosen due to its two C-terminal tags and the
accessibility of its cloning sites. The basic vector was successfully modified to allow
ligation of the three scTBB constructs in such a way that two C-terminal tags could
be utilised, whilst removing the pelB leader sequence that would otherwise facilitate
the export of the recombinant proteins into the periplasmic space. All three
recombinant scTBB proteins were produced using this expression system. Nickel
chelation chromatography was successfully optimised in the purification of each
construct, with each construct having the expected C-terminal tags. However, as
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predicted, protein refolding and disulphide bond formation of these recombinant
proteins proved challenging. Despite the similarities between each of the three
recombinant constructs, there was a varying degree of dimerization of the scTBB
proteins. This suggested differences in secondary and tertiary protein structure
between the three scTBB proteins that may have occurred due to subtle differences in
their production conditions, out with those already accounted for. Burrows' group
reported no such problems with either anion exchange or protein refolding,
experiencing no such disulphide dimerization problems (G. Burrows, personal
communication). Based on modifications of a number of techniques (Arimilli et al.,
1995, Kuhelj et al., 1995, Lilie et al., 1998, Rudolph, 1996, Rudolph and Lilie, 1996,
Stockel et al., 1997), and using Burrows' methodology as a base line (Burrows et al.,
1998), I developed a reproducible refolding strategy that minimised the degree of
dimerization using a redox-shuffle technique. Although this strategy did not
completely remove the dimeric scTBB forms, the hope is that the improved refolding
achieved would enhance functionality beyond these dimeric forms.
One possible improvement to the current purification and refolding strategy
would be to utilise on-column purification followed by refolding
(AmershamPharmaciaBiotech, 2001, Colangeli et al., 1998). This technique is
feasible, but would require some modification to the strategy used above in order to
reduce possible nickel oxidation on the chromatography column during refolding.
Moreover, further purification steps may well be required to improve protein
homogeneity and purity in the form of size-exclusion chromatography +/- anion
exchange chromatography (Burrows et al., 1998, Colangeli et al., 1998). Before
further purification was undertaken, I felt that it would be prudent to assess the
functionality of the scTBB proteins as described in the following chapter.
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Chapter 6
Results (IV)
Functional Evaluation of Tetramer Building Blocks
1 Introduction
Within the preceding chapters, I have described the design, construction,
expression and purification of recombinant murine and human MHC Class II
proteins. These recombinant proteins have the expected molecular size on SDS-
PAGE and the expected affinities for certain monoclonal antibodies. In this chapter,
1 will describe experiments that evaluate the conformational and functional nature of
the purified constructs. In particular, I demonstrate that both HLA-DR15LZ TBB
and HLA-DR15sc TBB specifically bind peptide ligands. Initial work used the
HLA-DR15 TBBs to develop appropriate assays that were then applied to the other
recombinant proteins.
2 Leucine Zipper-associated Heterodimeric HLA-DR
Tetramer Building Blocks
2.1 Conformational Nature of the Purified HLA-DR15LZ TBB
It was not straightforward to demonstrate that the HLA-DR 15LZ a and p
chains co-expressed in S2 cells associated to form HLA-DR15LZ a,p heterodimers
because, in the absence of proper peptide loading, recombinant HLA-DR15LZ ap
heterodimers dissociated under the conditions of SDS-PAGE (Figure 4.13).
Therefore, I chose two approaches to demonstrate the heterodimeric nature of the
recombinant HLA-DR15LZ. First, immunoprecipitation using the monoclonal
antibody L243. This monoclonal antibody binds to the HLA-DR a chain of HLA-
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DR ap heterodimers but not to isolated HLA-DR a chains (Fu and Karr, 1994).
Immunoprecipitation of HLA-DR15LZ by L243 would, therefore, bring down the
'conformationally' correct fraction of the recombinant F1LA-DR15LZ and confirm
the existence of aP heterodimers (Gorga et al., 1987, Lampson and Levy, 1980,
Stockel et al., 1994). Second, I captured total a chain (both free a and ap
heterodimers) onto Nickel-resin by exploiting the Flis-tag on the carboxy terminus of
the recombinant a chain. The aim was to demonstrate ap heterodimers in solution
by detecting co-precipitating P chain. These two approaches are shown in Figure
6.1. The results are shown in Figure 6.2. The key observations from the above
analysis are as follows:
a) A large proportion of the total HLA-DR15LZ alpha chain within the
dialysed supernatant is captured by the L243 monoclonal antibody
indicating their occurrence as 'conformationally correct' a,p
heterodimers (compare samples A, Al and A2).
b) Extraction of the HLA-DR15LZ alpha chain by nickel-chelation
chromatography results in almost complete extraction of the HLA-
DR15LZ beta chain (very little p chain staining in sample B1 and CI
compared to Al), indicating that almost all P chains are associated
with a chains.
c) The more evident alpha-chain staining in B1 and CI would suggest
that there might be a greater production of free alpha than beta chain.
d) The nickel-chelation chromatography column maintains the ap
heterodimeric association of HLA-DR15LZ TBB (compare C2 to
A2).
e) The column size, and hence protein over-loading of the column, has
resulted in protein losses from the nickel-chelation column (B), with a
proportion of this being conformationally correct (B2).
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f) The presence of the acid-base leucine-zipper motif is able to maintain
a significant proportion of HLA-DR15LZ TBB in a(3 heterodimeric
association (see samples A2 and C2).
In summary, this elaborate experiment has confirmed the occurrence of HLA-
DR15LZ ap heterodimers in the induced S2 cell supernatant and their survival
following nickel-chelation affinity chromatography.
Figure 6.1 - Immunoprecipitation with L243 to investigate the occurrence of ap heterodimers
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Figure 6.2 - L243 immunoprecipitation analysis of HLA-DR15LZTBB
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Samples from the immunoprecipitation analysis were separated by SDS-PAGE prior to electroblotting
onto nitrocellulose. The blots were probed using anti-His tag, DA6.231 and 9E10 monoclonal
antibodies. The former is expected to bind to HLA-DR15LZ alpha chain, whilst the latter two
antibodies are expected to bind to HLA-DR15LZ beta chain. The blots were developed using the
three-layer approach with 3-amino-9-ethylcarbazole. The HLA-DR15LZ alpha chain appears to be
running heavier than the expected 28kD, whilst the beta chain is found close to the expected 3 lkD.
2.2 Peptide-Binding Assessment of Purified HLA-DR15LZ TBB
2.2.1 Design of labelled peptide and binding conditions
A FITC-labelled peptide with a high predicted affinity for both HLA-DR15
and HLA-DR7 was made with which to examine the peptide-binding properties of
the recombinant MHC class II molecules. The choice of peptide was based upon
work previously undertaken on the Goodpasture antigen (Phelps et al., 2000, Phelps
et al., 1998, Phelps et al., 1996), and the reported peptide-binding characteristics of
HLA-DR7 and HLA-DR15 (Chicz et al., 1993, Marsh et al., 2000, Vogt et al., 1994,
Wucherpfennig et al., 1994). A synthetic peptide was manufactured containing the
a3(IV) collagen sequence between amino acid position 26-47 (p26-47), the
numbering being relative to the sequence 'SPAT' at the beginning of the NCI
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domain. In order to minimise alterations to the peptide conformation, yet allow ease
of peptide detection, the peptide was manufactured with an N-terminal fluorescein
tag (BACHEM (UK) Ltd.) (Figure 6.3).




The fluorescein-tagged synthetic peptide (F1-E-23-R) was based upon peptide p3b that is known to
bind both HLA-DR15 and HLA-DR7 with medium to high affinity (Phelps et al., 2000, Phelps et al.,
1998). Peptides F1-E23-R and p3b differ only by the additional residues (in red) in order to improve
the predicted solubility of the former. Both the additional residues and the fluorescein tag were
designed not to be close to the predicted residues involved in the F1LA-DR15 peptide-binding pockets
(underlined) (Marsh et al., 2000).
Recombinant and native purified MHC class II molecules are usually
obtained in complex with peptides within their peptide-binding domain. In the
former case the peptides presumably complex during refolding of the recombinant
structure, and are likely to be of relatively low affinity given the non-physiological
nature of their production. Therefore, in order to demonstrate the peptide-binding
capacity of MHC class II molecules it is necessary to test these molecules using a
labelled peptide under conditions that favour peptide exchange. Although exact
binding conditions vary between MHC class II types, several studies have identified
general principles such as:
• pH 5-7 (Coligan et al., 2001, Scheirle et al., 1992, Sette et al., 1992);
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• The presence of certain detergents, e.g. NP40, that increase the rate of
association of added peptide and the percent occupancy of the recombinant
MHC class II molecule, presumably because the dissociation of endogenous
peptide is the rate-limiting step in binding (Buelow et al., 1994);
• The presence of hydroxy1 groups, e.g. in alcohols, that are able to disrupt the
hydrogen bonds between peptide ligands and MHC class II molecules and so
catalyse ligand exchange even at neutral pH (Falk et al., 2002).
I chose binding conditions based upon these principles of pH 5.0 using a citrate
buffer, in the presence of 0.5% NP40 and 5% ethanol. Two approaches were utilised
to examine fluorescein-tagged peptide/HLA-DR15LZ TBB interactions. Capture
ELISA and a novel approach using bead capture and FACS analysis.
2.2.2 Capture ELISA approach
In order to examine the association of the fluorescein-tagged peptide with
MHC class II complexes I first developed a capture ELISA using monoclonal
antibodies to trap the MHC class II complexes onto the surface of an ELISA plate,
analysing the test plate using a fluorescent plate reader.
Native HLA-DR15 from HLA-DR15-expressing B cell lysates was captured
onto flat-bottomed ELISA plates coated with either DA6.231 or L243 monoclonal
antibodies in carbonate buffer (35mM NaHCCVlSmM Na2CC>3 pH9.6). The
presence of captured MHC class II complexes was assessed by using the rat anti-
Human MHC class II monoclonal antibody YD1/63.4.10 (Pawelec et al., 1982), an
alkaline phosphatase-conjugated anti-rat IgG and p-nitrophenyl phosphate. The plate
was viewed at 405nm using an Anthos ht2 plate reader (Anthos Labtec Instruments,
Salzburg), and revealed the presence ofMHC class II complexes in the wells. Native
HLA-DR15 was then incubated with serial dilutions of either F1-E-23-R or a biotin-
labelled MBP peptide (MBPgs-ios) at 25°C for 90hours in citrate buffer pH5.0. Fl-E-
23-R was formed into a ImM solution using 2% DMSO/5% acetonitrile in dH20.
Fluorescence associated with the MHC complexes was measured by analysing
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emissions at 535nm following excitation at 485nm using a Wallac™ 1420 Victor2
Multilabel Counter (PerkinElmer Analytical Instruments (UK)). The presence of
biotin-labelled peptide was detected by developing the wells with Extravidin®
alkaline phosphatase and p-nitrophenyl phosphate, viewing the plate at 405nm using
an Anthos ht2 plate reader (Anthos Labtec Instruments, Salzburg). Although there
was no increase in fluorescence above background using F1-E-23-R indicating a lack
of peptide binding, the presence of biotin-labelled peptide was detected at the highest
concentration after prolonged colour development.
The results indicated that F1-E-23-R had a much lower affinity than expected,
and certainly lower than the biotin-labelled peptide our laboratory previously used
for HLA - peptide binding assays. Moreover, the results revealed a troublesome
tendency for F1-E-23-R to precipitate out of solution in aqueous buffers giving rise to
high levels ofnon-specific binding.
A limited investigation of F1-E-23-R - HLA-DR15LZ interaction using this
assay was, unsurprisingly, uninformative. The difficulties encountered above, and
the prohibitive expense of manufacturing another tagged peptide, led me to try
another technique to assess peptide binding.
2.2.3 Bead capture and FACS analysis approach
I reasoned that coating HLA-DR15LZ onto cell-sized beads would enable me
to exploit the sensitivity and versatility of FACS instruments. I used CELLection™
Dynabeads® (Dynal Biotech UK) pre-coated with a human IgG4 that recognises the
Fc portion of all murine IgG subclasses. FACS analysis of these beads showed a
well defined forward- and side-scatter profile with minimal auto-fluorescence.
Experimental analysis could be performed by gating the main population of beads to
reduce interference from non-bead bound fluorescent material (Figure 6.4).
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Figure 6.4 - Gating on Dynal® beads
a) b)
Forward Scatter Log Fluorescence Intensity
CELLection™ Dynabeads® were coated with 9E10 by mixing 5p.I of bead suspension with 0.5ml of
affinity purified 9E10 solution in PBS/1% BSA for 1.5 hours at room temperature. The beads were
washed in PBS/1% BSA using a magnetic particle concentrator (Dynal MPC®). The beads were
assessed by FACS using a Coulter Epics XL-MCL (Beckman Coulter (UK) Ltd). The major
population of beads was gated as shown and 10000 events within the gate used as the stopping point.
There was no significant difference in the fluorescence chromatogram using non-gated events. FACS
data was analysed using FCS Express2® software (De Novo Software (Canada)). This is
representative of five separate FACS analyses.
The 9E10-coated beads could, therefore, be used to capture the recombinant HLA-
DR15LZ TBB via the myc-tag and act as the framework for peptide-binding
assessment. An initial series of peptide-binding experiments were performed in
order to ascertain whether HLA-DR15LZ TBB could bind F1-E-23-R and whether
such binding could be detected within this assay system (Figure 6.5). Peptide
binding was performed at 37°C overnight in an attempt to strike a balance being
between improving binding kinetics and worsening peptide degradation.
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250(il of concentrated HLA-DR15LZ TBB in PBS was added to 1ml of citrate buffer pH5.0
containing Protease Inhibitor Cocktail® (for polyhistidine-tagged proteins - Sigma-Aldrich Inc.), 0.5%
NP40 and 5% ethanol. F1-E-23-R was added such that the final concentration of peptide was 4pM,
0.8|iM, 0.4|iM or 0.08pM. The resulting mixtures were incubated at 37°C overnight with gentle
shaking. A similar series ofpeptide concentrations were incubated without HLA-DR15LZ TBB. The
mixtures were neutralised to pH7 with 80j.il 1M phosphate buffer pH8 prior to adding 80pl of 9E10
coated-beads (about 5xl05 beads) and incubating at RT for 4 hours using the Dynal Sample Mixer®.
The beads were washed twice in 1ml PBS. The beads were gated and analysed as previously. The
beads combined with peptide alone (b) were used to define the limit of background fluorescence
within the gated beads as shown by the positive marker region. This is representative of three peptide
loading experiments.
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Figure 6.5c shows peptide binding to the HLA-DR15LZ TBB at the highest
concentration of peptide used. The peak log fluorescence intensity within the
marked region increased from 43 (with 0.04pM FL-E-23-R) to 229 (with 4pM FL-E-
23-R). The increase was not due to non-specific interactions with the coated beads
as there was no significant increase in fluorescence in the absence of HLA-DR15LZ
TBB on the coated-beads (Figure 6.5b). The peak log fluorescence intensity
increased from 10 (with 0.04pM FL-E-23-R) to 16 (with 4pM FL-E-23-R).
In order to distinguish specific binding within the peptide-binding groove
from non-specific binding to another part of the HLA-DR15LZ TBB protein, I
examined the capacity of an unlabelled high affinity FILA-DR15 ligand ('AS346' -
SPHGWISLWKGFSFIMFFSAGR - pl34-145 of a3(IV)NCl (,Albachem Ltd.
UK)), and a non-binding peptide ('1634S' - REELFALHGFSCP (Albachem Ltd.
UK)) to inhibit the binding of F1-E-23-R to HLA-DR15LZ TBB (Figure 6.6). Figure
6.6 shows the peptide-specific nature of the fluorescent peptide binding to HLA-
DR15LZ TBB. The fluorescent-tagged peptide is displaced by the unlabelled
competitor peptide ('AS346'), whilst the control peptide ('1634S') has no effect on
fluorescent peptide binding. The peak log fluorescence intensity decreased from 165
with 0.8pM AS346 to the baseline value of 112 with 16pM AS346. The peak log
fluorescence intensity did not change significantly with 1634S (220 at 0.8pM and
212 at 16pM 1634S). The peak log fluorescence intensity for the beads combined
with 8pM F1-E-23-R without HLA-DR15LZ TBB was 114. This experiment was
successfully repeated with the same result. The DMSO introduced with the 'AS346'
did not account for the displacement of F1-E-23-R as DMSO at an equivalent
concentration had no effect on F1-E-23-R binding (Figure 6.7). Therefore, F1-E-23-R
binding to E1LA-DR15LZ TBB is specifically inhibited by a peptide with a high
HLA-DR15 binding affinity, and not by a non-binding peptide indicating that the
observed F1-E-23-R binding is occurring at the peptide-binding groove.
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250pl of concentrated HLA-DR15LZ TBB in PBS was added to 1ml of citrate buffer pH5.0/Protease
Inhibitor Cocktail®/0.5% NP40/5% ethanol. To this mixture prepared fluorescent-tagged peptide, Fl-
E-23-R, was added such that the final concentration of peptide was 8pM. To this mixture increasing
amounts of either 'AS346' (b) or '1634S' (c) were added such that their final concentrations were
0.8pM, 8pM or 16pM. These mixtures were incubated at 37°C overnight with gentle shaking. The
mixtures were then neutralized as above before adding 80pl of 9E10 coated-beads (about 5xl05 beads)
and incubating at room temperature for 4 hours using the Dynal Sample Mixer®. The beads were
washed twice in 1ml PBS using the Dynal MPC® prior to resuspending in PBS and analysing as
previously. This is representative of three peptide binding competition experiments.
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250|il of concentrated HLA-DR15LZ TBB in PBS was added to 1ml of citrate buffer pH5.0/Protease
Inhibitor Cocktail®/0.5% NP40/5% ethanol. To this mixture prepared fluorescent peptide, F1-E-23-R,
was added such that the final concentration of peptide was 8pM. To one sample DMSO was added
equivalent to the highest quantity used in the preceding experiment. These mixtures were incubated at
37°C overnight with gentle shaking. The mixtures were then neutralized as above before adding 80pl
of 9E10 coated-beads and incubating at room temperature for 4 hours using the Dynal Sample Mixer®.
The beads were washed twice in 1ml PBS using the Dynal MPC® prior to resuspending in PBS and
analysing as previously.
It was disappointing that peptide binding could only be detected using high
concentrations of F1-E-23-R. This in part reflects the unexpectedly low binding
affinity of F1-E-23-R for HLA-DR15LZ TBB. Another factor was poor bead coating
with 9E10 monoclonal antibody because significant quantities of HLA-DR15LZ
TBB alpha and beta chains could be detected following capture by the 9E10 coated
beads (Figure 6.8). Therefore, there is scope to improve the systems sensitivity
further if required in future analyses.
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Lane 1 - Perfect Protein® markers
Lanes 2 & 4 - Supernatant from Dynal beads
Lane 3 - HLA-DR15LZ TBB solution
HLA-DR15LZ beta chain
HLA-DR15LZ alpha chain* • ■ ■ *
9E10 Anti-His tag
A sample of the supernatant fluid was removed once the coated-beads had been collected following
HLA-DR15LZ capture and prior to washing the beads in PBS. The sample was separated by SDS-
PAGE. The gel was electro-blotted onto nitrocellulose overnight prior to probing with either 9E10 or
anti-His tag monoclonal antibody. The blot was developed using the three-layer approach and Sigma
Fast ™ 3,3'-Diaminobenzidine hydrochloride.
3 Single-chain Tetramer Building Blocks
3.1 Integrity of ap association of the Purified Single-chain TBB
The integrity of the tertiary a and P domain association of purified and
refolded single-chain fusion proteins (HLA-DR15sc and HLA-DR7sc) was assessed
using the heterodimer-specific L243 monoclonal antibody in an analogous
experiment to that used in the assessment of HLA-DR15LZ TBB (Figure 6.9). No
similar heterodimer-specific monoclonal antibody was available for the assessment
of I-Edsc as 2G9 is capable of binding the urea-solubilised crude inclusion body
preparation of I-Edsc (See Results III), and 14-4-4S binds free I-Ed alpha chain as
well as I-Edap heterodimers (Spencer et al., 1993, Spencer and Kubo, 1989).
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Figure 6.9 - L243 immunoprecipitation of HLA-DRlSsc TBB and HLA-DR7sc TBB
a) Anti-HSV Immunoblot
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0.5ml of refolded HLA-DR15sc and HLA-DR7sc in PBS were separately immunoprecipitated using
L243 and Protein A sepharose. Samples were collected from the antigen-L243 combinations
following their passage through the Mobicol® microcolumn. These samples represented the L243-
unbound postloads (Lanes 2, 4 &6). Samples were also collected from the microcolumn eluates that
represented the L243-bound fraction (Lanes 3, 5 &7). The samples were separated by SDS-PAGE
using a 4-12% NUPAGE ® Bis-Tris gradient gel (Invitrogen Ltd., UK) before electro-blotting onto
nitrocellulose overnight. The nitrocellulose membrane was probed with either the anti-HSV
monoclonal antibody or the secondaiy antibody (anti-mouse IgGAP) alone before developing using
the two-layer approach.
A small proportion ofHLA-DR15sc TBB and HLA-DR7sc TBB were bound
by L243 in solution indicating the correct tertiary a[3 heterodimeric association. This
can be seen by the presence of the expected 25kD band in Lanes 3 and 7.
Interestingly, a proportion of the dimeric HLA-DR15sc TBB, and to a lesser extent
HLA-DR7sc, also appears to have been immunoprecipitated as seen in Lanes 7 and 3
at around 50kD. The proportion immunoprecipitated is 5-10% although the correctly
folded proportion could be much higher as the L243 concentration in this experiment
was probably a limiting factor. These additional bands are not present in the I-Edsc
eluate that was used as a negative control (Lane 5), nor are they present using the
secondary antibody alone (Figure 6.9b), adding weight to the above findings.
3.2 Assessment of Biotinylation of scTBB
One of the advantages of the E.coli expression system is the possibility of
significant biotinylation of the recombinant single-chain fusion proteins by the
endogenous E.coli BirA enzyme. The occurrence of this biotinylation was assessed
by examining samples of the single-chain fusion proteins before and after adsorption
onto avidin-coated beads (Figure 6.10). The blot developed using Extravidin® alone
(Figure 6.10a) reveals only those proteins that are biotinylated, whereas the anti-HSV
immunoblot (Figure 6.10b) detects all the recombinant scTBBs. Biotinylated
proteins of the expected size are seen in comparing these blots, indicating that at least
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a proportion of the recombinant proteins are indeed biotinylated during their
formation. There is also a reduction in the quantity of these proteins following
avidin adsorption, both confirming the above and highlighting the utility of using this
interaction to adsorb the scTBBs on to a bead surface. Unfortunately, it would
appear that the avidin beads used were a limiting factor given the presence of
Extravidin® staining following adsorption (Figure 6.10a).
Figure 6.10 - Assessment of Biotinylation of scTBB
a) Extravidin immunoblot
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A sample of each of the three scTBB constructs was taken and mixed with 50|il of a 1:100 dilution of
streptavidin-coated 1pm beads (PolySciences Inc.). The resulting mixture was incubated for 1 hour at
room temperature with continuous mixing before pelleting the beads by centrifugation at 1800g for 30
seconds. Samples taken before and after combination with the streptavidin-coated beads were
separated by SDS-PAGE and electro-blotted onto nitrocellulose overnight. The nitrocellulose gel was
probed with either Extravidin® alone (Sigma-Aldrich") or anti-HSV monoclonal antibody, and
developed using the two-layer approach.
3.3 Peptide-Binding Assessment of Purified HLA-DR15sc TBB by
FACS
I performed a pilot experiment to delineate the peptide-binding capacity of
the purified refolded HLA-DR15sc TBB by loading the scTBB with fluorescent-
tagged peptide under two pH conditions (Figure 6.11). This showed that in the
absence of favourable peptide-binding conditions i.e. citrate buffer pH5.0, there was
no increase in fluorescence above baseline and hence no specific peptide binding.
This finding supported specific peptide binding to HLA-DR15sc. It was, therefore,
important to determine the specificity of the binding and further optimise the
peptide-binding conditions. In the first instance, all further peptide binding
experiments were performed using citrate buffer pH5.0. Note that although 10000
events were captured for further analysis the total number of beads with any
fluorescence is far less than this.
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Two 500(xl samples of HLA-DR15sc were taken and 5ul of ImM Fl-E-23-R peptide was added to
each sample. The final concentration of F1-E-23-R was approximately 3pM. 1ml of citrate buffer
pH5.0 was added to one sample, leaving the other in PBS overnight at 4°C. Both samples were
separately mixed with 20pl of a 1:100 dilution of streptavidin-coated beads (approximately 9xl06
beads) at 4°C overnight. The beads were collected by centrifuging at 1 OOOOg for 2 minutes at room
temperature, removing the supernatant and re-suspending in 1ml 0.45pm-filtered PBS. The beads
were washed in this manner 3 times before analysing a 1:5 dilution using the Coulter Epics
XL.MCL®. 10000 events were recorded for further analysis. The main population of beads was gated
for analysis by comparing the three scatter diagrams (a-c) and gating of the maximal bead area in
order to obtain the fluorescence histogram (d). This is representative of two refolding experiments.
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Peptide-binding conditions were assessed using a series of experiments based
upon the general principles of peptide-binding conditions outlined above. I decided
to assess the effects of 0.5% NP40 (Buelow et al., 1994) and 5% ethanol (Falk et al.,
2002) upon HLA-DR15sc peptide-binding in the context of a citrate buffer pH5.0.
Non-specific binding of F1-E-23-R to the streptavidin-coated beads without captured
FILA-DR15sc was also assessed (Figure 6.12).
Non-specific binding of F1-E-23-R to the streptavidin-coated beads was
noted. There was a ten-fold increase in fluorescence over the range of F1-E-23-R
concentrations used (Figure 6.12a). In comparison, there was a striking increase in
fluorescence of the beads with captured HLA-DR15sc incubated with the same range
of F1-E-23-R concentrations. There was a thousand-fold increase in fluorescence
over the range of F1-E-23-R concentrations used (Figure 6.12b). The addition of 5%
ethanol, which is supposed to enhance peptide-binding (Falk et al., 2002) had no
further effect (Figure 6.12c). The striking findings are the duality of the fluorescence
peak and the disparity between the number of events captured and the actual number
of fluorescent beads analysed. One possibility for both these findings is that the
relative concentration of beads, HLA-DR15sc and F1-E-23-R was not optimised.
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Figure 6.12 - Optimising peptide-binding conditions of HLA-DR15sc with FI-E-23-R
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c) Beads with DR15sc + F1-E-23-R peptide in 0.5%NP40/5% Ethanol
Beads alone
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To 500gl samples ofHLA-DR15sc TBB in PBS 1ml of either of two peptide-binding buffer solutions
was added: citrate buffer pH5.0 with 0.5%NP40 (NP), or citrate buffer pH5.0 with 0.5%NP40+5%
ethanol (NP/Et). To each of the resulting mixtures a series of reducing concentrations of the Fl-E-23-
R peptide was added and the combinations mixed overnight at room temperature. Concurrently, the
series of reducing concentrations of F1-E-23-R peptide were also mixed with citrate buffer pH5.0/
0.5%NP40/ 5%ethanol in the absence ofHLA-DR15sc. The mixtures were neutralised using SOpI of
1M phosphate buffer pH8.0 before adding lOpl of a 1:100 dilution of streptavidin-coated beads
(PolySciences Inc.) previously blocked using a solution of PBS/1% BSA overnight (approximately
4.5x106 beads). The beads were mixed with the protein solutions for 4 hours at room temperature
before centrifuging at 10000g for 10 minutes at room temperature, and resuspending in 1ml filtered
PBS (0.45pm filter). The beads were washed in this manner 3 times before analysing a 1:5 dilution
using the Coulter Epics XL.MCL®. 10000 events were recorded for further analysis. Peptide-binding
was performed at room temperature in these experiments in order to minimize recombinant protein
degradation from contaminants of these bacterially derived recombinant proteins.
The specificity of the peptide binding was examined by comparing F1-E-23-R
peptide binding in the presence of the unlabelled competitor peptide 'AS346' (high
affinity for HLA-DR15), or the non-competitor peptide '1634S' (negligible affinity
for HLA-DR15) (Figure 6.13).
The distinct second peak of fluorescence with F1-E-23-R peptide binding to
HLA-DR15sc is clearly seen once more. Unexpectedly, the counts of fluorescence
beads increased with increasing concentrations of the competitor peptide 'AS346'.
The expected competitive displacement and loss of fluorescence was not seen even at
100 fold greater concentration of the competitor peptide (Figure 6.13b).
Furthermore, the lower fluorescence peak is lost at the highest concentration of
'AS346'. In contrast, no effect was seen with the non-competitor peptide '1634S'
(Figure 6.13c).
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Figure 6.13 - HLA-DR15sc peptide-binding inhibition (I)
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A series of reducing concentrations of both 'AS346' (b) and '1634S' (c) were separately combined
with 500pl ofHLA-DR15sc in PBS and a final concentration of lpM F1-E-23-R peptide in 1ml citrate
buffer pH5.0/ 0.5%NP40/ 5%ethanol/ Bacterial Protease Inhibitor Cocktail® (Sigma-Aldrich Inc.).
These solutions were gently mixed at room temperature overnight before neutralising with 80pl 1M
phosphate buffer pH8.0 and adding 20ul of a 1:100 dilution of streptavidin-coated beads previously
blocked in PBS/ 1% BSA. The beads were incubated for 4 hours at room temperature before
collection by centrifuging at 10000g for 2 minutes. The beads were washed twice in 1ml PBS/
1%BSA/ Bacterial Protease Inhibitor Cocktail® at 4°C by vortexing, prior to collecting by
centrifugation, resuspending in PBS/ 1%BSA/ Bacterial Protease Inhibitor Cocktail®, and analysing
using the Coulter Epics XL.MCL®. 10000 events were collected. This is representative of two
peptide-binding inhibition experiments.
The experiment was repeated with ten-fold and one hundred-fold less
fluorescent peptide in order to assess whether greater AS346:Fl-E-23-R ratios would
result in competitive displacement (Figure 6.14). The result mirrored that of the
previous experiment, with the only effect seen being a reduction in the mean
fluorescence of the fluorescent population of beads. Once again, there was a specific
'AS346'-modulated enhancement of F1-E-23-R binding to HLA-DR15sc. Although
unexpected, this does provide evidence of specific peptide to peptide-binding groove
interaction.
Figure 6.14 - HLA-DR15sc peptide-binding inhibition (II)
a) Competitive displacement ofO.lpM F1-E-23-R by 'AS346'
HLA-DR15sc alone
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HLA-DR15sc+0.1 pM FI-E-23-R+IOpM AS346
HLA-DR15sc+0.1pM FI-E-23-R+40pM AS346
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A series of reducing concentrations of both 'AS346' (a & c)and '1634S' (b & d) were separately
combined with 500pl of HLA-DR15sc in PBS and a final concentration of either 0.1 pM or 0.01 pM
F1-E-23-R peptide in 1ml citrate buffer pH5.0/ 0.5%NP40/ 5%ethanol/ Bacterial Protease Inhibitor
Cocktail® (Sigma-Aldrich Inc.). These solutions were gently mixed and incubated with streptavidin-
coated beads as previously before analysing using the Coulter Epics XL.MCL®. 10000 events were
collected. This is representative of two peptide-binding inhibition experiments.
Given that 'AS346' was dissolved in a DMSO based solution, a further
experiment was carried out in order to confirm the null effect of DMSO upon
fluorescence. A sample of the fluorescein-tagged peptide was, therefore, refolded in
the presence of an equivalent concentration of DMSO without 'AS346' (Figure
6.15). This experiment confirmed the null effect ofDMSO upon fluorescence.
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500pl of HLA-DR15sc in PBS was combined with a final concentration of 0.1 pM F1-E-23-R peptide
in 1ml citrate buffer pH5.0/ 0.5%NP40/ 5%ethanol/ Bacterial Protease Inhibitor Cocktail® (Sigma-
Aldrich Inc.). DMSO was added to one sample in an amount equivalent to that found in lOOpM
'AS346'. Further binding conditions and analysis remained unchanged.
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One possible explanation for the duality of the fluorescence peak was that the
relative concentrations of beads and HLA-DR15sc were not optimal for the assay.
This was assessed by reducing the amount of HLA-DR15sc by one fifth, in a series
ofpeptide-binding experiments using three different bead quantities (Figure 6.16).
Figure 6.16 - Optimisation of bead, HLA-DR15sc TBB and F1-E-23-R concentrations
a) Using lpl of undiluted streptavidin-coated beads (4.5xl07 beads)
HLA-DR15sc alone
HLA-DR15sc + 0.1 qM FI-E-23-R
HLA-DR15sc + 1pM FI-E-23-R
HLA-DR15sc + 10pM FI-E-23-R
1cP 101 1# 1CP 1tf
Log Fluorescence Intensity
b) Using lpl of 1:10 dilution of streptavidin-coated beads (4.5x10 beads)
'
FILA-DR15sc alone
HLA-DR15sc + 0.1 |JM FI-E-23-R
HLA-DR15SC + 1pM FI-E-23-R
HLA-DR15sc + 10|jM FI-E-23-R
1C? icf
Log Fluorescence Intensity
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lOOpl of HLA-DR15sc in PBS was combined with F1-E-23-R peptide at a final concentration of
0.1 pM, 1 uM, or lOpM in 1ml citrate buffer pH5.0/ 0.5%NP40/ 5%ethanol/ Bacterial Protease
Inhibitor Cocktail® (Sigma-Aldrich Inc.). These solutions were gently mixed at room temperature
overnight before neutralising with 80pl 1M phosphate buffer pH8.0. Streptavidin-coated beads were
added at one of three quantities (lpl neat suspension (a), lpl of a 1:10 dilution in PBS (b) and lpl of a
1:100 dilution in PBS (c)) having been previously blocked in PBS/ 1% BSA. Further binding
conditions and analysis remained unchanged. The fluorescence intensity chromatograms were derived
as previously and normalized at 0.1 pM F1-E-23-R peptide. This is representative of two peptide-
binding inhibition experiments.
Figure 6.16 suggests that the dual peak phenomenon was a result of less than optimal
bead/seTBB/'Fl-E-23-R' relative concentrations. At each bead concentration, the
fluorescence level is seen to increase ten fold with each ten fold rise in peptide
concentration. The peak log fluorescence intensity increased from a mean of 30 at
0.1 pM F1-E-23-R, to 280 at lpM F1-E-23-R, to 6500 at lOpM F1-E-23-R. At the
optimal relative concentration (lOOpl of HLA-DR15sc, 0.1 pM 'F1-E-23-R' peptide
and 1 pi of a 1:100 dilution of streptavidin-coated beads) a single fluorescence peak is
demonstrated. This suggests that under these conditions, both the streptavidin-coated
beads and the HLA-DR15sc TBB binding sites are saturated. Indeed, in reducing the
bead quantity the actual fluorescent bead count increases (compare bead counts in
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Figure 6.16a to c), indicating that with greater bead concentrations a greater
proportion of the beads had little if any HLA-DR15sc TBB bound. This optimisation
could be used to reassess the previous inhibition assays, although further adjustment
ofHLA-DR15sc amounts may be required if there is marked batch-to-batch variation
in concentration.
In essence, the evaluation of HLA-DR15sc TBB has suggested that this
recombinant protein is able to specifically bind peptide.
4 Discussion
The initial assessment of HLA-DR15LZ TBB by immunoprecipitation using
the conformationally sensitive L243 monoclonal antibody would strongly suggest
that the recombinant HLA-DR15LZ TBB formed is conformationally correct before,
during and after nickel-chelation purification. Moreover, the results would imply
that the addition of an L243-affinity column would be of value as a purification step
in keeping with previous work (Arimilli et al., 1995, Kalandadze et al., 1996).
However, it is certainly feasible for nickel-chelation chromatography to be the sole
purification stage necessary, particularly if protein production is carried out in
serum-free medium (Kuroda et al., 2000).
The ability of HLA-DR15LZ TBB to specifically bind peptide was initially
assessed using standard ELISA techniques but this approach was unsuccessful
because the fluorescein-tagged peptide bound too inefficiently to the HLA-DR15LZ
TBB for satisfactory detection by ELISA. A novel FACS-based technique was
developed using beads coated with human IgG4 specific for the Fc segment of
murine IgG to form the basis of a sensitive peptide-binding assay. This novel
technique provided clear evidence of specific and inhabitable binding of peptide to
HLA-DR15LZ TBB. The sensitivity of the technique requires further improvement
through the optimisation of the solid phase scaffold constitution. Coating of the
CELLection™ Dynabeads® (Dynal Biotech UK) with 9E10 can be optimised to
achieve complete saturation of the beads, and in the same vein, the quantity ofHLA-
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DR15LZ TBB used to bind to the beads can also be optimised for the same reason.
Optimisation can be checked using a fluorescent-tagged anti-murine IgG in the case
of the former, and a rat anti-human HLA-DR (eg YD 1/63.4.10 - Abeam Limited
(UK) (Pawelec et al., 1982)) monoclonal antibody with a fluorescent-tagged anti-rat
IgG secondary as the detecting antibody in the case of the latter. Importantly, the
data clearly indicate that HLA-DR15LZ TBB in significant proportions is
conformationally and functionally similar to native HLA-DR15.
Initial assessment of the scTBB fusion proteins began with an assessment of
their conformational integrity. Due to a lack of a heterodimer-specific monoclonal
antibody for I-Ed peptide-binding domain, the nature of the peptide-binding domain
of the human scTBB constructs alone was assessed using the monoclonal antibody
L243. Immunoprecipitation of each of the refolded scTBB constructs revealed that a
significant proportion of both HLA-DR7sc TBB and HLA-DR15sc TBB had the
correct pi-aj association. Moreover, this finding extended to a proportion of
apparently dimeric HLA-DRsc TBB proteins. This latter finding possibly indicates
that although the L243 monoclonal antibody is heterodimer-specific, this does not
equate to specificity for the correct tertiary structure of the peptide-binding domain
given that the disulphide bond within the Pi domain is integral to its structure. This
disulphide bond couples the carboxy-terminus of the Pi domain to the first strand of
the anti-parallel P-sheet platform and is thought to serve as the "linchpin" to a stable
tertiary structure (Chang et al., 2001). Further evaluation of these recombinant
scTBB proteins involved an assessment of their biotinylation as work with
recombinant MHC Class I produced in E.coli had suggested that further enzymatic
biotinylation was required (Denkberg et al., 2000). Certainly, my preliminary
findings would indicate that a significant proportion of the recombinant scTBB
proteins produced have already been biotinylated within the E.coli inclusion bodies.
Using the bead-based FACS analysis of peptide binding, initial results
indicated specific peptide binding to HLA-DR15sc TBB when refolded with the
fluorescent-tagged peptide 'F1-E-23-R'. This result was reproduced by combining
'F1-E-23-R' with HLA-DR15sc TBB in the presence of citrate buffer pH5.0.
Peptide-binding experiments showed increasing peptide binding to HLA-DR15sc
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TBB with increasing peptide concentrations. In order to clarify this further, a series
of binding-inhibition experiments were performed using two unlabelled peptides, one
of which ('AS346') was known to have a high affinity for native HLA-DR15 and so
would act as a competitive inhibitor to the 'F1-E-23-R' peptide. In the presence of
the non-competitor peptide ('1634S') there was no alteration to the degree of 'Fl-E-
23-R' binding to HLA-DR15sc TBB. Paradoxically there appeared to be increased
fluorescence with increasing concentrations of the competitor peptide ('AS346'). A
possible explanation for this is that the ratios of streptavidin-coated beads, HLA-
DR15sc and 'F1-E-23-R' require optimisation as suggested in Figure 6.16. A further
explanation for this specific peptide to peptide-binding groove interaction is that the
'AS346' is affecting the conformation of the recombinant HLA-DR15sc in a manner
that would improve its binding affinity, so allowing increased binding to the
fluorescein-tagged peptide (Kasson et al., 2000, Natarajan et al., 1999, Rabinowitz et
ah, 1998, Sadegh-Nasseri and Germain, 1991). Certainly, work performed by
Burrows' group would be in concordance with this hypothesis in that they also
demonstrated the importance of peptide binding in keeping the cq and Pi domain
helices in "relative register" (Chang et ah, 2001). One dilemma with this as a
possibility is that 'AS346' theoretically has a higher affinity for wild type HLA-
DR15 than the fluorescein-tagged peptide (Phelps et ah, 1998).
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Construction of MHC class II multimers is now well recognised to be very
challenging. Even today, there are few reports of successful assembly ofMHC class
II multimers, and whilst very interesting data have been acquired with these reagents,
it is striking that difficulties remain not only in their formation but also in their
application (Hackett and Sharma, 2002). Rarely have these reagents been
successfully transferred between laboratories, and unlike MHC class I multimers,
commercially available reagents have only recently become available through
Beckman Coulter Immunomics. Moreover, although the NIH Tetramer Facility is
able to custom synthesise MHC class I tetramers, it has only recently been able to
provide four MHC class II tetramers on a trial basis in collaboration with Dr W.
Kwok (http://www.niaid.nih.gov/reposit/tetramer/index.html).
In this context I am not too disappointed that my three years as a training
fellow did not yield functional multimers. I have described three strategies for the
generation of recombinant MHC class II molecules suitable for formation into
multimers in order to stain or stimulate populations of T cells bearing TCRs with
particular MHC class II-peptide specificities. Two of these approaches generated
recombinant MHC class II proteins that were shown to be functional. I believe that
this work has resulted in a more complete understanding of the problems of
functional MHC class II assembly, and of the importance of the many design
decisions that must be made. Importantly, I am confident that the TBBs I have
generated are likely to prove excellent substrates for MHC class II multimer
formation.
In this chapter I discuss aspects of the design and production ofMHC class II
TBBs that my work has shown to be essential.
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2 Formation of Tetramer Building Blocks
2.1 Maintaining MHC class II a and |3 chain association
The importance of the association of MHC class II a and (3 chains to the
stability of the heterodimeric structure let alone its peptide-binding groove is well
documented in the literature particularly in relation to the development ofMHC class
II tetramer technology (Scott et ah, 1996). MHC class II a[3 heterodimers are
naturally associated through an interaction of their transmembrane domains as well
as the presence of a bound peptide within the peptide-binding groove formed by the
a(3 heterodimer. In newly synthesised MHC class II molecules, this bound peptide is
derived from the invariant chain protein (Ii) and is called CLIP (class Il-associated
invariant-chain peptide). CLIP must either dissociate or be displaced in order to
allow an antigenic peptide to bind to the MHC class II molecule. As a result,
"empty" recombinant MHC class II molecules are unstable structures.
Heterodimer association has been attempted using a combination of at least
three techniques: covalently linked peptides (Kozono et ah, 1994), carboxy terminal
leucine zipper motifs (Smith et ah, 1998), and carboxy terminal linkage to an
immunoglobulin scaffold (Hamad et ah, 1998).
My results using a covalently linked peptide to maintain the stability of the I-
EdtBand3 construct indicated that this alone was not sufficient to maintain stability.
Indeed similar findings have been reported with recombinant I-As constructs (Reddy
et ah, 2003). However, other factors such as transcription/translation issues may
have been the reasons for the lack of success of the I-EdtBirA and I-EdtBand3
constructs. Nonetheless, these early results underscore the importance of
heterodimeric association.
Of the two alternative further methods of promoting heterodimeric
association, leucine zipper constructs were rapidly emerging as the most versatile
and most used. Their effectiveness at promoting MHC class II heterodimer
formation had been well documented (Gauthier et ah, 1998, Kalandadze et ah, 1996,
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Scott et al., 1996), and they had been successfully used to form recombinant HLA-
DR in the Drosophila S2 expression system (Novak et al., 1999). Furthermore, the
leucine-zipper of the heterodimeric associated constructs is likely to add a degree of
flexibility that may improve TCR binding to a greater extent than the rather
inflexible avidin-biotin backbone of the "standard" MHC tetramer construct (Casares
et al., 1997, Hackett and Sharma, 2002). By comparison, the use of an
immunoglobulin scaffold to solely promote chain pairing was not proving to be as
versatile (N. Glaichenhaus, personal communication). Therefore, I decided to adapt
a construct that had been successfully used in the formation ofmurine I-Au (Radu et
al., 1998) with permission from Drs E.S. Ward and C.G. Radu. The adaptation of the
construct involved the alignment of the extracellular portions of the I-Au a and p
chains with the respective chains from I~Ed, HLA-DR15 and HLA-DR7 in order to
align the acid-base leucine zipper motif correctly for the two chains to be precisely
paired. The possibility of covalently linking a peptide to the amino-terminus of the
Pi chain to further enhance both chain pairing and peptide loading remained. This
adaptation process also opened the possibility of alternative purification strategies
through the carboxy terminal c-myc and polyhistidine tags.
A novel technique for maintaining the peptide-binding domain ofMHC class
II proteins was developed by Burrows' group (Burrows et al., 1998). This method
exploited the functional role of the oq-Pi domains of MHC class II molecules as the
peptide-binding "superdomain" (Brown et al., 1993) as compared to the a2~lh
domains that appear to act as the "superdomain" for CD4 co-receptor interactions
(Konig, 2002, Konig et al., 1995). The method involved the linkage of the carboxy-
terminus of the Pi domain to the amino-terminus of the ai domain in such a manner
as to retain their quaternary peptide-binding association. Burrows' group have
demonstrated a very slow off-rate of the single-chain fusion protein construct once
bound to the TCR, and have successfully used it to stain antigen-specific T cells in
its monomeric form (Burrows et al., 1998). This finding is intriguing given that the
heterodimeric constructs appear to require a degree of CD4+ T cell activation for
their tetramer staining (Kwok, 2003) and the CD4-MHC interaction aids in the
stability of the immune synapse, with the latter occurring through the a2 and P2
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MHC class II domains (Konig, 2002). Acknowledging the early success of this
system, however, I used it as the basis of my construct. Comparisons were first
made between the RT1.B construct formed by Burrows' group and the sequence
crystallographic structures of HLA-DR1, HLA-DR15, HLA-DR7 and I-Ed. Once
these comparisons had been made, recombinant proteins were successfully produced
using the pET25b bacterial protein expression system. Again, the possibility of
covalent peptide linkage to the amino terminus of the Pi domain was left open during
construct design.
The latter two strategies were used in parallel in order to increase the chances
of a successful outcome. Furthermore, these two contrasting methods of TBB
formation can be assessed in parallel, which may well shed more light on the kinetics
of this evolving technology.
2.2 Recombinant MHC class II expression
As has been alluded to in the preceding chapters, although the production of
recombinant MHC class I proteins for multimer formation is via relatively
standardised bacterial expression, this is not the case for MHC class II proteins.
Indeed, bacterial expression has only been used to form a few heterodimeric MHC
class II proteins (Ferlin et ah, 2000), and of these only HLA-DR1 and I-Ek have been
used to form multimers (Cameron et al., 2001, Cochran et al., 2001, Gutgemann et
al., 1998). The primary drawback with bacterial expression systems is the need for
in vitro refolding. In order to overcome this inherent drawback, insect cell
expression systems have been used yielding several recombinant MHC class II
proteins. There is little in the literature to suggest that one eukaryotic expression
system is superior to another in terms of the yield of functional recombinant MHC
class II proteins, with both baculovirus and Drosophila expression systems being
successfully utilised (Ferlin et ah, 2000, Hugues et ah, 2002). Indeed, one group has
tried both systems for the same recombinant MHC class II protein and found that the
Drosophila expression system provided equivalent and possibly greater protein yield
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than the baculovirus system with less experimental effort (Cameron et ah, 2002).
This would indicate that there is little to be gained in switching insect expression
systems.
The difficulties encountered with HLA-DR7LZ construct would appear to
reside at the DNA preparation stage of the HLA-DRB7z construct, and should be
relatively straightforward to correct. Although using the baculovirus expression
system, Fourneau et al (Fourneau et al., 2004) have recently shown that co-expressed
chaperones e.g. calreticulin improve the yield of recombinant HLA-DR4. It is
conceivable that such a system could also be of value using the Drosophila
melanogaster expression system, indeed this group indicated that they had
successfully used chaperone co-expression in the Drosophila system. This group
also found that an imbalance in HLA-DRa and HLA-DRp chain expression lead to
limited heterodimer secretion, which could be in keeping with my own findings
regarding HLA-DR7LZ. Furthermore, Fourneau et al suggest that replacement of
the leader sequence with an optimised insect cell leader sequence could improve the
final protein yield (Fourneau et al., 2004). Moreover, it is conceivable that changing
cell culture conditions could also improve protein yield. Gauthier et al (Gauthier et
al., 1998) reported a near doubling of recombinant F1LA-DR2 yield from a
baculovirus expression system using roller bottles as compared to spinner flasks,
although it was unclear whether this was related to cell density. Advances continue
to be made in cell culture technology, improving viable cell density with the promise
of improved protein yield eg miniPERM Bioreactor® (Vivascience Ltd) (Schillo et al,
personal communication).
Changing cell culture conditions together with two-stage purification using a
combination of nickel-chelation and antibody-affinity (either using L243 or 9E10)
chromatography should improve both the yield and purity of the final product.
Certainly, one suggestion in the literature is that improving the purity of the
recombinant MHC class II constructs used in multimerisation may aid in the
detection of low avidity CD4+ T cells (Kwok, 2003).
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Despite the apparent ease of expression and purification ofRT1.B in a simple
bacterial expression vector without the need for affinity purification (Burrows et al.,
1999), I encountered numerous problems with transfer of the constructs into a
bacterial expression vector, and later with downstream purification. In order to
overcome these issues, a different bacterial expression vector was utilised with the
added benefit of protein tags that could be exploited for protein purification.
Although Burrows briefly alluded to the use of a polyhistidine tag in his seminal
paper (Burrows et al., 1998) this did not appear to be used thereafter, indeed in
discussing my construct with him he suggested that such tags may affect the tertiary
structure of the resulting protein. Nevertheless, all three recombinant single-chain
fusion proteins were successfully formed using pET25b and purified by nickel-
chelation chromatography from bacterial inclusion bodies. It is recognised that
different vector/bacterial host combinations may have to be tried to obtain the best
protein yield (Mierendorf et al., 1994), and that protein yield may be reduced or
negated by mRNA secondary structures such as loops and hair-pins (Dr B. Morris,
Senior Scientist, Novagen® product applications -personal communication).
2.3 Refolding Recombinant MHC class II Proteins
Under physiological conditions most proteins fold spontaneously into their
correct conformation as determined by their amino acid sequence (Anfinsen, 1973).
MHC class II molecules are no exception, however, their refolding within the
endoplasmic reticulum is in association with MHC class Il-associated invariant chain
(Ii). A portion of the Ii polypeptide chain lies within the MHC class II peptide-
binding groove, preventing the binding of peptides at this stage and also helping to
maintain the heterodimeric association of the MHC class II a and p chains. During
this assembly process, the components are associated with the chaperone protein
calnexin. Once assembly is complete, the Ii-MHC class II complex is released from
calnexin for transport out of the endoplasmic reticulum. The invariant chain is
believed to target delivery of the MHC class II molecules to a low-pH endosomal
compartment (the MHC class II compartment - MIIC) where the invariant chain is
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sequentially cleaved leaving CLIP still bound to the MHC class II molecule. CLIP is
later released through the association of an MHC-like molecule, called HLA-DM in
humans, allowing other peptides to bind. Empty MHC class II molecules are
retained within the endoplasmic reticulum and degraded.
Bacterial expression systems are capable of producing large quantities of
recombinant proteins rapidly, but the recombinant products tend to accumulate as
insoluble inactive inclusion bodies. These aggregates are highly enriched for the
recombinant protein and are protected from proteolytic cleavage whilst aggregated
(Clark, 1998, Williams et al., 1982). Recovery of active proteins from these
aggregates generally involves three steps: isolation and washing; solubilisation that
inevitably results in denaturation of the proteins; and finally refolding of the
solubilised protein. Whilst the first two stages can be performed efficiently, the final
stage still entails a trial-and-error approach despite the increasing knowledge base
regarding the competing reactions of refolding, misfolding and aggregation (Clark,
1998, Rudolph et al., 1997, Tsumoto et al., 2003).
Initial isolation then washing of the inclusion body pellet using solutions
containing detergent (eg Triton XI00) and low concentrations of chaotropes (eg
urea) is designed to remove proteinaceous contaminants that may have been
adsorbed onto the inclusion bodies and that may affect refolding yield (Clark, 1998).
The inclusion body pellet is then solubilised using either high concentrations of
chaotropes or ionic detergents (egN-lauroylsarcosine). The solubilised inclusion
bodies can then be further purified (eg ion exchange or metal affinity
chromatography) to remove both proteinaceous and non-proteinaceous contaminants
that may shift the aggregation-refolding balance towards aggregation of the desired
recombinant protein (Clark, 1998).
The next stage is refolding of the recombinant protein such that the protein
conformation returns to its native folded compact state. This process involves the
removal of the solubilising denaturant, and in so doing correct refolding should
ideally occur as the protein's conformation changes to a more compact structure.
Using chaotropes allows the use of intermediate concentrations of these denaturants
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to be utilized to positively affect refolding, including disulphide bond formation
through mixed disulphide formation (Rudolph and Lilie, 1996, Tsumoto et al., 2003).
Chaotropes can be removed using a multitude of techniques eg dilution, dialysis, and
gel filtration in order to effect variable rates of removal that need to be optimised for
each protein. Slower processes of chaotrope removal can successfully prevent
aggregation of protein if the recombinant protein is not prone to aggregation at
intermediate denaturant concentrations. In this way, higher protein concentrations
can be used without reducing refolding yield through aggregation (Clark, 1998,
Tsumoto et al., 2003).
For disulphide bonded proteins refolding also needs to promote disulphide
bond formation through oxidation of the reduced cysteines. This can be encouraged
through oxido-shuffling systems, eg reduced and oxidised glutathione (Ahmed et al.,
1975, Saxenat and Wetlaufert, 1970), which are optimal at slightly alkaline pH.
Such oxido-shuffling systems increase the rate and yield of correct disulphide bond
formation by enhancing both the formation of disulphide bonds and the reshuffling
of incorrect disulphide bonds. Correct disulphide bonds being relatively protected
within stable native protein structures (Fischer et al., 1992, Lilie et al., 1998,
Rudolph, 1996, Rudolph and Lilie, 1996). Both pFI and temperature can also affect
refolding yield, with the former more likely to be protein dependent (Altman et al.,
1993, Burrows et al., 1999).
Refolding yield can be enhanced by a variety of co-solutes that either
enhance refolding or suppress aggregation (Clark, 1998, Rudolph and Lilie, 1996,
Tsumoto et al., 2003). These folding aids include the 'folding enhancer' glycerol
(Gekkot and Timasheff, 1981, Meng et al., 2001, Ou et al., 2002) and the
'aggregation suppressor' L-arginine (Arora and Khanna, 1996). The presence of
certain salts can also benefit refolding (Arakawa and Timasheff, 1982). With the
refolding process acting as a bottleneck to protein production, chromatographic
techniques are being developed to improve the final refolding yield. By
immobilising the recombinant protein on a solid support, aggregation of partially
refolded proteins can be minimised as the concentration of denaturant is gradually
reduced (Colangeli et al., 1998, Li et al., 2004).
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The difficulties of efficient refolding are increased in multi-domain,
oligomeric, disulphide bonded proteins such as MHC class II proteins. This is the
main reason why, with two notable exceptions (I-Ek (Giitgemann et al., 1998) and
HLA-DR1 (Cochran et al., 2000)), most recombinant MHC class II molecules used
to generate MHC multimers have been produced in one of two eukaryotic expression
systems (Ferlin et al., 2000). Burrows et al (Burrows et al., 1998, Burrows et al.,
1999) appeared to have circumvented this issue to some extent through covalent
linkage of the two portions of the MHC class II peptide binding 'superdomain'.
Although protein refolding is still necessary, the multidomain and heterodimeric
nature of MHC class II proteins is evaded. Further stability was added through the
use of covalently linked peptides (Burrows et al., 2000a, Chang et al., 2001).
The current literature on the refolding of MHC class II proteins produced in
E.coli is limited. The main groups using this expression system use a combination of
a dilutional refolding strategy in association with glycerol as a viscous stabiliser and
reduced and oxidised glutathione as an oxido-shuffling system in order to refold
heterodimeric MHC class II proteins (Altman et al., 1993, Cameron et al., 2002).
Despite the single-chain fusion protein construction, the major problem that I
encountered with the E.coli expression of these single-chain MHC class II constructs
was predictably that of protein refolding and disulphide bond formation. This was
solved using a refolding strategy that has the potential to be performed "on-column"
to reduce the final effects of dilution on protein yield.
Further modifications to the refolding methodology may be needed for
optimisation of the final yield, eg the use of glycerol and/or L-arginine. The
possibility of covalently linking peptides to the constructs remains a further way of
optimising functional yield, and is currently being investigated in my former
laboratory. McMichael's group in Oxford have found that the inclusion of a linked
peptide improves both yield and stability of recombinant HLA-DR1 produced using
the E.coli expression system, although they indicated that linker design is critical and
likely to vary between epitopes (Cunliffe et al., 2002, Wyer et al., 2001).
Investigators have compared the staining ability of multimers containing covalently
attached peptide to those loaded with exogenous peptide and have found similar
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levels of staining under standard conditions (Kwok et al., 2002). These refolding
steps may need to be preceded by a further purification step to improve final purity
and refolding yield. Anion exchange chromatography may, therefore, need to be
revisited prior to nickel-chelation chromatography as the polishing step. In terms of
the latter, Burrows et al found that a six-histidine tag resulted in reduced thermal
stability of their rat RT1.B construct above 60°C, although the construct appeared to
be stable at physiological temperatures (Burrows et al., 1999). It is not clear whether
or not the addition of the polyhistidine tag, HSV tag and/or the BirA site-specific
biotinylation sequence will have detrimentally affected the functional stability ofmy
single-chain MHC class II constructs in terms of antigen-specific T cell activation.
The BirA sequence is a necessary part of the current multimerisation, whilst the other
two tags provide a means of purification and identification of the recombinant
proteins.
3 Functional Assessment of Tetramer Building Blocks
Functional assessment of recombinant MHC class II molecules used in
multimer formation can be undertaken using biochemical and biological assays,
usually in that order (see (Scott et al., 1996)).
A number of biochemical approaches have been reported in the literature.
The most commonly employed has been the assessment of binding to monoclonal
antibodies that are highly conformationally sensitive. L243 has been used in the
purification of recombinant HLA-DR (Arimilli et al., 1995, Godkin et al., 2001,
Kalandadze et al., 1996, Natarajan et al., 1999, Stern and Wiley, 1992), and has also
been used to specifically assess the conformational integrity of the recombinant
protein (Cunliffe et al., 2002). 14-4-4S has been used to confirm the conformational
integrity of recombinant I-Ed (Casares et al., 1997), with a panel of conformationally
sensitive monoclonal antibodies being used to immunoprecipitate recombinant HLA-
DR1 (Zhu et al., 1997). However, the absence of binding to a conformationally
sensitive monoclonal antibody does not necessarily imply a lack of functional
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integrity e.g. the recombinant HLA-DR15 T cell receptor ligand produced by Chang
et al (Chang et al., 2001) does not bind to L243 but does stimulate antigen-specific T
cells (G. Burrows, personal communication).
A second biochemical approach has been the use of spectroscopic techniques.
Circular dichroism has been used to assess the secondary structure of recombinant I-
Au (Radu et al., 1998) and the single-chain fusion protein of RT1.B (Burrows et al.,
1999). Surface plasmon resonance spectroscopy has been used to assess the binding
kinetics of recombinant HLA-DR2 - MBP peptide to its cognate TCR (Appel et al.,
2000, Boniface et al., 1998, Scott et al., 1996).
Finally, biochemical assays ofpeptide binding have been used. Cochran et al
(Cochran et al., 2000) crudely assessed specific peptide binding to recombinant
HLA-DR1 through the prevention of SDS-induced FILA-DR1 chain dissociation at
room temperature. Kwok et al (Kwok et al., 2000) used a competition peptide
binding assay in order to assess specific peptide binding to recombinant HLA-DQ6.
Biological assessment has been broadly based around assays of the ability of
the recombinant MHC class II - peptide multimers to stain and/or stimulate their
cognate antigen-specific T cells. In their seminal paper, Altman et al (Altman et al.,
1996) showed staining by MHC class I - peptide tetramers correlated with peptide-
dependent cytotoxicity, with these tetramers being able to stain antigen-specific
CD8+ T cells present in freshly isolated PBMCs, as well as antigen-specific CD8+ T
cell lines and clones. Subsequent groups working with MHC class II - peptide
multimers have shown the ability of these multimers to stain antigen-specific CD4+ T
cell lines (Kuroda et al., 2000) and hybridomas (Crawford et al., 1998, Liu et al.,
2000, Malherbe et al., 2000, Novak et al., 1999), as well as antigen-specific CD4+ T
cells present in freshly isolated PBMCs (Crawford et al., 1998, Novak et al., 1999).
In terms of antigen-specific CD4+ T cell stimulation, this has been assessed using a
variety ofmethods in both T cell clones and freshly isolated PBMCs:
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• T cell proliferation assays using both soluble and immobilised MHC class II
- peptide multimers (Appel et al., 2000, Casares et al., 1999, Hamad et al.,
1998, Quarsten et al., 2001, Radu et al., 1998).
• Cytokine release assays e.g. IL-2 (Kotzin et al., 2000, Radu et al., 2000,
Radu et al., 1998), IL-5 and interferon-y (Buckner et al., 2002).
• An assessment of CD4+ T cell activation markers e.g. CD69 and CD25
(Cochran et al., 2000).
• Antigen-specific inhibition of T cell proliferation by single-chain
recombinant T cell ligand (Burrows et al., 1998)
Functional assessment of the TBBs that I have developed used most of the
biochemical techniques mentioned above. First, the majority ofHLA-DR15LZ and a
substantial fraction of both HLA-DR15sc and HLA-DR7sc bound to L243. Binding
to this antibody demonstrated that these constructs had heterodimeric peptide-
binding superdomains that were 'conformationally correct'. Binding of L243 to
HLA-DR15sc contrasts with the findings of G. Burrows whose group could not
demonstrate L243 binding to their own HLA-DR15sc fusion protein. Our two
constructs differ significantly in two areas: Burrow's HLA-DR15sc construct does
not contain a short linker sequence between the Pi and ai domains of the fusion
protein, and neither does it have a carboxy BirA sequence with adjoining tags. These
difference could account for this observed difference in L243 binding. Second,
HLA-DR15LZ and HLA-DR15sc were shown to bind peptides specifically. This
important finding was made using a novel fluid phase peptide-binding assay using
micro-beads and FACS technology. Bead-FACS is used and continues to be
developed for many analytes including cytokine assays and nucleoprotein
interactions (Kellar and Iannone, 2002, Kellar et al., 2001, Vignali, 2000). One
development has been the use of beads as solid supports on which to assess protein-
protein interactions, more specifically peptide binding to HLA-A and HLA-B
proteins (Chersi et al., 2000). As an extension of this technique, I developed a
method to assess specific peptide binding to the recombinant TBBs.
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The next logical stage in functional assessment of the TBBs made would be
biological analysis. Suitable reagents for this only became available since I finished
my period of research. My former laboratory has made HLA-DR15 restricted T cell
hybridomas and is in the process of demonstrating their activation by peptide-loaded
TBBs at the time ofwriting.
4 Sensitivity and Specificity of MHC Class II Multimers
Although one of the first hurdles in the application of MHC class II
multimers has been their reliable production, the consistent problems now faced by
researchers using MHC class II multimers are the apparent low number of antigen-
specific T cells within the circulation as well as their low avidity. This has resulted
in the currently published detection limits of this technology being reached (Kotzin
et al., 2000, Meyer et al., 2000).
In terms of the problem of low abundance, groups involved in this area are
trying to extend the detection capacity of this technique, with reports of an ex vivo
detection of between 1:15000 (0.006%) (Kwok, 2003) and 1:33000 (0.003%) (Danke
and Kwok, 2003), and even 1:80000 (0.0001%) using a magnetic bead enrichment
technique (Day et al., 2003, Lucas et al., 2004). At the same time, researchers have
tried using other techniques to tip the balance in their favour. Transgenic mouse
models have been used with varying success (Giitgemann et al., 1998, Malherbe et
al., 2000, Radu et al., 2000). Others have resorted to a period of in vitro peptide
stimulation to increase antigen-specific T cell numbers (Kwok et al., 2002).
However, this latter technique diminishes to some extent the promise of tetramer
technology in being able to identify and characterise antigen-specific T cells ex vivo
without any in vitro manipulation that could affect T cell characteristics (Cameron et
al., 2002). Indeed, in order to minimise the antigen-specific T cell activation
resulting from MHC-peptide multimer staining, new reversible staining protocols
have been developed for MHC class I multimers to reduce the effect of prolonged
staining on T cell characteristics. These protocols are based on the streptagll-
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StrepTactin interaction that can be dissociated using d-biotin (Knabel et al., 2002).
This is significant given that MHC multimers have been documented to activate T
cells (Nepom et ah, 2002, Novak et al., 2001b).
With regards to the problem of low avidity, higher order multimers may well
be an answer as these would increase the overall avidity of the pMHC complex,
improving the detection of lower avidity T cells (Malherbe et al., 2000). Taking this
idea further may entail using microbeads as has been used with MHC Class I
constructs (Bodinier et al., 2000, Luxembourg et al., 1998, Prakken et al., 2000).
Mallet-Designe et al have successfully constructed such multimers using liposomes
to form artificial antigen presenting cells (AAPC). These liposomal AAPCs
incorporating MHC class II tetramers were used to stain low frequency low avidity
CD4+ T cells that could not be stained using the standard MHC class II tetramer
construct (Mallet-Designe et al., 2003). Moreover, some have suggested that the
rigidity of the "standard" avidin-biotin tetramer construct may be a hindrance to
optimal TCR contact, advocating a switch to a more flexible scaffold eg the leucine
zipper dimerisation domain with its flexible linker (Casares et al., 1997).
One contentious issue in this area of T cell detection is that of staining
conditions. FACS staining protocols are being developed to reduce background
staining and improve the detection of low frequency cells e.g. Single Epitope
Multiple Staining (SEMS) technique (Townsend et al., 2001), neuraminidase
treatment and detection of intracellular calcium flux (Reddy et al., 2003). However,
such techniques aimed at improving the sensitivity of multimer staining may not
necessarily improve the staining of low avidity CD4+ T cells directed to self-antigens
(Gebe et al., 2003). Despite the presence of background staining, MHC multimer
labelling has been noted to be specific, with single amino acid substitutions of the
bound peptide critically affecting T cell binding (Jang et al., 2003). Cameron et al
demonstrated a reduction in oligomer staining at 4°C and T cells made anergic by an
anti-CD3 monoclonal antibody (Cameron et al., 2001). The latter finding was
replicated by another research group (Quarsten et al., 2001). However, other groups
have produced opposing data in terms of T cell activation status. Reichstetter et al
were able to demonstrate that paraformaldehyde fixation did not abrogate oligomer
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staining (Reichstetter et al., 2000), whilst other groups have used anti-CD3 and/or
anti-TCR monoclonal antibodies to enhance oligomer staining (Kotzin et al., 2000,
Radu et al., 2000, Reddy et al., 2003). The role of staining temperature appears to
have been clarified to some extent, with the suggestion that the variability of staining
with temperature is related to T cell avidity (Reichstetter et al., 2000). Cunliffe et al
(Cunliffe et al., 2002) have also investigated the conditions used for tetramer
staining. Although this group found a variable element of background non-specific
staining of 0.01-0.03% in fresh PBMCs, they noted a detection sensitivity of
5:10000 (0.05%) using the same cells. Furthermore, although they noted 90%
staining of target T cells at room temperature, this rose to 99% at 37°C and fell to
30% on ice. No increase in staining intensity was seen beyond 1 hour. It would
therefore appear that each variable needs adjusting to optimise the staining
characteristics of each peptide/MHC class II multimer.
In order to improve the sensitivity ofMFIC class II multimers it is necessary
to load them homogeneously with the relevant antigenic peptide. In attempting to
improve this, many have covalently linked the peptide to the p chain of the MHC
class II (Crawford et al., 1998). However, as well as causing the manufacture of
MHC class II multimers to become more cumbersome, this method may have
detrimental effects on T cell recognition by affecting the TCR binding of some T
cells (Rees et al., 1999). The use of thrombin cleavage of the linker may well be a
necessary part of using this particular strategy. However, one group of researchers
has raised one proviso to the use of synthetic antigens. They have demonstrated that
peptide conformation may be affected by manufacture as well as sequence, and this
may well have a bearing on the peptide loading of MHC multimers (Peterson et al.,
1999, Viner et al., 1996). One group has recently developed a novel peptide loading
methodology using recombinant MHC class II proteins associated with covalently
linked invariant chain peptide (CLIP) as precursors to in vitro peptide exchange. The
covalently linked CLIP peptide can be cleaved by thrombin from the recombinant
MHC protein in vitro to allow efficient peptide exchange with a peptide of interest,
so improving functional yield whilst allowing a degree of ease in peptide loading
(Day et al., 2003, Jang et al., 2003). The difficulties in defining the exact T cell
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antigenic epitopes adds further difficulty, although here the multimers may prove
themselves to be useful through epitope mapping (Kwok et al., 2001, Stone et al.,
2005). The latter two techniques may prove effective in combination.
5 Application of MHC Class II Multimers
Over the period in which I have been generating TBBs several groups have
published results of their own attempts to apply these reagents, and as a result the
scope ofpotential applications has become clearer.
The multimers produced to date by a limited number of research groups have
been found to stain antigen-specific T cells in a consistent manner (Cameron et al.,
2002) resulting in their activation as evidenced by e.g. IL-2 production (Casares et
al., 1997, Radu et al., 1998). Moreover, the level of multimer binding has been
demonstrated to be proportional to the TCR affinity and expression level (Crawford
et al., 1998). Further assessment revealed that these soluble MHC class II multimers
had a variety of effects on their cognate T cell, from anergy, likely to be a result of a
lack of co-stimulation (Appel et al., 2001), through to TH2 differentiation with IL-4
production in both resting and activated T cells (Casares et al., 2001a, Casares et al.,
1999). These variations in response may well be due to both the extent of TCR
engagement, as well as the physical form of the ligand and the context in which it is
presented. The importance of TCR cross-linking and clustering for T cell activation
has also been elegantly demonstrated using MHC multimers. These experiments
revealed that at least one dimeric pMHC complex is needed to stimulate an antigen-
specific T cell through dimerisation of its receptors, with the T cell responding to the
number ofMHC molecules engaged in the multimer (Boniface et al., 1998, Cochran
et al., 2000). This would theoretically improve the sensitivity of the T cell to minor
changes in the pMHC as the whole process becomes more kinetic, involving serial
TCR engagement (Lanzavecchia, 1997, Valitutti et al., 1995) and clustering (Reich et
al., 1997) leading to more finely tuned T cell activation (Lanzavecchia et al., 1999,
Lanzavecchia and Sallusto, 2000). Taking this a stage further, CD4+ T cell
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activation can be studied using pMHC class II tetramers as they more closely
recreate physiological T cell activation (Mallone and Nepom, 2004).
One rather novel use of this technology has been the identification of T cell
epitopes by loading MHC class II tetramers with an overlapping panel of peptides
and using these to stain T cells. The immunodominant CD4+ T cell epitopes can be
rapidly identified using this technique. Additional subdominant epitopes that may
have partial agonist functions can also be identified in combination with cytokine
screening. This has been successfully used by William Kwok's group to identify the
immunodominant T cell epitopes of HSV-2 VP16 protein in HLA-DRB1*0401 and
*0404 restricted CD4+ T cells (Kwok et al., 2001, Novak et al., 2001a).
MHC class II multimers have been used to look more closely at the cellular
arm of the immune response in TCR transgenic mouse models. Giitgemann et al
used cytochrome c/I-Ek tetramer staining in order to demonstrate that following the
oral administration cytochrome c to TCR transgenic mice there was a rapid
activation of cytochrome c - specific T cells followed by a decline in their numbers
(Giitgemann et ah, 1998). Using the same tetramer with two transgenic mouse
strains Baldwin et al were able to demonstrate that thymic negative selection was
independent of positive selection, with those thymocytes having the greatest degree
of tetramer binding being more efficiently eliminated (Baldwin et ah, 1999). The
presence and importance of TCR plasticity has also been demonstrated using MHC
class II tetramers. Using HLA-DRB1*0401 and HLA-DRB1*0404 tetramers loaded
with influenza virus haemaglutinin peptide (HA307-319), Gebe et al established that a
proportion of CD4+ T cells were cross-reactive between these two HLA-DR alleles,
but that the pattern of cytokine production depended upon the DR-allele (Gebe et ah,
2001).
Having followed CD8+ T cells over the course of an infection, the
opportunity had now come to apply the same techniques to CD4+ T cells in non-TCR
transgenic models. Unfortunately, this has highlighted one of the main problems of
using MHC class II multimers, namely the relatively low frequency of antigen-
specific CD4+ T cells in circulation. This is presumed to be due to the relatively
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small "burst size" of the CD4+ T cell response which is often below the lower limit
of specific fluorescence detection (about 0.01%) (Nepom, 2003). William Kwok's
group have used HLA-DR4 tetramers loaded with HA307-319 in conjunction with
CFSE staining to identify antigen-specific T cells in the peripheral blood of a HLA-
DR4 donor who had been immunised with influenza vaccine 8 months previously
(Novak et al., 1999). This identification, however, required a period of in vitro
stimulation with influenza vaccine/ HA307-319 to allow detection of the specific T
cells above background, with the CFSE stain enabling the calculation of the number
of cell divisions undertaken by the cells identified. Further study revealed that
almost all of the antigen-specific T cells identified after 4 days of in vitro culture
could be found in the activated CD4hlgh population of T cells as a result of in vitro
stimulation (Novak et al., 2001b). A more recent study by the group has not only
achieved direct ex vivo identification of HA peptide specific CD4+ T cells, but has
used multicolour FACS to explore the phenotype of these cells (Danke and Kwok,
2003). The same group has produced HLA-DQ6 tetramers loaded with a series of
HSV-2 VP 16 peptides to isolate and characterise HSV-2-specific HLA-DQ6
restricted T cells from the peripheral blood of a HSV-2 seropositive individual
(Kwok et al., 2000). Using TCR transgenic mice and I-Ek tetramers loaded with
MCC peptide Savage et al demonstrated that the T cell repertoire narrows following
a secondary immune response with a loss of lower affinity T cells. This finding was
based on the half-life of tetramer binding (Savage et al., 1999). MHC class II
tetramers have also been used to analyse human memory CD4+ T cells specific for
hepatitis C virus ex vivo. This was possible using magnetic bead enrichment and
without a period of in vitro culture of the PBMCs (Day et al., 2003). Multimers have
been used in the setting of non-viral human infections with a small degree of success
given the complexity of possible peptide antigens. In the case of Lyme disease
caused by infection with Borrelia burgdorferi, HLA-DR4 tetramers were produced
loaded with a bacterial outer-surface protein A (OspA) peptide based on murine
mapping studies in HLA-DR4 transgenic mice. These multimers were used in eight
patients diagnosed with Lyme disease, only one ofwhom was homozygous for HLA-
DRB 1*0401. Despite the large number of less than perfect characteristics about this
study in terms of peptide specificity and HLA matching, the group were able to
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identify and clone Osp A-specific T cells, characterising these clones using
intracellular cytokine staining. This was performed directly from ex vivo PBMCs
(Meyer et al., 2000).
One of the great promises of MHC class II multimers was the possibility of
studying autoimmune disease processes. However, this area of research is likely to
involve pMHC-TCR interactions at the lower end of the affinity/avidity spectrum,
and certainly lower than foreign antigen specific T cells, stretching the sensitivity of
this group of multimers beyond their current detection limits. This assumption was
confirmed using MHC class I tetramers to look for influenza-nucleoprotein NP366-374-
specific T cells in influenza nucleoprotein-transgenic mice (B10NP mice). This
confirmed that it was the low avidity self-specific T cell that escaped from thymic
deletion (Visser et al., 2000). More recently, Gebe et al (Gebe et al., 2003)
confirmed the low structural and functional avidity of self-reactive CD4+ T cells.
This group defined structural avidity as the ability of T cells to bind MHC tetramers,
and functional avidity as the concentration of peptide required to obtain half-
maximal T cell proliferation. Various groups have made initial forays into this area
with variable results. Radu et al induced experimental autoimmune encephalitis (a
model for multiple sclerosis) in TCR transgenic mice. Using I-Au tetramers
covalently linked to rat MBPj.n (the core MBPi_9 sequence of this being identical to
its murine counterpart) this group were able to detect the expansion of MBP1.9-
specific T cells during the primary immune response to MBP in a manner akin to the
response to an infectious agent. The result would indicate an escape from central
tolerance. However, the low frequency of these cells in na'ive mice precluded their
detection despite the use of a TCR transgenic mouse (Radu et al., 2000). A similar
result was obtained by Liu et al using I-Ag7 tetramers covalently linked to one of two
glutamic acid decarboxylase peptides in NOD mice, a murine model of type I
diabetes mellitus (Liu et al., 2000).
Results have been more disappointing in human subjects, particularly where
HLA type and antigenic peptide specificity are not as clearly defined. Kotzin et al
used HLA-DR4 tetramers covalently linked to one of two peptides found to be
immunodominant in HLA-DRB 1*0401 and *0101 transgenic mice susceptible to
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collagen induced arthritis - human type II collagen peptide 259-272 or human
cartilage glycoprotein peptide 263-275 (Kotzin et al., 2000). Unfortunately, no
antigen-specific T cells were identified in either the peripheral blood or synovial
fluid of patients with rheumatoid arthritis. This negative result has many possible
explanations including patient HLA type, the nature of the immunodominant peptide
in man as compared to mice, T cell affinity and avidity, the presence of
immunosuppressive agents, as well as the lag time between disease onset and T cell
assessment. Two groups have used MHC class II multimers to characterise antigen-
specific T cells obtained from human subjects with coeliac disease or relapsing
polychondritis. In one, Quarsten et al generated HLA-DQ2 multimers carrying
covalently-linked gliadin epitopes that specifically stained the corresponding gliadin-
specific human T cell lines without exhibiting any cross-reactive staining for DQ2-
restricted T cells specific for different peptides (Quarsten et ah, 2001). In another,
Buckner et al formed HLA-DR4 multimers loaded with a human type II collagen
peptide in order to identify human type II collagen peptide 261-273-specific T cell
clones from a heterozygous patient with relapsing polychondritis (Buckner et ah,
2002). In this last study the group found CD4hlgh T cells that could be stimulated in a
peptide-specific manner by the HLA-DR4 monomers, but at the same time were not
stained by the same multimers, suggesting that they may represent recently activated
peptide-specific T cells. In contrast to this, a recent study, looking at the presence of
GAD65-specific T cells in newly diagnosed insulin-dependent diabetics and "at risk"
subjects, found that tetramer staining using GAD65 peptide-loaded HLA-DR4
multimers occurred within the activated CD25+/CD4hlgh T cell population. However,
this staining could only be achieved following incubation ofPBMCs with HLA-DR4
monomers, highlighting the need for activation and ex vivo amplification for tetramer
staining (Reijonen et ah, 2002).
In situ staining of tissue sections using MHC class II tetramers has been
achieved using a similar technique to that used with MHC class I tetramers (Bischof
et ah, 2004). Using multimers in association with monoclonal antibodies in a
multicolour FACS analysis to characterise CD4+ T cell phenotype has also been
achieved (Bischof et ah, 2004, Danke and Kwok, 2003).
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A role for MHC multimers at a therapeutic level has also been raised
(Eisenbarth and Nepom, 2002). Certainly, the group led by Teodor-Doru Brumeanu
have made advances in this field. They have demonstrated antigen-specific T cell
downregulation through the use of doxorubicin chemically bound to dimeric I-Ed
chimeras in mice (Casares et al., 2001b). Moreover, using soluble dimeric I-Ed they
were able to halt the development of diabetes in a double transgenic mouse model of
type I insulin dependent diabetes mellitus. This was found to be due to a
combination of effects including the induction of anergy in antigen-specific splenic T
cells and the stimulation of IL-10-secreting TrI cells in the pancreas (Casares et al.,
2002).
Much promise remains in developing and using MHC class II multimers.
Their capacity to identify and characterise antigen-specific T cells in infectious and
autoimmune disease processes will help in our understanding of these and may lead
to new therapeutic strategies. This could also be used to characterise clinical
heterogeneity within disease processes and even delineate responders from non-
responders in therapeutic strategies. The possibility of using these multimers as
therapy has even been raised, although safety and regulatory issues remain (Ferlin et
al., 2000, Nepom et al., 2002). Despite all this promise many hurdles remain.
6 Future Work
As a result of my work the first hurdle to the use of MHC class II tetramer
technology in anti-glomerular basement membrane disease has been overcome. I
have shown the consistent production and functionality of recombinant HLA-DR15
TBB and HLA-DR7 TBB using two different methods. Furthermore, with the
successful formation of the I-Edsc TBB, the possibility remains of using this
construct in the murine model of AIHA. This would enable the parallel assessment
of construct design and functionality in a separate disease model whose antigenic
epitope has been relatively well delineated (Elson and Barker, 2000, Perry et al.,
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1996). Colleagues within my former laboratory have both reproduced my findings
and continued the development of the recombinant TBB constructs.
Further possible improvements in both heterodimer and fusion-protein TBB
expression systems have been discussed. In summary, the following adaptations
could be assessed in terms of their efficacy in improving recombinant protein yield:
• Covalent peptide linkage is currently being assessed within my former
laboratory with regard to the single chain fusion protein constructs.
However, this could also be considered for the leucine zipper associated
heterodimeric constructs. Of interest would be the use of a covalently linked
CLIP peptide that could then be exchanged for a peptide of interest once the
recombinant MHC class II protein had been expressed (Day et al., 2003).
• Within the Drosophila expression system, the use of an insect cell leader
sequence as well as the co-expression of chaperone protein eg calreticulin
(Fourneau et al., 2004).
• Alteration of Drosophila culture conditions eg roller bottles (Gauthier et al.,
1998).
• The use of anion exchange chromatography in association with metal affinity
chromatography for the purification of the single-chain fusion protein
constructs prior to refolding.
• The use of glycerol and L-arginine during the refolding of the single-chain
fusion protein constructs.
Aside from the possibilities above, the biological evaluation of the
recombinant MHC class II constructs formed to date requires completion. With the
recent formation of Goodpasture antigen-specific HLA-DR15 restricted T cell
hybridomas within my former laboratory, an assessment of these constructs in vitro
has been initiated. Preliminary results indicate that these hybridomas are weakly
responsive to both heterodimer and fusion-protein TBBs. It is hoped that the HLA-
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DR15 transgenic mice lacking their murine MHC class II proteins developed within
my former laboratory will form the basis of ex vivo assessments of my HLA-DR15
constructs.
With the successful biological evaluation of the TBB constructs, the next
stage would be the formation and biological evaluation of multimeric assemblies.
There are two feasible strategies: the "standard" tetramer design using the avidin-
biotin interaction, or the use of higher order cross-linking using microbeads or
liposomes as a scaffold.
The "standard" tetramer design would first require biotinylation of the
heterodimeric TBB constructs using the recombinant BirA holoenzyme, the single-
chain fusion proteins appearing to be already biotinylated to some extent during their
synthesis. This is the more usual multimerisation strategy in terms of the
heterodimeric TBBs, and the leucine zipper domains would improve the flexibility of
MHC-TCR interactions so enhancing the avidity of the multimer. There would be no
such flexibility in the case of the single-chain fusion proteins, and so the avidity of
such multimers may require further optimisation through higher order
multimerisation.
In terms of higher order cross-linking, both microbead and liposomal
scaffolds have been successfully used in the case of MHC class I multimers
(Bodinier et al., 2000, Luxembourg et ah, 1998, Prakken et ah, 2000), with
promising early indications that both can be adapted for use with MHC class II
multimers in order to improve their avidity. Kwok's group have engineered artificial
antigen presenting cells using microbeads coated with recombinant HLA-DR4
tetramers based on the "standard" avidin-biotin scaffold (Maus et ah, 2003). The
beads were used on CD4+ T cell lines, so excluding possible non-specific
phagocytosis by e.g. macrophages. This group found that indirect conjugation of the
MHC class II tetramers via a monoclonal antibody resulted in both more efficient
coating of the beads and a better functional outcome. This finding may be due to
several factors including the directional binding of the tetramers to the beads, less
harsh binding conditions, and the greater flexibility afforded to the tetramers that
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would in turn improve the avidity of the construct. Teyton's group have successfully
engineered liposomal artificial antigen presenting cells, linking the MHC class II
tetramers to these via either a polyhistidine tag or an avidin-biotin interaction
(Mallet-Designe et al., 2003). This technique was noted to improve the structural
avidity of the MHC class II multimers, allowing the ex vivo identification of nai've
antigen-specific CD4+ T cells without the need for a period of activation, and without
increasing background staining. However, these encouraging results identifying
naive CD4+ T cells need to be tempered by the technical difficulties found by the
authors in consistent liposome production. Certainly, my TBB constructs would be
usable in this manner with either technique via their polyhistidine tags.
With the establishment functional multimeric TBB constructs, the intention
would be to use these in order to gain a greater understanding of the role of auto-
antigen specific CD4+T cells in a defined autoimmune process. The evidence to date
would suggest that the use of "standard" MHC class II tetramers to stain ex vivo
auto-antigen specific CD4+ T cells is unlikely to succeed for a variety of reasons
without the concomitant use of eg transgenic animal models or a period of in vitro
expansion to improve CD4+ T cell numbers. Therefore, although it may be
worthwhile comparing the TBB constructs using the "standard" tetramer design
before embarking on higher order multimerisation using microbeads, the use of
higher order cross-linking in combination with developing FACS techniques (eg
SEMS (Townsend et al., 2001)) places the ex vivo assessment of low affinity auto-
antigen specific CD4+ T cells within reach. Moreover, it would be of interest to
compare the lower and higher order multimers in terms of the information that the
techniques provide concerning auto-antigen specific CD4+ T cells. This would be
best achieved using transgenic animal models in order to improve "standard"
tetramer staining, so allowing an assessment of whether a period of in vitro
expansion significantly alters CD4+ T cell phenotype. The pMHC class II tetramer
constructs could be used as specific in vitro CD4+ T cell activation reagents (Buckner
et al., 2002, Reijonen et al., 2002).
Forays into autoimmune disease using MHC class II tetramers have not been
exceedingly successful to date. Although these forays have investigated important
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diseases in terms of their prevalence, they have been hampered to a greater or lesser
extent by lack ofHLA-restriction homogeneity and the presence ofmultiple possible
auto-antigenic specificities. These factors are better defined in the case of
Goodpasture's disease, improving the probability of the successful use ofMHC class
II multimer technology in a human autoimmune disease. I have formed
complementary MHC class II TBB constructs with respect to Goodpasture's disease:
HLA-DRB1*1501 has strong positive associations and HLA-DRB1*0701 has strong
negative associations with the disease as a direct effect of the alleles themselves
(Phelps and Rees, 1999). These constructs can be used in parallel to analyse antigen-
specific CD4+ T cell phenotypes in relation to disease and control populations, and
so try to delineate any differences in CD4+ T cell responses in relation to these two
presentation strategies. As Goodpasture's disease tends not to follow a relapsing-
remitting course, its kinetics with respect to changes in CD4+ T cell phenotype and
avidity can be more readily followed from near to the point of disease initiation
through to its natural or therapeutically induced remission. Recent work in insulin-
dependent diabetes mellitus would suggest that it is not the antigen responsiveness
per se, but rather the balance of T cell phenotypes that leads to an autoimmune
process (Arif et al., 2004). The constructs that I have formed would be ideally
placed to further investigate this suggestion. Furthermore, although the Goodpasture
antigen has been well characterised, and as a result the peptide antigens that would
be utilised within the MHC class II multimeric constructs have been better defined,
the possibility remains of confirming these epitopes using the MHC class II
constructs and overlapping peptide panels to perform an epitope mapping exercise
(Kwok et ah, 2001). This may be of relevance given that different epitopes may
predominate over the. natural history of the disease process, with these epitopes being
affected by both differences between individuals as well as APCs (Reijonen et ah,
1999, Reijonen et ah, 2003). Such epitope spreading may complicate the
interpretation of negative results, and in this setting epitope mapping using the
complementary MHC class II TBB constructs could be of value.
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Appendix 1
Heterodimeric MHC Class II Oligonucleotide Primers
1 l-Ed Heterodimer Constructs
1.1 BirA1 Sequence
CGCTAGCGGC GGTGGACTGC ATCATATTCT GGATGCACAG AAAATGGTGT
GGAATCATCG TTAAG
1.2 BirA2 Sequence
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ATCGGATCCA GATCTCTCGA GTGACGAGTT CTCTGTAGTC TC
2.3 ZipDRBL Sequence
CGAATTCTCG AGGCCCACGT TTCYTG Y = C or T
2.4 ZipDRBR Sequence
CGAATTCAAG CTTGGATCCG TCGACTGACG ACTTGCTCTG TGC
3 Peptide Binding cassette Construct
3.1 PCTop
GCTCGAGGGG AGATCTGGAG GTTCACTAGT GCCACGGGGC TCTGGAGGCG
GTCGACGGTA C
3.2 PCBottom
CGTCGACCGC CTCCAGAGCC CCGTGGCACT AGTGAACCTC CAGATCTCCC
CTCGAGCTGC A
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Appendix 2
Singie-chain MHC Class II Oligonucleotide Primers
SC1 Sequence
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Appendix 3
Solutions
1 Transformation and amplification of DNA in competent
cells
All solutions were produced following the methods laid out in Sambrook et al
(Sambrook et al., 1989).
2 Agarose mini gels
All solutions were produced following the methods laid out in Sambrook et al
(Sambrook et al., 1989).
3 SDS-PAGE gels
All solutions and gels were produced following the methods laid out in
Sambrook et al (Sambrook et al., 1989).
4 Antibody purification
4.1 Loading and wash buffer
0.1M sodium phosphate buffer (pH8.0) was formed by mixing 93.2ml of 1M
Na2HP04 with 6.8ml 1M NalFPCfi in 900ml of dH20, adjusting pH if necessary. To
this sodium chloride was added to a final concentration of 0.5M prior to filtering
through a 0.45pm filter (PAL Gelman corporation) and storing at room temperature
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5 Bacterial inclusion body preparation
5.1 Triton wash solution
0.5% Triton X-100
ImM EDTA
The above was made in 11 of dEEO prior to storing at room temperature.




The above was freshly prepared in dEEO prior to use.
6 Nickel chelation chromatography
All solutions were passed through a 0.45pm filter (PAL Gelman Corporation)
prior to use.
6.1 Column stripping solution
lOOmM EDTA
lMNaCl
The above was formed in dtUO, adjusting to pH 8.0 using 1M NaOH to
allow dissolution ofEDTA.
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6.2 Column metal loading solution
lOOmM NiCl2
1 OmM sodium acetate
The above was formed in dH20, adjusting pH to 4.5 using 1M HC1 prior to
storing at room temperature.
6.3 Column wash solution for heterodimer
0.1M sodium phosphate buffer (pH8)
lMNaCl
lOmM imidazole
The above was mixed in dH20 prior to filtering and storing at room
temperature.
6.4 Column elution solution for heterodimer
To the above wash solution, EDTA was added to a final concentration of
0.1M, adjusting the pH with sodium hydroxide to 8.0.
6.5 Column wash solution for single chain
The following were mixed prior to adjusting the pH to 8.0, filtering and
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6.6 Column elution solution for single chain
To the above solution, EDTA was added to a final concentration of 0.1M,
adjusting the pH with sodium hydroxide to 8.0.
7 Miscellaneous solutions
7.1 Cell lysis solution




5mM EDTA, ImM phenylmethanesulphonyl fluoride (PMSF), ImM
Iodoacetamide, 1 pg/ml Leupeptin and 1 pg/ml Pepstatin A
Once formed the solution was stored at -20°C until required.
7.2 Immunoprecipitation solutions
All solutions were produced following the methods laid out in Sambrook et al
(Sambrook et al., 1989).
7.3 Citrate buffer for peptide binding experiments
Stock solutions of 0.1M citric acid (19.21 g/1) and 0.2M dibasic sodium
phosphate were first formed. A pH5.0 buffer was then made by combining 24.3ml of
0.1M citric acid and 25.7ml 0.2M dibasic sodium phosphate and diluting to 100ml
with dFEO.
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